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Abstract: Background 
It is not known whether switching antipsychotics or early use of 
clozapine improves outcome in (first-episode) schizophrenia.  
 
Methods 
The study was conducted in 27 centres in 14 European countries and Israel 
consisting of general hospitals and psychiatric specialty clinics. 
(Clinicaltrials.gov identifier is NCT01248195). Patients with 
schizophrenia or schizophreniform disorder were treated for four weeks 
with up to 800 mg/day amisulpride in an open design. Patients who did not 
meet symptomatic remission criteria at four weeks were randomized to 
continue amisulpride or switch to olanzapine (max 20 mg/day) during a 
six-week double blind phase. Patients who were not in remission at ten 
weeks were given clozapine (max 900 mg/day) for an additional 12 weeks in 
an open design. Data were analyzed using a generalised linear mixed 
model, with a logistic link and binomial error distribution.  
 
Findings 
Participants were recruited between May 26, 2011 and May 15, 2016 with 
481 signing informed consent. Of the 446 patients in the ITT sample, 371 
(83.2%) completed open amisulpride treatment, of whom 250 (67.4%) were in 
remission. 93 of the patients who were not in remission continued to the 
six-week double-blind switching trial with 72 patients (77.4%) completing 
it (39 on olanzapine and 33 on amisulpride); 15 (45.5%) of the patients 
taking amisulpride reached remission versus 17 (43.6%) on olanzapine 
(p=.87). Of the 40 patients who were not in remission after 10 weeks of 
treatment, 28 (70.0%) were started on clozapine; 18 patients (64.3%) 




In the large majority of patients in the early stages of schizophrenia, 
symptomatic remission can be achieved using a simple treatment algorithm 












Comments from the editor 
1) Please ensure the NCT number you have provided is correct (the one cited is only for the part 
of the study in Denmark). 
The correct NCT number is NCT01248195, this has been adjusted in the manuscript. 
 
2) Please describe the whole study (as in the protocol); you may then state, and reference, that 
parts of the study have/will be published elsewhere (eg, imaging, biomarker, psychosocial). 
The following information is now included in the Methods section of the manuscript: 
“Blood was drawn at the beginning and end of each treatment phase in order to relate 
proteomics, immune parameters and genetics to treatment outcome. In addition, patients who 
had remitted were randomised to a specific psychosocial intervention versus treatment as usual 
to test the effect on adherence. The results from these studies are not yet available and will be 
reported separately. Finally, MRI and MRS assessments were conducted in a subsample of 
participants.” 
 
3) Discuss your protocol amendments in the protocol: what was changed and the dates for all 
changes need to be provided. 
As there were six amendments over the years; an overview of dates and content is provided in 
the Appendix. 
 
4) Your protocol states that the secondary outcome will be measured by GAF but PSP is stated 
in your manuscript. Can you explain this discrepancy in the text? Also, subjective wellbeing is 
measured and reported in the manuscript but is absent from the protocol. Can we please 
include this as an exploratory endpoint? Also please report on secondary data in the results 
section and provide data (in an appendix please, to include study medication discontinuation 
Kaplan Meier and all other secondary outcomes).  
Although the initial plan was to measure social function through GAF, early in the project 
(before the first patient was enrolled) it was decided to use the PSP instead, as this is a more 
elaborate assessment of social functioning. The protocol was not corrected in this regard as an 
*Reply to Reviewers Comments
oversight. GAF was never assessed within this study. Subjective wellbeing is measured using the 
Subjective Wellbeing under Neuroleptics (SWN), as described in the protocol. These data have 
not yet been analyzed and – in view of the fast-track procedure – it was decided not to include 
them here. 
 
A Kaplan Meier curve of dropout over time has been added to the appendix. 
 
The following text was added to the Methods section: 
“To assess the proportion of dropouts over time, a Kaplan Meier curve was used. Follow-up time 
was defined as the number of weeks between the date of the baseline visit and the date of the 
last visits of a patient. Patients who did not progress to a next phase because they were in 
remission were censored.” 
 
5) Please include abdominal circumference and frequency and severity of adverse effects in 
your methods and results, if these were measured. Please include an Adverse events table with 
total events, and with events separated by study phase. Please report all adverse events and 
not just those deemed to be related to study medication, though you are welcome to indicate 
which ones were or were not deemed to be related according to your criteria. 
The abdominal circumference as well as the frequency and severity of side effects have been 
added to the Methods section:  
“Frequency and severity of adverse events were assessed at each visit. In addition, weight, 
abdominal circumference and height were measured (..)”.  
Data for abdominal circumference are reported in the Results section, tables 1 (start of each 
phase) and 4 (end of each phase). As there were a large variety of adverse events, the full listing 
(apart from the more relevant side effects as listed in the tables of the manuscript) has been 
added to the appendix. 
 
6) Did you complete the 48 and 74 week follow-up as mentioned in your protocol? If so please 
include, or explain in your methods why these were not completed 
The two long-term follow up visits are now described in the Methods section: 
“Patients who did not meet remission criteria after completion of phase III, returned for a 
follow-up visit 48 weeks after baseline (26 weeks after the final phase III visit), where PANSS was 
assessed and rehospitalisation data was collected. For all patients who started phase I, a follow-
up visit at 74 weeks post-baseline was scheduled to assess symptom severity and the current 
clinical diagnosis, as well as to collect data on hospitalisation.”  
 
Data from these visits are now described in the Results section:  
“48-week follow-up visit 
For patients who did not meet remission criteria after completion of phase III, a follow-up visit 
was scheduled, 48 week post- baseline (26 weeks after the final phase III visit). Out of the 11 
non-remitters at the end of phase III, 8 patients returned for this visit. The mean total PANSS 
score was 70.5 (SD 22.3, range 40-104). Three patients met remission criteria during this visit. 
None of the patients were rehospitalised since the end of phase III. 
 
74-week follow-up visit 
For all patients who entered phase I, a follow-up visit was scheduled 74 weeks post-baseline. 
This visit was conducted for 167 patients. The clinical diagnosis at that time point was 
established: 13 patients (7.8%) were diagnosed with schizophreniform disorder, 22 patients 
(13.2%) with schizoaffective disorder, 123 patients (73.7%) with schizophrenia and 9 patients 
(5.3%) received other diagnoses (e.g. psychosis NOS, bipolar disorder, unspecified non-organic 
psychosis). PANSS data was available for 140 patients; the mean total PANSS score was 50.2 (SD 
15.0; range 30-105). 95 patients (56.9%) met remission criteria. Seventeen out of 140 patients 
(10.2%) were hospitalized at least once since the most recent study visit.”  
 
7) Please include contraceptive use in your inclusion/exclusion criteria, as in the protocol. 
This has been added to the Methods section of the manuscript:  
“Female patients of childbearing potential were required to use a proper method of 
contraception.” 
 
8) Missing data: how were these handled? Please add a sentence to your Statistical analysis 
section in the methods. 
We added the following to the Methods Section: 
 “Missing values were not imputed, as the GLMM analysis incorporates all available 
measurements, assuming that patients with available measurements are representative for all 
patients, including the patients with missing values. For side effects, we assumed that missing 
values indicated absence of side effects.” 
 
9) Please provide a CONSORT checklist, and ensure that your manuscript has been completed 
according to the guidelines. You have done this on the most part, but we need a check for our 
records. 
The CONSORT checklist is provided separately. 
 
10) Please ensure that all numbers are provided with % and vice-versa throughout the text and 
tables. 
This has been checked and adjusted where applicable. 
 
11) Please provide p values to 4 decimal places, or 2 significant figures (ie, exact to p<0.0001). 
This has been checked and adjusted where applicable. 
 
12) The declaration of interest and acknowledgment section of the manuscript are missing 
(acknowledgments are optional!). Please provide author statements and ICMJE forms for all 




The required forms (author statements and ICMJE forms) for all authors have been submitted 
with the original submission to ‘The Lancet’. In case these were not forwarded to ‘The Lancet 
Psychiatry’, we can provide them immediately. We apologize for the missing summary 
statements, they have been added to the current version of the manuscript. 
 
13) Would it be possible to include information about study sites and participants who are not 
authors in the appendix? 
An overview of the ‘OPTiMiSE Study Group’ authors and all participating centers is included in 
the appendix. 
 
14) Would it be possible for you to provide editable versions of all figures to be included in the 





We have created new versions in EPS format. 
 
15) To enable readers to better appreciate research findings and to encourage full and 
transparent reporting of outcomes, The Lancet family journals offer to publish a webaddress in 
accepted paper that links to the study's protocol on the author's institutional website (see 
Lancet 2009; 373: 992). This is particularly encouraged for randomised controlled trials, but is 
welcome for all types of research. 
A specific website for the project is available. Even though it is separate from the author’s 
institutional website, we would appreciate it when this address could be published: 
www.optimisetrial.eu  
 
16) Finally, we encourage authors to share any additional data, that would facilitate the 
replication or further analysis of their work—eg, the raw numbers underlying their analysis or 
the code for any modelling. Mendeley Data is a secure online repository for research data, 
permitting archiving of any file type and assigning a permanent and unique digital object 
identifier (DOI) so that the files can be easily referenced. If authors wish to share their 
supporting data, and have not already made alternative arrangements, a Mendeley DOI can be 
referred to in a section entitled "Data sharing" at the end of the Methods section, ahead of 
"Role of the funding source". If authors have already deposited their data in another repository, 
or have made other arrangements for data to be shared (eg, by means of an adjudication 
process or contacting the authors), they should use this section to elaborate. 
Although we are in favor of data sharing, the informed consent documents used for the current 
study do not allow for data sharing outside our project Consortium without additional consent 
from the participant.  
 
Additional comment received per email on April 22 from the editor: 
I just wanted to follow up with one more comment that needs addressing that I accidentally 
omitted from the initial email: your power calculations appear to be missing from the Methods 
section of your manuscript, and the fact that the Phase II part of your study did not reach 
power is concerning. You mention in your discussion that having a higher number of 
participants in this phase probably would not have changed the study conclusions (which may 
well be true); however, the reporting of your power calculations needs to be present and 
transparent. Would you also be able to add this to your revision? 
The power calculation has been added to the Methods Section of the manuscript, “Power 
analysis and statistical analysis”. 
 
“Data of the EUFEST study (1) showed that about 40% of the patients on amisulpride were in 
symptomatic remission within four weeks. However, halfway through the study almost 60% of 
phase I patients met remission criteria. Subsequently, the power analysis was adjusted to the 
following:    based on EUFEST we expect that 50% of the four-week non-responders who stay on 
amisulpride will be in symptomatic remission after another six weeks of treatment (10 weeks 
from treatment initiation). If the percentage of patients in remission increases from 50% to 70% 
as a result of switching to olanzapine (which is an estimation, as there are no prior studies on 
this topic), the two treatment arms will have to contain 90 patients each to obtain a statistical 
power of .79 with a type-I error rate of .05. If we consider that the drop out rate is 
approximately 30% and the remission rate 60% (both observations after 250 patients had been 
enrolled into the study), than this implies that at least 487 patients will have to be included at 




Reviewer #1: Comments to the author: 
In my opinion this is an important study, but the authors failed to explain why in any detail. 
 
We have added the following paragraph in the Introduction: 
“Indeed, one of the most relevant questions in the treatment of the early phase of schizophrenia 
– and an essential ingredient in any treatment algorithm - is whether switching to another 
antipsychotic improves outcome when a patient has not responded to the treatment that was 
initiated.” 
 
1. The authors spent many words on the lead-in and the open-label extension but did not 
adequately present full details about Phase 2, the important part of the study. The emphasis 
should be on Phase 2 and some of the details in the lead-in could go in the web supplement. 
 
We have added to the Introduction: 
 
“Another aspect that has often been lacking in treatment studies in schizophrenia is a clinically 
relevant outcome measure. Generally, response to treatment has been defined as a reduction in 
the Positive and Negative Syndrome Scale (PANSS) total score of >20% but it has been argued 
that a more stringent outcome is ‘remission’, analogous to cancer treatment and reflecting an 
almost complete absence of the psychotic symptoms of schizophrenia.3 This measure is clinically 
relevant and useful as an outcome in clinical trials.4,5 “ 
 
We have added to the Results: 
“Baseline characteristics of the 93 patients for the two treatment groups are depicted in 
Supplemental Table 1. There were no statistically significant differences in proportion or means 
between the two randomized groups, as expected.” 
“An extensive report of all side effects reported is provided in a table in the appendix.” 
 
2. I would recommend adding several tables that systematically report the critical statistics for 
both the intent-to-treat analysis and the observed case analysis of Phase 2, giving baseline 
mean standard deviations and sample size, with values for intermediate time points as well as 
the endpoint. Most studies test for baseline differences to see if randomization worked and 
baseline differences should be evaluated for the 92 patients who received medication in phase  
 
Please see above. We have added Tables on Baseline characteristics and side-effects of Phase II. 
We added the following to the results section: 
“Baseline characteristics of the 93 patients for the two treatment groups are depicted in Table 
5. There were no statistically significant differences in proportion or means between the two 
randomized groups.” 
 
2. The authors failed to give the statistical methods in any detail for Phase 2, allowing only one 
sentence with only the statement: "a factor in the GLMM.". In any case we only know what the 
factor is. What we don't know is what the other variables are. Since the readers are 
psychiatrists, this doesn't mean much.  I'm not questioning the statistics and I'm sure they were 
well done, but there should be enough detail in any methodology that a person could replicate 
the study using the same design. I have no problem 
with the conservative estimate of number of responders at endpoint of any given phase. 
However, I think it would be appropriate to give full numerical statistics on the qualitative 
response versus non-response at each time point for Phase 2 in a numerical table. It should also 
be clear what statistics were done for the continuous data as well as for the remission data.  
 
The description of statistical methods has been extended with more details. We have also 
created a table (Table 5) with baseline characteristics in the two randomized groups of phase II. 
No statistical significant differences between the groups were found. 
 
We added the following (additions are underlined): 
Remission, as assessed at the final visit of each phase, was first summarized as counts and 
percentages. Subsequently, remission at each visit was analysed using a generalised linear 
mixed model (GLMM), with a logistic link and binomial error distribution. Variables included 
were visit number as a categorical variable and the baseline PANSS score as a continuous 
covariate. In this way, all visits contributed to the estimate of the between patient variance, 
thereby making the estimate of remission at the final visit more robust while accounting for 
dropout. For phase II a comparison was made between the amisulpride and olanzapine arm, by 
including the treatment arm as a factor in the GLMM. The cumulative proportion of patients in 
remission over all three study phases was calculated using the number of patients in remission 
at the last visit of each phase, i.e. the phase completers in remission. We used the conservative 
assumption that dropouts within a phase did not reach remission throughout the study. Patients 
eligible for a next study phase, but not continuing into that phase, were assumed not to be 
different from patients who did continue. To assess the proportion of dropouts over time, a 
Kaplan Meier curve was used. Follow-up time was defined as the number of weeks between the 
date of the baseline visit and the date of the last visits of a patient. Patients who did not 
progress to a next phase because they were in remission were censored. Side effects were 
summarized per visit and per phase and expressed as percentages. Missing values were not 
imputed, as the GLMM analysis incorporates all available measurements, assuming that 
patients with available measurements are representative for all patients, including the patients 
with missing values. For side effects, we assumed that missing values indicated absence of side 
effects. All quantitative scores, including the PANNS, were summarized as means and standard 
deviation and differences between groups were assessed by a t-test. Dichotomous variables 
were expressed as counts and percentages and differences between groups were assessed by 
Chi square tests. Differences between groups in proportions were calculated and a 95%CI 
according to Wilson’s method. In all analyses, the criterion for statistical significance was P < 
0.05. SPSS version 25 was used for all analyses. A Data Safety Monitoring Board oversaw the 
study. 
 
3. There were a number of instances in the paper where I could not get the numbers to add up. 
In the text the author mentioned that seven patients dropped out of the olanzapine arm, but in 
the consort diagram six are noted. It is important not to confuse patients randomization with 
not entered in the study with dropouts on drug. I also could not calculate some of the 
percentages in the text. Some of the numbers and percentages in text or in Table 4 or 
elsewhere didn't make sense. Side-effect data should reflect every patient exposed to the drug. 
I realize that some of these problems are trivial but they should be fixed in the revision.  
 
We went through the manuscript and tables in detail to resolve the issues with inconsistencies in 
the numbers. Regarding the side effect data, we strongly prefer to report the presence of 
adverse events for those patients who have side effect data available for the applicable visit 
only. In case we would use the full sample of patients exposed to drug, we would assume that 
patients for whom side effect data is missing did not experience these particular effects, which 
may result in misleading numbers. 
 
4. One could make more of the limitation of sample size of only a limited number of Phase 2 
completers, but this is mitigated by the nonsignificant trend of olanzapine to do worse. If 
switching produced benefit. Olanzapine would've had to do better, for a positive results but it 
treaded to do worse and 92 is a reasonable N. I think that is a logical fallacy for any family of 
drugs where efficacy differences might potentially occur to conclude that because to drug with 
similar efficacy do not differ on switching, that switching from one drug low in efficacy to 
another drug high in efficacy might yield a better result. I do not think you can rule out the 
possibility that those responding to Clozapine were true drug responders because you had no 
placebo or other comparator for this phase for the passage of time. This is minor and can be 
fixed with several words.  
Indeed, we had indicated as such in the discussion: 
“Third, it could be argued that a comparison between continuation with amisulpride and 
switching to clozapine in Phase III would have been of interest; the current design cannot 
address that question. Indeed, whether clozapine has an added benefit over continuation with 
amisulpride after ten weeks of its use needs further study.” 
 
5. It's been known for many years the first-episode patients have high remission rates. I do feel 
that the author adequately discussed the implication that Phase 1 is open. The discussion of 
reference #16 seems convoluted and the discussion of reference #17 might benefit from a 
change of word order, moving the last sentence up in the paragraph. There are various other 
studies using switching strategies, but I agree with the author's choice of just discussing these 
two studies. I think this is a fine study and there's something not quite right about saying that 
you are the first to study this question in first-episode patients and then stating the results of 
another previous study. I think this issue might be fixed by adding one word. Nevertheless, this 
paragraph is rather convoluted. I recognize that my criticisms are small except for the need for 
systematic tables of both observed-case and intent-to-treat and an explicit statement of 
methodology and I do think the paper could 
benefit from a revision. 
 
We have changed both paragraphs. 
The first paragraph on reference 16 now reads:  
“To our knowledge, this is the first study to examine the effects of switching antipsychotics in 
patients with (first-episode) schizophrenia who do not respond to their initial antipsychotic 
treatment (response has been defined differently in the various studies; we used remission in the 
current study). With the exception of one study, all previous studies were conducted in the later, 
chronic, stage of the illness. Moreover, the single study in first-episode schizophrenia did not 
assess whether switching was more effective than staying on the original treatment (for review 
see14)).” 
 
The paragraph on reference 17 now reads: 
“The only double-blind study that compared switching versus continuation in non-responders 
was conducted in patients with chronic schizophrenia (age around 42 years). Response in the 
first two weeks was defined as ≥20% reduction in total PANSS scores. This corresponds to a 
lesser degree of clinical improvement than the symptomatic remission criterion used in the 
present study.17 Patients who did not respond to a two-week open trial with risperidone (2-6 
mg/day) were randomized to either continuing on risperidone or were switched to olanzapine 
(10-20 mg/day). Switching resulted in a small but significantly greater reduction in total PANSS 
scores after four weeks.” 
 
It is a truly excellent study, clinically important, but not systematical written up. 
 
Reviewer #2:  
1. Composite outcomes, in which multiple endpoints are combined, are actually used as the 
primary outcome measures in this trial. Multiplicity adjustment is necessary. 
The primary outcome is remission, a single binary variable. Only in phase II a comparison 
between randomized groups is made. Therefore, we do not consider this to be multiple 
endpoints. 
 
2. On page 8, Missing Completely at Random (MCAR) is assumed in the statistical analysis. This 
is a strong assumption. More discussions on the missing data mechanism is necessary. 
We have added details about missing values and the way the GLMM method deals with it in the 
Method section. 
“Missing values were not imputed, as the GLMM analysis incorporates all available 
measurements, assuming that patients with available measurements are representative for all 
patients, including the patients with missing values. For side effects, we assumed that missing 
values indicated absence of side effects.” 
 
3. For the key secondary endpoint, a large p value in a null hypothesis significance testing does 
not indicate the equivalence between olanzapine and amisulpride. A confidence interval is a 
good way to present this result. An equivalence test is an even better choice. 
The difference in proportion with 95%CI has been added to the text. 
 
4. It is not easy to distinguish the remission rate of olanzapine from that of amisulpride in Phase 
2 in Figure 4 and 6. The ends of error bars may use different symbols for olanzapine and 
amisulpride. 
We have created editable versions of the figures, and we suggest to leave this to a graphical 
artist of the journal. 
 
Reviewer #3: This is the first study to investigate the efficacy of switching of antipsychotic 
among patients with first episode schizophrenia who do not respond to their first antipsychotic 
treatment. Therefore, it is enormously important study concerning clinical practice. I have a few 
comments: 
 
1. The results show that remission can be reached among ¾ of patients by continuation of 
amisulpride (and in some cases switching to clozapine). However, I think that reaching 
remission is not the main issue in the treatment of schizophrenia, but STAYING in remission is 
the essential goal. I think that this should be dealt in the Discussion. 
 
We have added the following to the discussion: 
“Finally, although our results show that a large majority of first-episode schizophrenia patients 
reaches remission within a few months of treatment, failing to stay in remission remains a 
major impediment in the treatment of schizophrenia (22).” 
 
2. Cohort studies show that about half of the first-episode patients do not go to pharmacy to 
pick-up any antipsychotic treatment after their first hospital discharge. This indicates that in 
real-life setting, compliance/adherence to use oral medication is rather low and use of LAIs 
might partially overcome this problem.  
We did not specifically mention the use of LAIs in this study (since it is outside its scope) 
although we did address, as suggested by this reviewer (see above), the issue of failing to stay in 
remission (which has many causes). 
 
3. Minor issues: In the abstract, "Interpretation" does not answer to "Background" question. 
("It is not known whether switching antipsychotics or early use of clozapine improves outcome 
in (first-episode) schizophrenia").  I think that the text in the "Interpretation" should be 
replaced by text from "Research in context" paragraph ("The results suggest that in the large 
majority of patients in the early stages of schizophrenia, symptomatic remission can be 
achieved using a simple treatment algorithm comprising the sequential administration of 
amisulpride and clozapine.").  
 
We have followed the suggestion by this reviewer and used the text from the Research In 
Context “Implications” for the “Interpretation” in the abstract. The Interpretation section of the 
abstract therefore now reads: 
“In the large majority of patients in the early stages of schizophrenia, symptomatic remission 
can be achieved using a simple treatment algorithm comprising the sequential administration of 
amisulpride and clozapine.”  
 
4. In the Abstract, it is stated "… 18 patients completed the 12-week treatment, of whom five 
(17.9%) met remission criteria". 5 of 18 is 27.8%. (It seems that 17.9% refers to ITT, i.e., 5 of 28.)  
Thank you for pointing this out, the applicable text has been adjusted as follows: ‘18 patients 
(64.3%) completed the 12-week treatment, of whom five (27.8%) met remission criteria.’ 
 
Reviewer #4: THELANCETPSYCH-D-18-00228 
This is an important study that investigates the value of switching antipsychotic agents for 
individuals with a first episode of schizophrenia and schizoaffective disorder who have not 
remitted with their first trial of antipsychotic medication. The results of the study are clear but 
the appropriate interpretation is less clear cut due to limitations in the study design. It would 
be valuable for the authors to address the following issues: 
 
1. While the choice of amisulpiride over olanzapine as a first line antipsychotic is justifiable, it 
would be valuable to be more clear about their rational for considering amisulpiride to be the 
less toxic alternative. The current wording is overly simplistic. This would provide the authors 
with opportunity of articulating the relative risks of these two medications. Olanzapine carried 
a greater risk of weight gain and metabolic complications including diabetes while current 
evidence suggest that amisulpiride is thought to be associated with greater QTc prolongation 
and a tardive dyskinesia risk that is greater by a modest degree compared to olanzapine though 
substantially lower than the risk associated with first generation antipsychotics.  
 
We have changed the text as follows. 
“Although both drugs have multiple side-effects, in the case of amisulpride these are mostly 
limited to extrapyramidal symptoms and hyperprolactinaemia (although QTc prolongation can 
occur at higher doses), while those associated with olanzapine increase the risk of 
cardiovascular complications - and are therefore more serious in the long term than those 
associated with amisulpride6. It would therefore make sense to initiate treatment with 
amisulpride.”  
 
2. It is incorrect to state that in clinical practice the interval between the onset of treatment 
and the initiation of clozapine is 10-12 years. My understanding is that more recent studies 
have reported somewhat shorter delays. Perhaps this could be worded as "as long as 10-12 
years".  
The applicable text in the Introduction has been adjusted to reflect the reviewer’s comment:  
However, in clinical practice the interval between the onset of treatment and the initiation of 
clozapine is as long as 10-12 years.10 
 
3. Two objectives of the study are described. The first objective is clear but the second objective 
less so. It seems very straightforward that a simple treatment algorithm would facilitate earlier 
treatment with clozapine. The question is really whether earlier treatment with clozapine leads 
to improvement in patients who have not remitted after 10 weeks of antipsychotic treatment. 
Rewording of the second objective would be valuable. 
 
We have changed the wording of the second objective as follows: 
“Can earlier treatment with clozapine improve outcome in patients who have not remitted after 
10 weeks of antipsychotic treatment?” 
 
4. The title of the paper states that this is a study of first episode schizophrenia and 
schizoaffective disorder but the Methods section also includes schizoaffective disorder. It may 
be better to just use the term "schizophrenia", "schizophrenia spectrum disorders" or "non-
affective psychoses" in the title. 
 
Although this is correct, we refrained from changing the title in this respect. The proportion of 
schizoaffective patients in this study was quite small (6%) and adding this group to the title 
would have made it overly long. 
 
5. "Patients were required to provide written informed consent." This is poorly worded as it 
could be interpreted to mean that patients were not given a choice. "All study participants 
provided written informed consent" would be more accurate. 
The applicable text in the Methods has been adjusted to reflect the reviewer’s comment: ‘All 
study participants provided written informed consent.’ 
 
6. Individuals were excluded if they had psychotic symptoms that interfered with their 
functioning for over two years. It is not clear why this exclusion was used. It likely impacted 
substantially on their results as there is evidence that those with more insidious onset and 
longer DUP are less responsive. The rationale for this exclusion criteria and its likely impact on 
the study results should be discussed in the Discussion.  
Thank you for pointing this out. The applicable text in the Methods section has been adjusted in 
line with the text in the study protocol: ‘Patients were excluded if the time interval between the 
onset of psychosis and study entry exceeded two years.’ 
 
7. The most controversial aspect of the study is likely to be the decision to limit the initial trial 
of amisulpiride to 4 weeks. Previous research (Samara et al 2015) has reported that patients 
with schizophrenia who have not experienced minimal improvement after two weeks on a 
given antipsychotic are unlike to improve with that agent. That is very different from what was 
done in the current study, i.e. switching at 4 weeks if criteria for remission were not met. It is 
not surprising that many patients who stayed on amisulpiride continued to improve to the 
point that they met remission criteria after 10 weeks of treatment. 
 
Many authors would argue that 4 weeks is more than adequate to address non-response, as this 
reviewer also suggests by quoting Samara et al, 2015, where it is concluded that 2 weeks is 
adequate to make the decision whether or not the patient has responded to treatment. In fact, 
to quote from that paper: “…. the assessment of final nonresponse at week 4 was associated 
with higher specificity of the diagnostic test than was assessment of nonresponse at week 6 or 
later.” This does suggest that 4 weeks is in fact sufficient for an initial trial. 
We have added to the Discussion: 
“Fourth, it may be argued that a 4-week trial is not sufficiently long to decide whether to switch 
or not. However, a recent meta-analysis suggests this period is sufficient (22).” 
 
 This is important because those patients randomized to olanzapine should not be considered 
to have been amisulpiride non-responders. In the seminal study of clozapine versus 
chlorpromazine (CPZ) for first episode schizophrenia (Lieberman et al. 2003), clozapine was not 
found to be superior to CPZ. Because the response rate to first line antipsychotics is 
so high, it was not possible to demonstrate additional benefit from chlorpromazine. 
Subsequent studies of first episode non-responders have shown clozapine to be more effective. 
The current study is also limited by a similar issue. It is possible that olanzapine is more 
effective for first episode patients who have not responded to amisulpiride. The current study 
did not really test this as many of the patients in Phase II of the study were not amisulpiride 
non-responders.  As a result, it would be reasonable to conclude that patients who have not 
remitted after four weeks of amisulpiride treatment do not benefit from switching to 
olanzapine. However, this might not be the case if patients had been given a longer trial (e.g. 12 
weeks) to more definitively establish poor response to amisulpiride.  
 
It is important to point out here that we studied remission, not just response. The reviewer is 
right that some of the patients who continued into Phase II may have been ‘responders’ 
depending on the criteria used in some of the studies the reviewer is referring to. However, as 
we have now added to the Introduction, one of the unique characteristics of the current study is 
that we defined outcome as the more clinically relevant (and stringent) outcome, remission. 
Also, as argued by the reviewer, there is no convincing evidence that longer treatment would 
improve chances of remission (except for clozapine). 
 
8. It is of note that the dropout rate was not significantly different for olanzapine versus 
amisulpiride in this study. Given that a number of previous studies including the CATIE study 
have found that olanzapine has been associated with lower dropout rates (though not 
compared to amisulpiride), it is striking that the dropout rate was twice as high in the 
amisulpiride group. One certainly wonders whether the lack of statistical significance is best 
explained by low statistical power. It would be worth reporting the effect size and comparing it 
to effect sizes for discontinuation rates seen after four weeks of treatment in the CATIE study 
and the 2003 Lieberman et al study comparing olanzapine and haloperidol in first episode 
schizophrenia. 
 
We have now added the confidence intervals of the drop our rates in Phase II: 
 
“Dropout rates between the two treatment arms did not differ significantly, although there was 
a trend in favor of olanzapine; 29.8% of patients randomized to amisulpride dropped out (n=14) 
versus 15.2 % (n=7) on olanzapine, a difference of 14.5%, 95%CI -2.5% to 30.7%  (p=.093).” 
  
 
9. Given the brevity of the Phase I trial of amisulpiride, the requirement that remission criteria 
not be met to enter Phase II, and the substantially lower dropout rate seen with olanzapine, the 
question of whether there might be value in having a trial with olanzapine for those who fail to 
remit after a full trial of asenapine has not addressed in this study. 
 
We assume the reviewer means amisulpride (not asenapine). As indicated above, we do not 
consider a 4-week trial insufficient to achieve remission. To wit, 56% of patients reached 
remission during those weeks, more than was initially assumed on the basis of prior data. It is 
unclear what the reviewer considers a full trial.  
 
10. A variety of clinical scales were used including the SWN, CDSS, and PSP. However, no data is 
provided for these measures or their change during the different phases of the study.  
 
As indicated in our response to the editor, these data are not yet available. 
 
11. Rates of EPS and sexual side effects during open label amisulpiride treatment were very 
high. The 2013 metaanalysis by Leucht et al. in Lancet also found amisulpiride to have amongst 
the largest effects on QTc. Does this not raise questions about whether amisulpiride should be 
considered as the ideal first line treatment for a first episode of schizophrenia? 
 
We never make the claim in our paper that amisulpride is the ‘ideal’ first line treatment for 
schizophrenia. We chose the drug on the basis of the efficacy and side-effect data from the 
Eufest trial. 
 
12. Twelve patients decided not to continue into the 12-week open label Phase III for various 
reasons and 10 dropped out during Phase 3. It would be important to know whether these 
individuals were followed and how their improvement compared with those who were treated 
with clozapine. 
None of the phase II non-remitters who decided not to continue into phase III, attended the 74 
week post-baseline follow-up visit, so no information is available on their illness progression. 
Only two of the phase III drop outs attended the 74 week visit, both were not meeting remission 
criteria at the time. As this data is very scarce and therefore not very informative, we chose not 
to include this in the manuscript. 
 
13. Those treated with clozapine showed a mean improvement of 18.4 points relative to their 
phase III baseline. However, the change in PANSS shown in Figure 6 for those treated with 
clozapine appears to be much smaller. Figure 6 should be reviewed for accuracy. 
The reason for the difference is that 18.4 points is the difference with baseline within patients 
who completed phase III, while in Figure 6, the data per visit are used: at the baseline, more 
patients have data, than the ones completing phase III. 
   
14. "Extrapolating, these data suggest that if a patient fails to achieve remission on their first 
antipsychotic drug, switching to a different drug is no more effective than remaining on the 
same medication and waiting to see if remission is achieved at a later stage." This conclusion is 
not supported by the results of the study and should be revised.  
 
This is indeed true. That is why we stated in the discussion: 
“Although these results need to be replicated and broadened (using different 
antipsychotics)…….” 
 
The study is remarkable in demonstrating that, using a structured algorithm for treating a first 
episode of schizophrenia, over 75% of patients met criteria for remission within 22 weeks. 
There was no advantage to switching from amisulpiride to olanzapine after four weeks if 
remission had not been achieved. It is not possible to generalize this finding to other 
antipsychotics as amisulpiride and olanzapine were selected due to their comparable and 
superior effectiveness compared to other second generation antipsychotics (SGA) in clinical 
trials and recent meta-analyses. It is not correct to assume that the study results would have 
been the same if another SGA such as risperidone or aripiprazole were to replace amisulpiride 
as the first medication used in the algorithm.  
 
Again, we refer to our response above. We do realize that these results cannot simply be 
broadened to all antipsychotics. That is why we stated in the discussion: 
“Although these results need to be replicated and broadened (using different 
antipsychotics)…….” 
 
In countries where amisulpiride is available, this may be of little consequence since it can be 
argued that amisulpiride should be the first drug tried in the treatment algorithm. It becomes 
relevant if amisulpiride cannot be tolerated by a patient. The implications of this study for the 
treatment of patients in North America, where amisulpiride is not available, are quite different. 
This should be discussed in the Discussion section.  
 
We thought that commenting on the unavailability of amisulpride in the USA and its 
consequences would be belaboring the obvious. We therefore refrained from doing so. 
 
This study in no way addressed the issue of whether switching to olanzapine at 4 weeks or 
following a more extended period of a first line agent might be beneficial as I have explained 
above. This is undoubtedly an important study but it is important that the study results be 
interpreted critically and accurately. 
 
Many authors would argue that 4 weeks is more than adequate to address non-response, as this 
reviewer also suggests by quoting Samara et al, 2015, where it is concluded that 2 weeks is 
adequate to make the decision whether or not the patient has responded to treatment. In fact, 
to quote from that paper: “…. the assessment of final nonresponse at week 4 was associated 
with higher specificity of the diagnostic test than was assessment of nonresponse at week 6 or 
later.” This does suggest that 4 weeks is in fact the right time for an initial trial. 
 
We therefore feel that 4 weeks was adequate. We have therefore added the following sentence 
tot he discussion: 
Fourth, it may be argued that a 4-week trial is not sufficiently long to decide whether to switch 
or not. However, a recent meta-analysis suggests this period is sufficient (22). 
 
15. "this study is the first study to examine the effects of switching …in patients who do not 
respond to their first antipsychotic treatment". This is not accurate. Patients were included in 
Phase II if they failed to meet remission criteria after 4 weeks. This is not the same as response 
as clearly many of these patients were responding but not so rapidly that they met criteria for 
remission after only four weeks of treatment. 
 
In our opinion this statement is correct since there have been no studies examining the effect of 
switching vs. continuation in first-episode schizophrenia. The fact that we defined non-response 
as failure to reach remission does not conflict with that statement. Nevertheless we changed the 
sentence to clarify this issue, as follows: 
“To our knowledge, this is the first study to examine the effects of switching antipsychotics in 
patients with (first-episode) schizophrenia who do not respond to their initial antipsychotic 




16. Reference 14 is not correct. 
This is a review article; this may have been unclear. We have changed the sentence as follows:  
 
“Moreover, the single study in first-episode schizophrenia did not assess whether switching was 
more effective than staying on the original treatment (for review see14)).” 
 
17. "…it may be feasible to define non-response on the basis of a single course of antipsychotic 
treatment." While this may be the case, the current study does not provide support for this for 
the reasons articulated in Points 7-9 above. 
 
The reviewer is right that we should have used non-remission instead of non-response. We have 
therefore changed the sentence as follows: 
 
"…it may be feasible to define non-response (operationalized as failure to achieve remission) on 
the basis of a single course of antipsychotic treatment." 
 
18. No information was provided about rates of smoking. This is an issue for both dosing of 
olanzapine and clozapine as smoking induces cytochrome P450A12. This may have led to under-
dosing of olanzapine which may have biased the results in favor of amisulpiride. 
 
Smoking status was not assessed. However, as we reported, doses of olanzapine were actually 
numerically HIGHER in the non-remitters. Thus, under-dosing is an unlikely explanation of non-
remission (as we had stated in the discussion). 
 
“Critically, the doses in remitters and non-remitters were similar, with those in the non-remitters 
numerically higher in all phases for all drugs, suggesting that non-remission was not 
attributable to underdosing.” 
 
 
Reviewer #5: Please address the following: 
 
The MS is rather poorly written, particularly in its persistent alternating of terms such as 
improvement, response and remission, when the trial examined only remission. 
 
We have addressed this throughout the manuscript. 
 
The definition of remission should be more explicit. 
 
We could not have been more explicit than we were, stating in the Method section: 
Symptomatic remission was defined according to the criteria of Andreasen: eight specific 
symptoms rated by the PANSS (items P1, P2, P3, N1, N4, N6, G5 and G9) are at the most only 
mildly present (maximum rating of ‘3’), meaning that they do not interfere with daily life 
functioning.15 
 
Many people not reaching 'remission' would have palpably improved. This is important in phase 
II - I suspect all of the amisulpride remitters in this phase were improvers in Phase I. 
 
This may certainly be true. However, the main objective of this study was to adhere to a far 
more stringent outcome than just improvement –because it is considered clinically more 
relevant; that is why we chose to use remission as an outcome. To further clarify this, we added 
the following to the introduction: 
 
“Another aspect that has often been lacking in treatment studies in schizophrenia is a clinically 
relevant outcome measure. Generally, response to treatment has been defined as a reduction in 
the Positive and Negative Syndrome Scale (PANSS) total score of >20% but it has been argued 
that a more stringent outcome is ‘remission’, analogous to cancer treatment and reflecting an 
almost complete absence of the psychotic symptoms of schizophrenia.3 This measure is clinically 
relevant and useful as an outcome in clinical trials.4,5 ” 
 
I do not agree that adverse effects were as expected: amisulpride seems much more 'atypical' 
than olanzapine in terms of movement disorders - a strange finding.  
 
In fact, we proposed an explanation for this ‘strange’ finding. We stated: 
 
In phase II, side effects were more prominent in the patients on olanzapine compared to 
amisulpride: this may have been because those intolerant to amisulpride had dropped out in the 
earlier phase or had developed tolerance. 
 
Note spelling of akathisia. 
‘Akathesia’ has been adjusted to ‘akathisia’ in the applicable table. The data have been checked 
and no errors were found. 
 
The main finding is that switching to olanzapine is a waste of time. This is not mentioned in the 
abstract. It is a crucial finding. 
 
This conclusion in our opinion (and that of reviewer 4) seems a bit too broad. Since we only 
tested olanzapine vs amisulpride in this study, such a sweeping conclusion is not supported by 
our results. We therefore did not alter our conclusion.  
 
Other studies (Lieberman) show patients reaching improvement thresholds for a year after 
treatment initiation.  Was each phase long enough? 
 
We (had) addressed this as follows: 
“Moreover, because we only followed patients on clozapine for 12 weeks, and the full treatment 
response may take several months to materialize, remission rates may have improved further 
had we followed our patients for longer.18” 
 
We added to the Discussion: 
 
“Fourth, it may be argued that a 4-week trial is not sufficiently long to decide whether to switch 
or not. However, a recent meta-analysis suggests this period is sufficient (22).” 
 
Remission rates do not start at zero on two graphs. 
The reviewer is right, however the first time point in these graphs is after the visit in which 
inclusion in the phase was determined, so some patients already were in remission at the first 
visit.  
 
What is the evidence that amisulpride has less serious adverse effects? 
 
We added to the Introduction: 
“Although both drugs have multiple side-effects, in the case of amisulpride these are mostly 
limited to extrapyramidal symptoms and hyperprolactinaemia (although QTc prolongation can 
occur at higher doses), while those associated with olanzapine increase the risk of 
cardiovascular complications - and are therefore more serious in the long term than those 
associated with amisulpride6. It would therefore make sense to initiate treatment with 
amisulpride.”  
 
Findings of the Howes paper are mis-stated.  
 
This was changed, also in response to reviewer 4. We now state: 
However, in clinical practice the interval between the onset of treatment and the initiation of 
clozapine is as long as 10-12 years.10 
 
Make a statement about capsule opacity. 
This information has been added to the Methods section: ‘Blinding was achieved by 
overencapsulating two 2.5 mg olanzapine tablets or one 200 mg amisulpride tablet into one 
capsule, utilizing the same manufacturing process to ensure that appearance, shape, smell, 
mass and taste of the opaque capsules were indistinguishable.’ 
 1 
The OPTiMiSE trial: a three-phase, double blind randomised switching study in first episode 
schizophrenia and schizophreniform disorder comparing amisulpride and olanzapine followed 
by open treatment with clozapine. 
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Research in context 
 
Evidence before this study 
There is no established treatment algorithm for patients with schizophrenia. Fundamental 
questions about its treatment, such as whether switching antipsychotics improves outcome, 
remain unaddressed. PubMed was searched until Oct 2017 for randomized trials in which 
patients with schizophrenia, schizophreniform, or schizoaffective disorder (any diagnostic 
criteria) had been treated prospectively with a first antipsychotic drug. Nonresponders were 
subsequently randomized to either switching the antipsychotic or another pharmacological 
strategy. Search terms used were schizophreni* AND (antipsychot* OR neurolept* OR drug 
OR treat*) AND (switch* OR alternative* OR consecutive* OR subsequent OR shift OR 
change) AND (nonrespon* OR not respon* OR fail OR resistant* OR refract* OR ineffect*), 
article types “clinical trials” or “randomized controlled trials”. 
 
Added value of this study 
This is the first study examining the relevance of switching antipsychotic medication in 
patients with first-episode schizophrenia who have not responded to their initial course of 
treatment. 
 
Implications of all the available evidence 
The results suggest that in the large majority of patients in the early stages of schizophrenia, 
symptomatic remission can be achieved using a simple treatment algorithm comprising the 







It is not known whether switching antipsychotics or early use of clozapine improves outcome 
in (first-episode) schizophrenia.  
 
Methods 
The study was conducted in 27 centres in 14 European countries and Israel consisting of 
general hospitals and psychiatric specialty clinics. (Clinicaltrials.gov identifier is 
NCT01248195NCT01555814). Patients with schizophrenia or schizophreniform disorder 
were treated for four weeks with up to 800 mg/day amisulpride in an open design. Patients 
who did not meet symptomatic remission criteria at four weeks were randomized to continue 
amisulpride or switch to olanzapine (max 20 mg/day) during a six-week double blind phase. 
Patients who were not in remission at ten weeks were given clozapine (max 900 mg/day) for 
an additional 12 weeks in an open design. Data were analyzed using a generalised linear 
mixed model, with a logistic link and binomial error distribution.  
 
Findings 
Participants were recruited between May 26, 2011 and May 15, 2016 with 481 signing 
informed consent. Of the 446 patients in the ITT sample, 371 (83.2%) completed open 
amisulpride treatment, of whom 250 (56.167.4%) were in remission. 93 of the patients who 
were not in remission continued to the six-week double-blind switching trial with 72 patients 
(77.4%) completing it (39 on olanzapine and 33 on amisulpride); 15 (45.5%) of the patients 
taking amisulpride reached remission versus 17 (43.6%) on olanzapine (p=.879). Of the 40 
patients who were not in remission after 10 weeks of treatment, 28 (70.0%) were started on 
clozapine; 18 patients (64.3%) completed the 12-week treatment, of whom five (17.927.8%) 
met remission criteria. 
 
Interpretation 
In the large majority of patients in the early stages of schizophrenia, symptomatic remission 
can be achieved using a simple treatment algorithm comprising the sequential administration 
of amisulpride and clozapine.  
Employing a treatment algorithm with a single antipsychotic for ten weeks and subsequent 
use of clozapine, remission can be achieved within 22 weeks in over three quarters of patients 
 4 
with first-episode schizophrenia who complete treatment and almost two thirds of patients in 













While effective antipsychotic medications have been available for over half a century, the 
application and implementation of these treatments is far from optimal. In particular, there is 
no established treatment algorithm for the use of antipsychotics in schizophrenia. In clinical 
practice, when a patient has not responded to the initial treatment, they are often switched 
from one antipsychotic medication to another. However, there is surprisingly little evidence 
that this improves clinical outcomes. Indeed, one of the most relevant questions in the 
treatment of the early phase of schizophrenia – and an essential ingredient in any treatment 
algorithm - is whether switching to another antipsychotic improves outcome when a patient 
has not responded to the treatment that was initiated. 
 
Another aspect that has often been lacking in treatment studies in schizophrenia is a clinically 
relevant outcome measure. Generally, response to treatment has been defined as a reduction 
in the Positive and Negative Syndrome Scale (PANSS) total score of >20% but it has been 
argued that a more stringent outcome is ‘remission’, analogous to cancer treatment and 
reflecting an almost complete absence of the psychotic symptoms of schizophrenia.
1
 This 
measure is clinically relevant and useful as an outcome in clinical trials.
2,3  
 
In a previous clinical trial, we found that amisulpride and olanzapine were comparably 
effective in the treatment of first episode schizophrenia
4
 despite their different receptor-
binding profiles
5-8
. These results are consistent with those of meta-analyses comparing the 
efficacy of antipsychotics in the treatment of schizophrenia
9-11
. In treatment algorithms, given 
equal effectiveness, one would choose to initiate treatment with the least toxic medication. 
Although both drugs have multiple side-effects, in the case of amisulpride these are mostly 
limited to extrapyramidal symptoms and hyperprolactinaemia (although QTc prolongation 
can occur at higher doses), while those associated with olanzapine increase the risk of 
cardiovascular complications - and are therefore more serious in the long term than those 
associated with amisulpride
9






In the minority of patients with schizophrenia who do not respond to antipsychotic 
medication, the intervention best supported by evidence is treatment with clozapine.
12
 Current 
guidelines therefore recommend that clozapine be offered to patients who have not responded 
to two different antipsychotics, given at adequate doses for at least six weeks each. In theory, 
a first episode patient could therefore receive clozapine within 12 weeks after the start of 
treatment. However, in clinical practice the interval between the onset of treatment and the 




The present study addressed two key issues: 1) In first-episode patients who do not respond to 
their first trial of antipsychotic medication, is switching to another antipsychotic effective?  2) 
Can earlier treatment with clozapine improve outcome in patients who have not remitted after 
10 weeks of antipsychotic treatmenta simple treatment algorithm facilitate the earlier 







The study comprised a combination of treatment designs: the first phase consisted of an open-
label single-treatment arm, followed by a randomized, double blind phase. The third and final 
phase was again an open-label single-treatment arm. The study was conducted in 27 centres 
located in 14 European countries (Austria, Belgium, Bulgaria, Czech Republic, Denmark, 
France, Germany, Italy, the Netherlands, Poland, Romania, Spain, Switzerland and the United 
Kingdom) and Israel, consisting of general hospitals and psychiatric specialty clinics. Each 
country obtained ethics approval. The trial complied with the Declaration of Helsinki.
14
 The 
University Medical Center Utrecht monitored the trial according to Good Clinical Practice 
and International Conference on Harmonization guidelines.
15




Patients were recruited at the participating hospitals, from nearby healthcare facilities and 
through public advertisements. Eligible patients were aged 18–40 years and met criteria of the 
Diagnostic and Statistical Manual of Mental Disorders (fourth edition) for schizophrenia, 
schizophreniform disorder, or schizoaffective disorder; diagnoses were confirmed by the Mini 
International Neuropsychiatric Interview plus (MINI-plus).
16
 Female patients of childbearing 
potential were required to use a proper method of contraception. Patients were excluded if the 
time interval between the onset of psychosis and study entry exceeded two years; if any 
antipsychotic medication had been used for more than two weeks in the previous year and/or 
for a total of six weeks or more in their lifetime; if patients had a known intolerance to one of 
the study drugs; if patients met any of the contraindications for any of the study drugs as 
mentioned in the (local) package insert texts; if patients were coercively treated and/or 
represented by a legal guardian or under legal custody; or if patients were pregnant or breast 
feeding. All study participants provided written informed consent. 
 
Randomisation and masking 
The study design is shown in Figure 1 and described earlier in detail by Leucht and 
colleagues, including references for the scales used.
17
 
The trial was divided into three treatment phases; patients were eligible for participation in the 
subsequent phase if they did not meet criteria of ‘symptomatic remission’ at the end of the 
 8 
previous phase. ‘Symptomatic remission’ is based on the Andreasen criteria of remission, 
including the same items on the Positive and Negative Syndrome Scale. However, in contrast 
to the Andreasen criteria, the minimum duration of six months concerning the symptom 
severity was not applied.
1 
All patients started with a four-week open label treatment with 
amisulpride 200-800 mg/day (Phase I). At the start of phase II, non-remitters from phase I 
were randomized 1:1 to double blind flexible dose treatment with olanzapine (5-20 mg/day) 
or amisulpride (200-800 mg/day). A randomisation table was generated by the Data 
Management department of the Julius Center, University Medical Center Utrecht, the 
Netherlands, using VB.Net with access to a SQL Server back end database. Study medication 
was packaged-in line with this randomisation table, using sequentially numbered kits. 
Randomization was performed online by a randomization website, also developed by the 
Julius Center, which provided the applicable kit number only. The application 
implemented stratification by site and gender, and applied the minimization method for 
randomization. The data management group was not involved in patient recruitment, which 
was conducted at each participating center. The complete study teams at each center as well 
as the participating patients were blind to treatment allocation. Blinding was achieved by 
overencapsulating two 2.5 mg olanzapine tablets or one 200 mg amisulpride tablet into one 
capsule, utilizing the same manufacturing process to ensure that appearance, shape, smell, 
mass and taste of the opaque capsules were indistinguishable. Olanzapine and amisulpride 
were purchased commercially and overencapsulated by Piramal Healthcare UK. Patients as 
well as study team members were masked to group assignment of each individual participant. 
Non-remitters in phase II continued into 12-week open label treatment with clozapine 100-
900 mg/day (phase III).  
Blood was drawn at the beginning and end of each treatment phase in order to relate 
proteomics, immune parameters and genetics to treatment outcome. In addition, patients who 
had remitted were randomised to a specific psychosocial intervention versus treatment as 
usual with the goal to improve adherence. The results from these studies are not yet available 
and will be reported separately. Finally, MRI and MRS assessments were conducted in a 
subsample of participants.” 
 
Procedures 
After signing informed consent, the screening visit was conducted during which eligibility 
was assessed. Baseline data was obtained regarding demographics, diagnoses, present 
treatment setting, psychopathology (Positive and Negative Syndrome Scale; PANSS), 
 9 
severity of illness (Clinical Global Impression; CGI), depression (Calgary Depression  Scale 
for Schizophrenia; CDSS), personal and social functioning (Personal and Social Performance 
scale; PSP), subjective wellbeing (Subjective Wellbeing under Neuroleptic use; SWN), 
adverse effects (Udvalg for Kliniske Undersogelser; UKU), and alcohol and drug use. 
Frequency and severity of adverse events were assessed at each visit. In addition, weight, 
abdominal circumference and height were measured and an electrocardiogram was done as 
per amisulpride Summary of Product Characteristics. Data was collected at baseline and after 
1, 2, 4, 6, 8, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 and 22 weeks, for most or all of the 
efficacy, safety and tolerability outcomes. Patients who did not meet remission criteria after 
completion of phase III, returned for a follow-up visit 48 weeks after baseline (26 weeks after 
the final phase III visit), where PANSS was assessed and rehospitalisation data was collected. 
For all patients who started phase I, a follow-up visit at 74 weeks post-baseline was scheduled 




The primary outcome measures were the symptomatic remission rates at the final visits of 
phase I (after four weeks of open treatment with amisulpride), phase II (after six weeks of 
double-blind treatment with amisulpride or olanzapine, comparison between arms) and phase 
III (after 12 weeks of open label treatment with clozapine). If remission criteria were met, the 
patient had completed the trial. If they were not met, the patient progressed to the next phase. 
Symptomatic remission was defined according to the criteria of Andreasen: eight specific 
symptoms rated by the PANSS (items P1, P2, P3, N1, N4, N6, G5 and G9) are at the most 
only mildly present (maximum rating of ‘3’), meaning that they do not interfere with daily life 
functioning.
15
 All raters were certified through a standardised PANSS training and 
examination, provided by the sponsor. Halfway through the study, an inter-rater reliability 
assessment was conducted across all sites (ICC=0.82). 
The main secondary outcome measure was a comparison between amisulpride and olanzapine 
on all-cause treatment discontinuation. Other secondary outcomes include the severity and 
improvement scores of the CGI, levels of depression (CDSS), personal and social functioning 
(PSP) and subjective wellbeing (SWN). Safety outcomes include the UKU side effects rating 




Data of the EUFEST study
4
 showed that about 40% of the patients on amisulpride were in 
symptomatic remission within four weeks. However, halfway through the study almost 60% 
of phase I patients met remission criteria. Subsequently, the power analysis was adjusted to 
the following:    based on EUFEST we expect that 50% of the four-week non-responders who 
stay on amisulpride will be in symptomatic remission after another six weeks of treatment (10 
weeks from treatment initiation). If the percentage of patients in remission increases from 
50% to 70% as a result of switching to olanzapine (which is an estimation, as there are no 
prior studies on this topic), the two treatment arms will have to contain 90 patients each to 
obtain a statistical power of .79 with a type-I error rate of .05. If we consider that the drop out 
rate is approximately 30% and the remission rate 60% (both observations after 250 patients 
had been enrolled into the study), than this implies that at least 487 patients will have to be 
included at baseline, taking into account a drop-out of 30% during phase II (observation in 
first 50 phase II patients).  
Remission, as assessed at the final visit of each phase, was first summarized as counts and 
percentages. Subsequently, remission at each visit was analysed using a generalised linear 
mixed model (GLMM), with a logistic link and binomial error distribution. Variables 
included were visit number as a categorical variable and the baseline PANSS score as a 
continuous covariate. In this way, all visits contributed to the estimate of the between patient 
variance, thereby making the estimate of remission at the final visit more robust while 
accounting for dropout. For phase II a comparison was made between the amisulpride and 
olanzapine arm, by including the treatment arm as a factor in the GLMM. The cumulative 
proportion of patients in remission over all three study phases was calculated using the 
number of patients in remission at the last visit of each phase, i.e. the phase completers in 
remission. We used the conservative assumption that dropouts within a phase did not reach 
remission throughout the study. Patients eligible for a next study phase, but not continuing 
into that phase, were assumed not to be different from patients who did continue. To assess 
the proportion of dropouts over time, a Kaplan Meier curve was used. Follow-up time was 
defined as the number of weeks between the date of the baseline visit and the date of the last 
visits of a patient. Patients who did not progress to a next phase because they were in 
remission were censored. Side effects were summarized per visit and per phase and expressed 
as percentages. Missing values were not imputed, as the GLMM analysis incorporates all 
available measurements, assuming that patients with available measurements are 
representative for all patients, including the patients with missing values. For side effects, we 
assumed that missing values indicated absence of side effects. All quantitative scores, 
including the PANNS, were summarized as means and standard deviation and differences 
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between groups were assessed by a t-test. Dichotomous variables were expressed as counts 
and percentages and differences between groups were assessed by Chi square tests. 
Differences between groups in proportions were calculated and a 95%CI according to 
Wilson’s method. In all analyses, the criterion for statistical significance was P < 0.05. SPSS 
version 25 was used for all analyses. A Data Safety Monitoring Board oversaw the study. 
 
Role of the funding sources 
The funder of the study (FP7 EU) had no role in study design, data collection, data analysis, 
data interpretation, or writing of the report. The corresponding author had full access to all the 






Participants were recruited between May 26, 2011 and May 15, 2016. The final study visit 
took place on November 1, 2017. The trial was stopped on May 15, 2016, as the project end 
date was reached. Figure 2 shows the trial profile. 481 patients signed informed consent. In 16 
patients (3.3%), the diagnosis could not be confirmed. Another 19 (4.0%) dropped out before 
the baseline visit for various reasons (n=7 screen failure; n=1 discontinuation of pre-existing 
antipsychotic unsuccessful; n=1 involuntary hospital admission; n=1 physician decision; n=9 
changed their mind). Thus, 446 patients (92.7%) met diagnostic criteria and initiated the first 
phase: four-week open label treatment with amisulpride 200-800 mg daily. Baseline 
characteristics are displayed in Table 1 for the Intent To Treat (ITT) sample (n=446), as well 
as the subgroups of patients who continued into the subsequent treatment phase II (n=93) and 
phase III (n=28).  
 
Phase I (4-week open amisulpride) 
Out of the 446 patients in the ITT sample who initiated the open label amisulpride treatment 
phase, 371 completed the four-week treatment (83.2%). A total of 250 patients met remission 
criteria at end of phase I, a remission rate of 67.4% amongst completers. The remission rate 
within the whole ITT sample (n=446) was 56.1%, when patients without a known remission 
status at the end of phase I were categorized as non-remitters. Figure 3 shows the remission 
rates over the course of phase I. Symptom scores and changes in weight are shown in Table 4. 
 
There was no significant difference between remitters and non-remitters in gender (30.4% 
versus 24.0% female respectively, P=.20), but they did differ in age (26.3 [SD 6.3] vs 24.5 
[SD 5.4] years respectively; p=.004); duration of the current psychotic episode (6.0 [SD 6.0] 
vs 7.7 [SD 7.0] months respectively, p=.025) and age at onset (25.9 [SD 6.3) and 23.8 [SD 
5.4] years, respectively p=.001).  
 
The mean amisulpride dose at the end of Phase I was 490.4 mg/day (SD 207.4); in the 
remitters it was 463.8 mg/day (SD 196.0) and 535.2 md/day (SD 209.2; p=.001) in the non 
remitters. Remitters were more likely to have a diagnosis of schizophreniform disorder 
(44.0% versus 33.1% for non-remitters, p=.044) and less likely to have a diagnosis of 
schizophrenia (52.0% versus 71.1% for non-remitters, p<.001). No differences in alcohol 
dependency or substance abuse were found. 
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Phase II (6-week double blind switching vs continuation) 
Of the 121 non-remitters at the end of phase I, 93 (76.9%) continued to phase II, in which 
they were randomized 1:1 to 6 weeks of continued treatment with amisulpride (n=47), or they 
were  switched to 6 weeks of treatment with olanzapine (n=46). 28 phase I non-remitters 
decided not to continue into phase II for various reasons (refer to Figure 2); this subgroup had 
a shorter duration of illness (5.6 [SD 5.3] months versus 8.4 [SD 7.3] months, respectively; 
p=.040) than those who initiated phase II treatment, but there were no significant differences 
in gender, age, diagnosis, or alcohol / substance abuse. Baseline characteristics of the 93 
patients for the two treatment groups are depicted in Table 5. There were no statistically 
significant differences in proportion or means between the two randomized groups. 
 
Of the 93 patients randomized, 72 completed phase II (77.4%): 33 taking amisulpride versus 
39 taking olanzapine. At the end of phase II, 32 patients met remission criteria, an overall 
remission rate amongst completers of 44.4%. Within the IIT sample, the remission rate was 
35.5%. Remission rates per treatment arm over the phase II visits are depicted in Figure 4. 
There was no significant difference in remission rate between the two treatment arms: the rate 
for amisulpride was 45.5% (n=15) versus 43.6% (n=17) for olanzapine (P=.87). Symptom 
scores and changes in weight are shown in Table 4. The mean dose of amisulpride at the end 
of Phase II was 590.9 mg/day (SD 236.1); remitters 586.7 mg/day (SD 220.0), non remitters 
600.0 mg/day (SD 237.6; p=.87) The mean dose of olanzapine at the end of Phase II was 15.6 
mg/day (SD 6.5); remitters 14.4 mg/day (SD 5.6), non-remitters 17.5 (SD 6.3; p=.12). 
 
A logistic generalized linear model was used to analyze the remission data using all three 
repeated PANSS assessments, while adjusting for the PANSS score at the start of phase II 
(week four; phase II baseline). The odds ratio for meeting remission criteria at the end of 
phase II for amisulpride relative to olanzapine was 1.07 (95% CI: 0.38 to 2.96). Using a linear 
mixed model, PANSS scores at the end of phase II were compared between treatment groups, 
again adjusting for the PANSS score at the start of phase II (phase II baseline). The reduction 
in PANSS score was not significantly different between treatments; the phase II baseline-




Dropout rates between the two treatment arms did not differ significantly, although there was 
a trend in favor of olanzapine; 29.8% of patients randomized to amisulpride dropped out 
(n=14) versus 15.2 % (n=7) on olanzapine, a difference of 14.5%, 95%CI -2.5% to 30.7%  
(p=.093). Patients treated with olanzapine gained significantly more weight than patients 
treated with amisulpride: 4.40 (SD 3.65) kg versus 2.29 (SD 3.07) kg (P=.021). Otherwise, 
the two treatment arms did not differ on the incidence of side effects, corrected for phase II 
baseline assessments.  
   
Phase III (12-week open clozapine) 
Of the 40 phase II non-remitters, 12 patients (30.0%) decided not to continue into the 12-
week open label phase III for various reasons (refer to Figure 2). A further ten patients 
dropped out during phase III (drop-out rate during phase III 35.7%), leaving a total of 18 
patients who completed the clozapine treatment. Five patients met remission criteria, resulting 
in a remission rate of 27.8% among those who completed treatment. Within the IIT sample 
(which classified dropouts as not meeting remission criteria), the remission rate was 17.9%;  
 
Despite the relatively low remission rate, patients demonstrated symptom improvement 
during clozapine treatment, as shown in Figure 6. The phase III completers improved a total 
of 24.9 points on the PANSS score relative to study baseline (visit 2: p<.001) and 18.4 points 
relative to the phase III baseline (at week ten: p=.002). The mean dose of clozapine at the end 
of Phase III was 279.0 mg/day (SD 130.2); remitters 280.0 mg/day (SD 115.1), non remitters 
317.3 (SD 146.7; p=.62). Clozapine blood concentration was assessed at the end of phase III. 
Remitters (n=5) had a mean clozapine blood concentration of 321 ng/ml (SD 226), non-
remitters (n=13) had a mean clozapine concentration of 350 ng/ml (SD 391). 
 
Phase I-III 
Out of the 446 patient who initiated the first treatment phase, a total of 287 patients met 
remission criteria at one of the three treatment phases, adding up to an overall remission rate 
of 64.3% after a maximum of 20 treatment weeks. The cumulative remission rate based on the 
completers of the three phases was 76.4%. Figure 6 shows a steady decline in the mean total 
PANSS scores over the course of each individual treatment phase. In supplemental Figure 1, 
the Kaplan-Meier curve for dropout over time is depicted. After 20 week of follow-up, the 
proportion still under study, censoring for remission, was still 0.651. 
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The mean doses of amisulpride, olanzapine and clozapine in the three treatment phases are 
included in Table 2; for drop outs, the dose at the last visit has been used. The use of 
concomitant medication in each phase is shown in Table 3. 
 
Sexual dysfunction and extrapyramidal symptoms are reported in Table 4. Weight changes 
included in Table 4 are relative to the baseline of the corresponding study phase. An extensive 
report of all side effects reported is provided in a table in the appendix. The incidence of 
Serious Adverse Events did not differ between the treatment arms in phase II: one patient 
randomized to olanzapine was hospitalized due to an epileptic seizure, and one patient 
randomized to amisulpride was hospitalized twice during phase II due to exacerbations of 
psychotic symptoms. Over the course of the trial, two serious suicide attempts were reported. 
One resulted in the only death during the trial, seven days after discontinuing amisulpride. 
The other attempt was during amisulpride treatment in phase I.  
 
48-week follow-up visit 
For patients who did not meet remission criteria after completion of phase III, a follow-up 
visit was scheduled, 48 weeks post- baseline (26 weeks after the final phase III visit). Out of 
the 11 non-remitters at the end of phase III, 8 patients returned for this visit. The mean total 
PANSS score was 70.5 (SD 22.3), ranging from 40 to 104. Three patients met remission 
criteria during this visit. None of the patients were rehospitalised since the end of phase III. 
 
74-week follow-up visit 
For all patients who entered phase I, a follow-up visit was scheduled 74 weeks post-baseline. 
This visit was conducted for 167 patients. The diagnosis at that time point was established: 13 
patients (7.8%) were diagnosed with schizophreniform disorder, 22 patients (13.2%) with 
schizoaffective disorder, 123 patients (73.7%) with schizophrenia and 9 patients (5.3%) 
received other diagnoses (e.g. psychosis NOS, bipolar disorder, unspecified non-organic 
psychosis). PANSS data was available for 140 patients; the mean total PANSS score was 50.2 
(SD 15.0, range 30-105). 95 patients (56.9%) met remission criteria. Seventeen out of 140 





Our first major finding is that switching from amisulpride to olanzapine in first-episode 
schizophrenia did not improve clinical outcome. In fact, of the 93 patients who were 
randomized an almost equal proportion (45%) achieved remission whether they continued 
treatment with amisulpride or were switched to olanzapine. Moreover, the clinical outcome in 
the two groups was also similar when this was defined in terms of symptomatic improvement 
(as a continuous variable). Extrapolating, these data suggest that if a patient fails to achieve 
remission on their first antipsychotic drug, switching to a different drug is no more effective 
than remaining on the same medication and waiting to see if remission is achieved at a later 
stage.  
 
To our knowledge, this is the first study to examine the effects of switching antipsychotics in 
patients with (first-episode) schizophrenia who do not respond to their initial antipsychotic 
treatment (response has been defined differently in the various studies; we used remission in 
the current study). With the exception of one study, all previous studies were conducted in the 
later, chronic, stage of the illness. Moreover, the single study in first-episode schizophrenia 





 compared risperidone and olanzapine in 287 patients with 
first-episode schizophrenia in a non-randomized, open design, with the patient’s clinician 
selecting which medication was used first. Response was defined as much improved or better 
on the CGI. Patients who failed to meet response criteria after four weeks were switched to 
the other antipsychotic; thus switching versus staying on the first medication was not 
examined. Clozapine was given when there was no response to both antipsychotics. In that 
study, 75% of patients met response criteria after four weeks, with more responding to 
olanzapine (82%) than to risperidone (66%). In the second phase of the study, response rates 
dropped to 17%, with olanzapine again doing better than risperidone. Important differences 
compared to the present study were that the first antipsychotic was selected by the treating 
clinician, the definition of response was less stringent, and switching was open. Moreover, it 
is unclear whether data were analysed on the basis of completers only or whether an ITT 
analysis was done.  
 
The only double-blind study that compared switching versus continuation in non-responders 
was conducted in patients with chronic schizophrenia (age around 42 years). Response in the 
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first two weeks was defined as ≥20% reduction in total PANSS scores. This corresponds to a 
lesser degree of clinical improvement than the symptomatic remission criterion used in the 
present study.
19 
Patients who did not respond to a two-week open trial with risperidone (2-6 
mg/day) were randomized to either continuing on risperidone or were switched to olanzapine 
(10-20 mg/day). Switching resulted in a small but significantly greater reduction in total 
PANSS scores after four weeks. However, response in the first two weeks was defined as 
≥20% reduction in total PANSS scores. This corresponds to a lesser degree of clinical 




In the current study, after ten weeks of treatment most of the patients were either in 
symptomatic remission or had dropped out, leaving only 28 of the initial 446 patients (6.3%) 
eligible for switching to clozapine. Although only five patients treated with clozapine reached 
remission, there was still a substantial symptomatic improvement in the sample overall, with 
an average reduction in total PANSS scores of more than 18 points. These results suggest that 
providing clozapine early in the treatment of patients with first episode schizophrenia may 
result in clinical improvement, even if this is short of full symptomatic remission. Moreover, 
because we only followed patients on clozapine for 12 weeks, and the full treatment response 
may take several months to materialize, remission rates may have improved further had we 




Symptomatic remission rates in our study were high: after only four weeks of (open) 
treatment with amisulpride, 56% of all 446 patients had reached remission, even when 
assuming that all drop outs were non-remitters; the remission rate increased to 67% when the 
analysis was restricted to patients who completed the initial 4-week treatment period. This 
proportion is impressive for two reasons: first, it corresponds to clinical remission, and not 
just a numerical reduction of symptoms on a rating scale; second, remission was achieved 
after only four weeks of treatment. Our results therefore suggest that a majority of patients 
show a clinically meaningful improvement after only a few weeks of treatment - corroborated 
by the reduction in the Clinical Global Improvement scale. An additional six weeks of 
treatment led to more improvement, with a further 45% of patients (in both arms) achieving 
remission. However, because this was based on a smaller sample (due to the high initial 
remission rate and the drop out between phases), the total remission rate in completers 
calculated from baseline at the end of Phase II was 65%. Additional treatment with clozapine 
increased the cumulative remission rate to 76% - again assuming all drop-outs did not achieve 
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remission. This indicates that for the large majority of patients with first episode of 
schizophrenia, a rapid and (almost) complete symptomatic recovery can be expected with 
antipsychotic treatment. The high and rapidly occuring symptomatic response found here is 
consistent with results reported in other studies in first episode schizophrenia.
21,22
 
Nevertheless, some first-episode patients will respond only after continuous treatment lasting 




The doses of antipsychotics used in the present study are consistent with those generally 
administered in first episode schizophrenia; amisulpride was given in a mean dose of 591 
mg/day, olanzapine 15.6 mg/day and clozapine 279 mg/day (with blood levels a little under 
350 ng/L). Critically, the doses in remitters and non-remitters were similar, with those in the 
non-remitters numerically higher in all phases for all drugs, suggesting that non-remission 
was not attributable to underdosing. Similarly, although the clozapine dose given was 
relatively low (280-300 mg/day), blood levels in the non-remitters were adequate (> 350 
ng/L), so the low remission rate is unlikely to be related to inadequate dosing. Moreover, the 
clozapine dose we used was comparable to that given in the first-episode study by Lieberman 
et. al.
20
 where 80% of patients on clozapine reached remission.  
 
Side effects were as expected: amisulpride was associated with extrapyramidal side effects 
and those related to increased prolactin levels; olanzapine and clozapine induced substantial 
weight gain, even over the relatively short six and twelve-week periods of treatment, 
respectively. In phase II, side effects were more prominent in the patients on olanzapine 
compared to amisulpride: this may have been because those intolerant to amisulpride had 
dropped out in the earlier phase or had developed tolerance. All drugs were associated with a 
substantial gain in weight over the course of treatment, although it was most pronounced on 
olanzapine and clozapine. 
  
The results should be viewed in the context of the study’s limitations. First, the sample in the 
second, randomized phase (II) was relatively modest, comprising 93 patients. This was more 
the result of the high remission rate in Phase I than the number of dropouts, which was less 
than 17%. However, remission rates in the amisulpride and olanzapine arms were virtually 
identical, suggesting a larger sample size may not have changed the results. Second, both the 
initial treatment with amisulpride and the subsequent one with clozapine were open label. 
This may have increased the remission rates in both phases. It was felt though, that the initial 
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treatment should be pragmatic, reflecting clinical reality as much as possible, whereas the 
comparison between two drugs in Phase II needed to be as un-biased as possible and therefore 
double blind. Third, it could be argued that a comparison between continuation with 
amisulpride and switching to clozapine in Phase III would have been of interest; the current 
design cannot address that question. Indeed, whether clozapine has an added benefit over 
continuation with amisulpride after ten weeks of its use needs further study. Fourth, it may be 
argued that a 4-week trial is not sufficiently long to decide whether to switch or not. However, 
a recent meta-analysis suggests this period is sufficient
24
. Finally, although our results show 
that a large majority of first-episode schizophrenia patients reaches remission within a few 





Current guidelines recommend that clozapine should be offered to patients who have not 
responded to treatment with two different antipsychotics. However, if the likelihood of non 
response to one antipsychotic given for a sufficient length of time is similar to that with two 
courses of different antipsychotics, it may be feasible to define non-response (operationalized 
as failure to achieve symptomatic remission) on the basis of a single course of antipsychotic 
treatment, as long as it is given for long enough. Adopting a simpler treatment algorithm with 
one course of antipsychotic treatment would allow these patients to be identified earlier and 
reduce the delay before they can be treated with clozapine.  
 
In summary, our results suggest that switching antipsychotics in minimally treated patients 
with first-episode schizophrenia does not improve outcome in those who are not in 
symptomatic remission after their first antipsychotic regimen. Although switching to 
clozapine early in the treatment did not dramatically improve remission rates, it did result in a 
substantial improvement in symptoms, albeit that many first-episode patients did not tolerate 
the side effects associated with its treatment.  
Employing an algorithm of treatment with a single antipsychotic for up to ten weeks and 
subsequent use of clozapine in non-remitters, remission can be achieved within 22 weeks for 
over three quarters of first-episode patients who complete treatment and for almost two thirds 
of patients where treatment was initiated. Although these results need to be replicated and 
broadened (using different antipsychotics), they suggest that achieving remission in the early 
stages of schizophrenia is possible in the large majority of patients using a simple treatment 
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The OPTiMiSE trial: a three-phase, double blind randomised switching study in first episode 
schizophrenia and schizophreniform disorder comparing amisulpride and olanzapine followed 
by open treatment with clozapine. 
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Research in context 
 
Evidence before this study 
There is no established treatment algorithm for patients with schizophrenia. Fundamental 
questions about its treatment, such as whether switching antipsychotics improves outcome, 
remain unaddressed. PubMed was searched until Oct 2017 for randomized trials in which 
patients with schizophrenia, schizophreniform, or schizoaffective disorder (any diagnostic 
criteria) had been treated prospectively with a first antipsychotic drug. Nonresponders were 
subsequently randomized to either switching the antipsychotic or another pharmacological 
strategy. Search terms used were schizophreni* AND (antipsychot* OR neurolept* OR drug 
OR treat*) AND (switch* OR alternative* OR consecutive* OR subsequent OR shift OR 
change) AND (nonrespon* OR not respon* OR fail OR resistant* OR refract* OR ineffect*), 
article types “clinical trials” or “randomized controlled trials”. 
 
Added value of this study 
This is the first study examining the relevance of switching antipsychotic medication in 
patients with first-episode schizophrenia who have not responded to their initial course of 
treatment. 
 
Implications of all the available evidence 
The results suggest that in the large majority of patients in the early stages of schizophrenia, 
symptomatic remission can be achieved using a simple treatment algorithm comprising the 







It is not known whether switching antipsychotics or early use of clozapine improves outcome 
in (first-episode) schizophrenia.  
 
Methods 
The study was conducted in 27 centres in 14 European countries and Israel consisting of 
general hospitals and psychiatric specialty clinics. (Clinicaltrials.gov identifier is 
NCT01248195). Patients with schizophrenia or schizophreniform disorder were treated for 
four weeks with up to 800 mg/day amisulpride in an open design. Patients who did not meet 
symptomatic remission criteria at four weeks were randomized to continue amisulpride or 
switch to olanzapine (max 20 mg/day) during a six-week double blind phase. Patients who 
were not in remission at ten weeks were given clozapine (max 900 mg/day) for an additional 
12 weeks in an open design. Data were analyzed using a generalised linear mixed model, with 
a logistic link and binomial error distribution.  
 
Findings 
Participants were recruited between May 26, 2011 and May 15, 2016 with 481 signing 
informed consent. Of the 446 patients in the ITT sample, 371 (83.2%) completed open 
amisulpride treatment, of whom 250 (67.4%) were in remission. 93 of the patients who were 
not in remission continued to the six-week double-blind switching trial with 72 patients 
(77.4%) completing it (39 on olanzapine and 33 on amisulpride); 15 (45.5%) of the patients 
taking amisulpride reached remission versus 17 (43.6%) on olanzapine (p=.87). Of the 40 
patients who were not in remission after 10 weeks of treatment, 28 (70.0%) were started on 




In the large majority of patients in the early stages of schizophrenia, symptomatic remission 
can be achieved using a simple treatment algorithm comprising the sequential administration 














While effective antipsychotic medications have been available for over half a century, the 
application and implementation of these treatments is far from optimal. In particular, there is 
no established treatment algorithm for the use of antipsychotics in schizophrenia. In clinical 
practice, when a patient has not responded to the initial treatment, they are often switched 
from one antipsychotic medication to another. However, there is surprisingly little evidence 
that this improves clinical outcomes. Indeed, one of the most relevant questions in the 
treatment of the early phase of schizophrenia – and an essential ingredient in any treatment 
algorithm - is whether switching to another antipsychotic improves outcome when a patient 
has not responded to the treatment that was initiated. 
 
Another aspect that has often been lacking in treatment studies in schizophrenia is a clinically 
relevant outcome measure. Generally, response to treatment has been defined as a reduction 
in the Positive and Negative Syndrome Scale (PANSS) total score of >20% but it has been 
argued that a more stringent outcome is ‘remission’, analogous to cancer treatment and 
reflecting an almost complete absence of the psychotic symptoms of schizophrenia.
1
 This 
measure is clinically relevant and useful as an outcome in clinical trials.
2,3  
 
In a previous clinical trial, we found that amisulpride and olanzapine were comparably 
effective in the treatment of first episode schizophrenia
4
 despite their different receptor-
binding profiles
5-8
. These results are consistent with those of meta-analyses comparing the 
efficacy of antipsychotics in the treatment of schizophrenia
9-11
. In treatment algorithms, given 
equal effectiveness, one would choose to initiate treatment with the least toxic medication. 
Although both drugs have multiple side-effects, in the case of amisulpride these are mostly 
limited to extrapyramidal symptoms and hyperprolactinaemia (although QTc prolongation 
can occur at higher doses), while those associated with olanzapine increase the risk of 
cardiovascular complications - and are therefore more serious in the long term than those 
associated with amisulpride
9






In the minority of patients with schizophrenia who do not respond to antipsychotic 
medication, the intervention best supported by evidence is treatment with clozapine.
12
 Current 
guidelines therefore recommend that clozapine be offered to patients who have not responded 
to two different antipsychotics, given at adequate doses for at least six weeks each. In theory, 
a first episode patient could therefore receive clozapine within 12 weeks after the start of 
treatment. However, in clinical practice the interval between the onset of treatment and the 




The present study addressed two key issues: 1) In first-episode patients who do not respond to 
their first trial of antipsychotic medication, is switching to another antipsychotic effective?  2) 
Can earlier treatment with clozapine improve outcome in patients who have not remitted after 







The study comprised a combination of treatment designs: the first phase consisted of an open-
label single-treatment arm, followed by a randomized, double blind phase. The third and final 
phase was again an open-label single-treatment arm. The study was conducted in 27 centres 
located in 14 European countries (Austria, Belgium, Bulgaria, Czech Republic, Denmark, 
France, Germany, Italy, the Netherlands, Poland, Romania, Spain, Switzerland and the United 
Kingdom) and Israel, consisting of general hospitals and psychiatric specialty clinics. Each 
country obtained ethics approval. The trial complied with the Declaration of Helsinki.
14
 The 
University Medical Center Utrecht monitored the trial according to Good Clinical Practice 
and International Conference on Harmonization guidelines.
15




Patients were recruited at the participating hospitals, from nearby healthcare facilities and 
through public advertisements. Eligible patients were aged 18–40 years and met criteria of the 
Diagnostic and Statistical Manual of Mental Disorders (fourth edition) for schizophrenia, 
schizophreniform disorder, or schizoaffective disorder; diagnoses were confirmed by the Mini 
International Neuropsychiatric Interview plus (MINI-plus).
16
 Female patients of childbearing 
potential were required to use a proper method of contraception. Patients were excluded if the 
time interval between the onset of psychosis and study entry exceeded two years; if any 
antipsychotic medication had been used for more than two weeks in the previous year and/or 
for a total of six weeks or more in their lifetime; if patients had a known intolerance to one of 
the study drugs; if patients met any of the contraindications for any of the study drugs as 
mentioned in the (local) package insert texts; if patients were coercively treated and/or 
represented by a legal guardian or under legal custody; or if patients were pregnant or breast 
feeding. All study participants provided written informed consent. 
 
Randomisation and masking 
The study design is shown in Figure 1 and described earlier in detail by Leucht and 
colleagues, including references for the scales used.
17
 
The trial was divided into three treatment phases; patients were eligible for participation in the 
subsequent phase if they did not meet criteria of ‘symptomatic remission’ at the end of the 
 8 
previous phase. ‘Symptomatic remission’ is based on the Andreasen criteria of remission, 
including the same items on the Positive and Negative Syndrome Scale. However, in contrast 
to the Andreasen criteria, the minimum duration of six months concerning the symptom 
severity was not applied.
1 
All patients started with a four-week open label treatment with 
amisulpride 200-800 mg/day (Phase I). At the start of phase II, non-remitters from phase I 
were randomized 1:1 to double blind flexible dose treatment with olanzapine (5-20 mg/day) 
or amisulpride (200-800 mg/day). A randomisation table was generated by the Data 
Management department of the Julius Center, University Medical Center Utrecht, the 
Netherlands, using VB.Net with access to a SQL Server back end database. Study medication 
was packaged-in line with this randomisation table, using sequentially numbered kits. 
Randomization was performed online by a randomization website, also developed by the 
Julius Center, which provided the applicable kit number only. The application 
implemented stratification by site and gender, and applied the minimization method for 
randomization. The data management group was not involved in patient recruitment, which 
was conducted at each participating center. The complete study teams at each center as well 
as the participating patients were blind to treatment allocation. Blinding was achieved by 
overencapsulating two 2.5 mg olanzapine tablets or one 200 mg amisulpride tablet into one 
capsule, utilizing the same manufacturing process to ensure that appearance, shape, smell, 
mass and taste of the opaque capsules were indistinguishable. Olanzapine and amisulpride 
were purchased commercially and overencapsulated by Piramal Healthcare UK. Patients as 
well as study team members were masked to group assignment of each individual participant. 
Non-remitters in phase II continued into 12-week open label treatment with clozapine 100-
900 mg/day (phase III).  
Blood was drawn at the beginning and end of each treatment phase in order to relate 
proteomics, immune parameters and genetics to treatment outcome. In addition, patients who 
had remitted were randomised to a specific psychosocial intervention versus treatment as 
usual with the goal to improve adherence. The results from these studies are not yet available 
and will be reported separately. Finally, MRI and MRS assessments were conducted in a 
subsample of participants.” 
 
Procedures 
After signing informed consent, the screening visit was conducted during which eligibility 
was assessed. Baseline data was obtained regarding demographics, diagnoses, present 
treatment setting, psychopathology (Positive and Negative Syndrome Scale; PANSS), 
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severity of illness (Clinical Global Impression; CGI), depression (Calgary Depression  Scale 
for Schizophrenia; CDSS), personal and social functioning (Personal and Social Performance 
scale; PSP), subjective wellbeing (Subjective Wellbeing under Neuroleptic use; SWN), 
adverse effects (Udvalg for Kliniske Undersogelser; UKU), and alcohol and drug use. 
Frequency and severity of adverse events were assessed at each visit. In addition, weight, 
abdominal circumference and height were measured and an electrocardiogram was done as 
per amisulpride Summary of Product Characteristics. Data was collected at baseline and after 
1, 2, 4, 6, 8, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 and 22 weeks, for most or all of the 
efficacy, safety and tolerability outcomes. Patients who did not meet remission criteria after 
completion of phase III, returned for a follow-up visit 48 weeks after baseline (26 weeks after 
the final phase III visit), where PANSS was assessed and rehospitalisation data was collected. 
For all patients who started phase I, a follow-up visit at 74 weeks post-baseline was scheduled 




The primary outcome measures were the symptomatic remission rates at the final visits of 
phase I (after four weeks of open treatment with amisulpride), phase II (after six weeks of 
double-blind treatment with amisulpride or olanzapine, comparison between arms) and phase 
III (after 12 weeks of open label treatment with clozapine). If remission criteria were met, the 
patient had completed the trial. If they were not met, the patient progressed to the next phase. 
Symptomatic remission was defined according to the criteria of Andreasen: eight specific 
symptoms rated by the PANSS (items P1, P2, P3, N1, N4, N6, G5 and G9) are at the most 
only mildly present (maximum rating of ‘3’), meaning that they do not interfere with daily life 
functioning.
15
 All raters were certified through a standardised PANSS training and 
examination, provided by the sponsor. Halfway through the study, an inter-rater reliability 
assessment was conducted across all sites (ICC=0.82). 
The main secondary outcome measure was a comparison between amisulpride and olanzapine 
on all-cause treatment discontinuation. Other secondary outcomes include the severity and 
improvement scores of the CGI, levels of depression (CDSS), personal and social functioning 
(PSP) and subjective wellbeing (SWN). Safety outcomes include the UKU side effects rating 




Data of the EUFEST study
4
 showed that about 40% of the patients on amisulpride were in 
symptomatic remission within four weeks. However, halfway through the study almost 60% 
of phase I patients met remission criteria. Subsequently, the power analysis was adjusted to 
the following:    based on EUFEST we expect that 50% of the four-week non-responders who 
stay on amisulpride will be in symptomatic remission after another six weeks of treatment (10 
weeks from treatment initiation). If the percentage of patients in remission increases from 
50% to 70% as a result of switching to olanzapine (which is an estimation, as there are no 
prior studies on this topic), the two treatment arms will have to contain 90 patients each to 
obtain a statistical power of .79 with a type-I error rate of .05. If we consider that the drop out 
rate is approximately 30% and the remission rate 60% (both observations after 250 patients 
had been enrolled into the study), than this implies that at least 487 patients will have to be 
included at baseline, taking into account a drop-out of 30% during phase II (observation in 
first 50 phase II patients).  
Remission, as assessed at the final visit of each phase, was first summarized as counts and 
percentages. Subsequently, remission at each visit was analysed using a generalised linear 
mixed model (GLMM), with a logistic link and binomial error distribution. Variables 
included were visit number as a categorical variable and the baseline PANSS score as a 
continuous covariate. In this way, all visits contributed to the estimate of the between patient 
variance, thereby making the estimate of remission at the final visit more robust while 
accounting for dropout. For phase II a comparison was made between the amisulpride and 
olanzapine arm, by including the treatment arm as a factor in the GLMM. The cumulative 
proportion of patients in remission over all three study phases was calculated using the 
number of patients in remission at the last visit of each phase, i.e. the phase completers in 
remission. We used the conservative assumption that dropouts within a phase did not reach 
remission throughout the study. Patients eligible for a next study phase, but not continuing 
into that phase, were assumed not to be different from patients who did continue. To assess 
the proportion of dropouts over time, a Kaplan Meier curve was used. Follow-up time was 
defined as the number of weeks between the date of the baseline visit and the date of the last 
visits of a patient. Patients who did not progress to a next phase because they were in 
remission were censored. Side effects were summarized per visit and per phase and expressed 
as percentages. Missing values were not imputed, as the GLMM analysis incorporates all 
available measurements, assuming that patients with available measurements are 
representative for all patients, including the patients with missing values. For side effects, we 
assumed that missing values indicated absence of side effects. All quantitative scores, 
including the PANNS, were summarized as means and standard deviation and differences 
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between groups were assessed by a t-test. Dichotomous variables were expressed as counts 
and percentages and differences between groups were assessed by Chi square tests. 
Differences between groups in proportions were calculated and a 95%CI according to 
Wilson’s method. In all analyses, the criterion for statistical significance was P < 0.05. SPSS 
version 25 was used for all analyses. A Data Safety Monitoring Board oversaw the study. 
 
Role of the funding sources 
The funder of the study (FP7 EU) had no role in study design, data collection, data analysis, 
data interpretation, or writing of the report. The corresponding author had full access to all the 






Participants were recruited between May 26, 2011 and May 15, 2016. The final study visit 
took place on November 1, 2017. The trial was stopped on May 15, 2016, as the project end 
date was reached. Figure 2 shows the trial profile. 481 patients signed informed consent. In 16 
patients (3.3%), the diagnosis could not be confirmed. Another 19 (4.0%) dropped out before 
the baseline visit for various reasons (n=7 screen failure; n=1 discontinuation of pre-existing 
antipsychotic unsuccessful; n=1 involuntary hospital admission; n=1 physician decision; n=9 
changed their mind). Thus, 446 patients (92.7%) met diagnostic criteria and initiated the first 
phase: four-week open label treatment with amisulpride 200-800 mg daily. Baseline 
characteristics are displayed in Table 1 for the Intent To Treat (ITT) sample (n=446), as well 
as the subgroups of patients who continued into the subsequent treatment phase II (n=93) and 
phase III (n=28).  
 
Phase I (4-week open amisulpride) 
Out of the 446 patients in the ITT sample who initiated the open label amisulpride treatment 
phase, 371 completed the four-week treatment (83.2%). A total of 250 patients met remission 
criteria at end of phase I, a remission rate of 67.4% amongst completers. The remission rate 
within the whole ITT sample (n=446) was 56.1%, when patients without a known remission 
status at the end of phase I were categorized as non-remitters. Figure 3 shows the remission 
rates over the course of phase I. Symptom scores and changes in weight are shown in Table 4. 
 
There was no significant difference between remitters and non-remitters in gender (30.4% 
versus 24.0% female respectively, P=.20), but they did differ in age (26.3 [SD 6.3] vs 24.5 
[SD 5.4] years respectively; p=.004); duration of the current psychotic episode (6.0 [SD 6.0] 
vs 7.7 [SD 7.0] months respectively, p=.025) and age at onset (25.9 [SD 6.3) and 23.8 [SD 
5.4] years, respectively p=.001).  
 
The mean amisulpride dose at the end of Phase I was 490.4 mg/day (SD 207.4); in the 
remitters it was 463.8 mg/day (SD 196.0) and 535.2 md/day (SD 209.2; p=.001) in the non 
remitters. Remitters were more likely to have a diagnosis of schizophreniform disorder 
(44.0% versus 33.1% for non-remitters, p=.044) and less likely to have a diagnosis of 
schizophrenia (52.0% versus 71.1% for non-remitters, p<.001). No differences in alcohol 
dependency or substance abuse were found. 
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Phase II (6-week double blind switching vs continuation) 
Of the 121 non-remitters at the end of phase I, 93 (76.9%) continued to phase II, in which 
they were randomized 1:1 to 6 weeks of continued treatment with amisulpride (n=47), or they 
were  switched to 6 weeks of treatment with olanzapine (n=46). 28 phase I non-remitters 
decided not to continue into phase II for various reasons (refer to Figure 2); this subgroup had 
a shorter duration of illness (5.6 [SD 5.3] months versus 8.4 [SD 7.3] months, respectively; 
p=.040) than those who initiated phase II treatment, but there were no significant differences 
in gender, age, diagnosis, or alcohol / substance abuse. Baseline characteristics of the 93 
patients for the two treatment groups are depicted in Table 5. There were no statistically 
significant differences in proportion or means between the two randomized groups. 
 
Of the 93 patients randomized, 72 completed phase II (77.4%): 33 taking amisulpride versus 
39 taking olanzapine. At the end of phase II, 32 patients met remission criteria, an overall 
remission rate amongst completers of 44.4%. Within the IIT sample, the remission rate was 
35.5%. Remission rates per treatment arm over the phase II visits are depicted in Figure 4. 
There was no significant difference in remission rate between the two treatment arms: the rate 
for amisulpride was 45.5% (n=15) versus 43.6% (n=17) for olanzapine (P=.87). Symptom 
scores and changes in weight are shown in Table 4. The mean dose of amisulpride at the end 
of Phase II was 590.9 mg/day (SD 236.1); remitters 586.7 mg/day (SD 220.0), non remitters 
600.0 mg/day (SD 237.6; p=.87) The mean dose of olanzapine at the end of Phase II was 15.6 
mg/day (SD 6.5); remitters 14.4 mg/day (SD 5.6), non-remitters 17.5 (SD 6.3; p=.12). 
 
A logistic generalized linear model was used to analyze the remission data using all three 
repeated PANSS assessments, while adjusting for the PANSS score at the start of phase II 
(week four; phase II baseline). The odds ratio for meeting remission criteria at the end of 
phase II for amisulpride relative to olanzapine was 1.07 (95% CI: 0.38 to 2.96). Using a linear 
mixed model, PANSS scores at the end of phase II were compared between treatment groups, 
again adjusting for the PANSS score at the start of phase II (phase II baseline). The reduction 
in PANSS score was not significantly different between treatments; the phase II baseline-




Dropout rates between the two treatment arms did not differ significantly, although there was 
a trend in favor of olanzapine; 29.8% of patients randomized to amisulpride dropped out 
(n=14) versus 15.2 % (n=7) on olanzapine, a difference of 14.5%, 95%CI -2.5% to 30.7%  
(p=.093). Patients treated with olanzapine gained significantly more weight than patients 
treated with amisulpride: 4.40 (SD 3.65) kg versus 2.29 (SD 3.07) kg (P=.021). Otherwise, 
the two treatment arms did not differ on the incidence of side effects, corrected for phase II 
baseline assessments.  
   
Phase III (12-week open clozapine) 
Of the 40 phase II non-remitters, 12 patients (30.0%) decided not to continue into the 12-
week open label phase III for various reasons (refer to Figure 2). A further ten patients 
dropped out during phase III (drop-out rate during phase III 35.7%), leaving a total of 18 
patients who completed the clozapine treatment. Five patients met remission criteria, resulting 
in a remission rate of 27.8% among those who completed treatment. Within the IIT sample 
(which classified dropouts as not meeting remission criteria), the remission rate was 17.9%;  
 
Despite the relatively low remission rate, patients demonstrated symptom improvement 
during clozapine treatment, as shown in Figure 6. The phase III completers improved a total 
of 24.9 points on the PANSS score relative to study baseline (visit 2: p<.001) and 18.4 points 
relative to the phase III baseline (at week ten: p=.002). The mean dose of clozapine at the end 
of Phase III was 279.0 mg/day (SD 130.2); remitters 280.0 mg/day (SD 115.1), non remitters 
317.3 (SD 146.7; p=.62). Clozapine blood concentration was assessed at the end of phase III. 
Remitters (n=5) had a mean clozapine blood concentration of 321 ng/ml (SD 226), non-
remitters (n=13) had a mean clozapine concentration of 350 ng/ml (SD 391). 
 
Phase I-III 
Out of the 446 patient who initiated the first treatment phase, a total of 287 patients met 
remission criteria at one of the three treatment phases, adding up to an overall remission rate 
of 64.3% after a maximum of 20 treatment weeks. The cumulative remission rate based on the 
completers of the three phases was 76.4%. Figure 6 shows a steady decline in the mean total 
PANSS scores over the course of each individual treatment phase. In supplemental Figure 1, 
the Kaplan-Meier curve for dropout over time is depicted. After 20 week of follow-up, the 
proportion still under study, censoring for remission, was still 0.651. 
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The mean doses of amisulpride, olanzapine and clozapine in the three treatment phases are 
included in Table 2; for drop outs, the dose at the last visit has been used. The use of 
concomitant medication in each phase is shown in Table 3. 
 
Sexual dysfunction and extrapyramidal symptoms are reported in Table 4. Weight changes 
included in Table 4 are relative to the baseline of the corresponding study phase. An extensive 
report of all side effects reported is provided in a table in the appendix. The incidence of 
Serious Adverse Events did not differ between the treatment arms in phase II: one patient 
randomized to olanzapine was hospitalized due to an epileptic seizure, and one patient 
randomized to amisulpride was hospitalized twice during phase II due to exacerbations of 
psychotic symptoms. Over the course of the trial, two serious suicide attempts were reported. 
One resulted in the only death during the trial, seven days after discontinuing amisulpride. 
The other attempt was during amisulpride treatment in phase I.  
 
48-week follow-up visit 
For patients who did not meet remission criteria after completion of phase III, a follow-up 
visit was scheduled, 48 weeks post- baseline (26 weeks after the final phase III visit). Out of 
the 11 non-remitters at the end of phase III, 8 patients returned for this visit. The mean total 
PANSS score was 70.5 (SD 22.3), ranging from 40 to 104. Three patients met remission 
criteria during this visit. None of the patients were rehospitalised since the end of phase III. 
 
74-week follow-up visit 
For all patients who entered phase I, a follow-up visit was scheduled 74 weeks post-baseline. 
This visit was conducted for 167 patients. The diagnosis at that time point was established: 13 
patients (7.8%) were diagnosed with schizophreniform disorder, 22 patients (13.2%) with 
schizoaffective disorder, 123 patients (73.7%) with schizophrenia and 9 patients (5.3%) 
received other diagnoses (e.g. psychosis NOS, bipolar disorder, unspecified non-organic 
psychosis). PANSS data was available for 140 patients; the mean total PANSS score was 50.2 
(SD 15.0, range 30-105). 95 patients (56.9%) met remission criteria. Seventeen out of 140 





Our first major finding is that switching from amisulpride to olanzapine in first-episode 
schizophrenia did not improve clinical outcome. In fact, of the 93 patients who were 
randomized an almost equal proportion (45%) achieved remission whether they continued 
treatment with amisulpride or were switched to olanzapine. Moreover, the clinical outcome in 
the two groups was also similar when this was defined in terms of symptomatic improvement 
(as a continuous variable). Extrapolating, these data suggest that if a patient fails to achieve 
remission on their first antipsychotic drug, switching to a different drug is no more effective 
than remaining on the same medication and waiting to see if remission is achieved at a later 
stage.  
 
To our knowledge, this is the first study to examine the effects of switching antipsychotics in 
patients with (first-episode) schizophrenia who do not respond to their initial antipsychotic 
treatment (response has been defined differently in the various studies; we used remission in 
the current study). With the exception of one study, all previous studies were conducted in the 
later, chronic, stage of the illness. Moreover, the single study in first-episode schizophrenia 





 compared risperidone and olanzapine in 287 patients with 
first-episode schizophrenia in a non-randomized, open design. Response was defined as much 
improved or better on the CGI. Patients who failed to meet response criteria after four weeks 
were switched to the other antipsychotic; thus switching versus staying on the first medication 
was not examined. Clozapine was given when there was no response to both antipsychotics. 
In that study, 75% of patients met response criteria after four weeks, with more responding to 
olanzapine (82%) than to risperidone (66%). In the second phase of the study, response rates 
dropped to 17%, with olanzapine again doing better than risperidone. Important differences 
compared to the present study were that the first antipsychotic was selected by the treating 
clinician, the definition of response was less stringent, and switching was open. Moreover, it 
is unclear whether data were analysed on the basis of completers only or whether an ITT 
analysis was done.  
 
The only double-blind study that compared switching versus continuation in non-responders 
was conducted in patients with chronic schizophrenia (age around 42 years). Response in the 
first two weeks was defined as ≥20% reduction in total PANSS scores. This corresponds to a 
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lesser degree of clinical improvement than the symptomatic remission criterion used in the 
present study.
19 
Patients who did not respond to a two-week open trial with risperidone (2-6 
mg/day) were randomized to either continuing on risperidone or were switched to olanzapine 
(10-20 mg/day). Switching resulted in a small but significantly greater reduction in total 
PANSS scores after four weeks.  
 
In the current study, after ten weeks of treatment most of the patients were either in 
symptomatic remission or had dropped out, leaving only 28 of the initial 446 patients (6.3%) 
eligible for switching to clozapine. Although only five patients treated with clozapine reached 
remission, there was still a substantial symptomatic improvement in the sample overall, with 
an average reduction in total PANSS scores of more than 18 points. These results suggest that 
providing clozapine early in the treatment of patients with first episode schizophrenia may 
result in clinical improvement, even if this is short of full symptomatic remission. Moreover, 
because we only followed patients on clozapine for 12 weeks, and the full treatment response 
may take several months to materialize, remission rates may have improved further had we 




Symptomatic remission rates in our study were high: after only four weeks of (open) 
treatment with amisulpride, 56% of all 446 patients had reached remission, even when 
assuming that all drop outs were non-remitters; the remission rate increased to 67% when the 
analysis was restricted to patients who completed the initial 4-week treatment period. This 
proportion is impressive for two reasons: first, it corresponds to clinical remission, and not 
just a numerical reduction of symptoms on a rating scale; second, remission was achieved 
after only four weeks of treatment. Our results therefore suggest that a majority of patients 
show a clinically meaningful improvement after only a few weeks of treatment - corroborated 
by the reduction in the Clinical Global Improvement scale. An additional six weeks of 
treatment led to more improvement, with a further 45% of patients (in both arms) achieving 
remission. However, because this was based on a smaller sample (due to the high initial 
remission rate and the drop out between phases), the total remission rate in completers 
calculated from baseline at the end of Phase II was 65%. Additional treatment with clozapine 
increased the cumulative remission rate to 76% - again assuming all drop-outs did not achieve 
remission. This indicates that for the large majority of patients with first episode of 
schizophrenia, a rapid and (almost) complete symptomatic recovery can be expected with 
antipsychotic treatment. The high and rapidly occuring symptomatic response found here is 
 18 
consistent with results reported in other studies in first episode schizophrenia.
21,22
 
Nevertheless, some first-episode patients will respond only after continuous treatment lasting 




The doses of antipsychotics used in the present study are consistent with those generally 
administered in first episode schizophrenia; amisulpride was given in a mean dose of 591 
mg/day, olanzapine 15.6 mg/day and clozapine 279 mg/day (with blood levels a little under 
350 ng/L). Critically, the doses in remitters and non-remitters were similar, with those in the 
non-remitters numerically higher in all phases for all drugs, suggesting that non-remission 
was not attributable to underdosing. Similarly, although the clozapine dose given was 
relatively low (280-300 mg/day), blood levels in the non-remitters were adequate (> 350 
ng/L), so the low remission rate is unlikely to be related to inadequate dosing. Moreover, the 
clozapine dose we used was comparable to that given in the first-episode study by Lieberman 
et. al.
20
 where 80% of patients on clozapine reached remission.  
 
Side effects were as expected: amisulpride was associated with extrapyramidal side effects 
and those related to increased prolactin levels; olanzapine and clozapine induced substantial 
weight gain, even over the relatively short six and twelve-week periods of treatment, 
respectively. In phase II, side effects were more prominent in the patients on olanzapine 
compared to amisulpride: this may have been because those intolerant to amisulpride had 
dropped out in the earlier phase or had developed tolerance. All drugs were associated with a 
substantial gain in weight over the course of treatment, although it was most pronounced on 
olanzapine and clozapine. 
  
The results should be viewed in the context of the study’s limitations. First, the sample in the 
second, randomized phase (II) was relatively modest, comprising 93 patients. This was more 
the result of the high remission rate in Phase I than the number of dropouts, which was less 
than 17%. However, remission rates in the amisulpride and olanzapine arms were virtually 
identical, suggesting a larger sample size may not have changed the results. Second, both the 
initial treatment with amisulpride and the subsequent one with clozapine were open label. 
This may have increased the remission rates in both phases. It was felt though, that the initial 
treatment should be pragmatic, reflecting clinical reality as much as possible, whereas the 
comparison between two drugs in Phase II needed to be as un-biased as possible and therefore 
double blind. Third, it could be argued that a comparison between continuation with 
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amisulpride and switching to clozapine in Phase III would have been of interest; the current 
design cannot address that question. Indeed, whether clozapine has an added benefit over 
continuation with amisulpride after ten weeks of its use needs further study. Fourth, it may be 
argued that a 4-week trial is not sufficiently long to decide whether to switch or not. However, 
a recent meta-analysis suggests this period is sufficient
24
. Finally, although our results show 
that a large majority of first-episode schizophrenia patients reaches remission within a few 





Current guidelines recommend that clozapine should be offered to patients who have not 
responded to treatment with two different antipsychotics. However, if the likelihood of non 
response to one antipsychotic given for a sufficient length of time is similar to that with two 
courses of different antipsychotics, it may be feasible to define non-response (operationalized 
as failure to achieve symptomatic remission) on the basis of a single course of antipsychotic 
treatment, as long as it is given for long enough. Adopting a simpler treatment algorithm with 
one course of antipsychotic treatment would allow these patients to be identified earlier and 
reduce the delay before they can be treated with clozapine.  
 
In summary, our results suggest that switching antipsychotics in minimally treated patients 
with first-episode schizophrenia does not improve outcome in those who are not in 
symptomatic remission after their first antipsychotic regimen. Although switching to 
clozapine early in the treatment did not dramatically improve remission rates, it did result in a 
substantial improvement in symptoms, albeit that many first-episode patients did not tolerate 
the side effects associated with its treatment.  
Employing an algorithm of treatment with a single antipsychotic for up to ten weeks and 
subsequent use of clozapine in non-remitters, remission can be achieved within 22 weeks for 
over three quarters of first-episode patients who complete treatment and for almost two thirds 
of patients where treatment was initiated. Although these results need to be replicated and 
broadened (using different antipsychotics), they suggest that achieving remission in the early 
stages of schizophrenia is possible in the large majority of patients using a simple treatment 
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FIGURES: The OPTiMiSE trial: a three-phase, double blind randomised switching study in first 
episode schizophrenia and schizophreniform disorder comparing amisulpride and olanzapine 
followed by open treatment with clozapine. 
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Informed consent signed: 
481 
16x diagnosis not confirmed 
19x drop out before baseline visit 
Started amisulpride at 
baseline: 446* 
Completed phase I:  
371  
(Week 4) 
In remission                       
end of phase I: 250  
Non-remitters not starting in 
phase II: 28 
Reasons: 20x withdrew consent, 
4x AE, 1x physician decision,        
1x worsening symptoms 
Non-remitters starting in 
phase II: 93* 
Completed phase II: 72        
(Week 10) 
In remission                        
end of phase II: 32 
Non-remitters starting in 
phase III: 28* 
Completed phase 3: 18 
(Week 22) 
Non-remitters not starting in 
phase III: 12 
Reasons: 10x withdrew consent, 
1x lost to f/u, 1x non-compliance 
protocol 
In remission phase III: 5  
Dropped out phase I: 75 
Reasons: 28x withdrew consent, 
16x AE, 9x protocol non-
compliance, 8x lost to f/u, 7x 
physician decision, 5x involuntary 
hospitalization, 2x suicide attempt 
Dropped out phase III: 10  
Reasons: 4x AE, 2x lost to f/u, 2x 
withdrew consent, 2x other 
Dropped out phase II: 21.  
AMI: n=14. Reasons: 6x AE, 1x lack 
of efficacy, 4x protocol 
noncompliance, 3x other.  
OLZ: n=7. Reasons: 1x AE, 1x lack 
of efficacy, 2x lost to f/u, 3x other.  





TABLES: The OPTiMiSE trial: a three-phase, double blind randomized switching study in first 
episode schizophrenia and schizophreniform disorder comparing amisulpride and olanzapine 
followed by open treatment with clozapine. 
 
Table 1. Characteristics of patient samples at the start of each treatment phase.  
 Start phase I Start phase II Start phase III 
Sample size 446 93 28 
Age 26.0 (6.0) 25.2 (5.4) 26.3 (6.5) 
Women 134/446 (30.0%) 23/93 (24.7%) 7/28 (25.0%) 
White 386/446 (86.5%) 86/93 (92.5%) 27/28 (96.4%) 
Years of education at 
baseline*  
12.3 (3.0) 11.9 (2.7) 11.4 (2.4) 
Living independently at 
baseline 
83/446 (18.6%) 20/93 (21.5%) 8/28 (28.6%) 
Employed or student at 
baseline 
185/446 (41.5%) 33/93 (35.5%) 10/28 (35.7%) 
Schizophreniform disorder 
at baseline† 
190/446 (42.6%) 28/93 (30.1%) 8/28 (28.6%) 
Schizoaffective disorder at 
baseline† 
27/446 (6.1%) 2/93 (2.2%) 2/28 (7.1%) 
Schizophrenia at baseline† 229/446 (51.3%) 63/93 (67.7%) 18/28 (64.3%) 
Comorbid Major 
Depressive Disorder at 
baseline† 
34/429 (7.9%) 9/91 (9.7%) 3/28 (10.7%) 
Suicidality at baseline† 55/429 (12.8%) 10/91 (11%) 17/28 (17.9%) 
Substance abuse and/or 
dependence in past 12 
months at baseline† 
75/429 (17.5%) 9/91 (9.9%) 1/28 (3.6%) 
Inpatient status at baseline 276/446 (61.9%) 53/93 (57.0%) 17/28 (60.7%) 
Table
Duration of untreated 
psychosis at baseline 
(months) 
6.3 (6.2) 8.4 (7.3)  8.0 (6.5) 
Antipsychotic naïve at 
baseline 
187/446 (42.0%) 54/93 (58.1%) 13/28 (46.4%) 
PANSS total score§ 78.2 (18.7) 85.7 (16.4) 89.0 (16.8) 
PANSS Positive 
Subscale§ 
20.2 (5.5) 21.7 (5.1) 21.5 (4.6) 
PANSS Negative 
Subscale§ 
19.4 (7.1) 22.4 (7.0) 23.3 (6.8) 
PANSS General 
Subscale§ 
38.6 (9.8) 41.6 (9.3) 44.1 (10.1) 
CGI Severity¶ 4.5 (0.9) 4.7 (0.8) 4.7 (0.9) 
Depression score at 
baseline‡ 
13.5 (4.6) 14.2 (4.8) 14.6 (4.4) 
BMI 23.4 (5.0) 23.9 (4.3) 25.0 (2.6) 
Overweight BMI 25 or 
more 
119/436 (26.6%) 25/82 (30.5%) 11/20 (55%) 
Abdominal 
circumference**  
83.3 (12.4) 84.1 (10.5) 86.8 (8.5) 
Baseline is visit 2, the visit at which study medication is initiated. Data are n/N (%) or mean 
(SD). Denominators change due to incomplete data. PANSS=Positive and Negative Syndrome 
Scale. CGI=Clinical Global Impression. BMI=Body Mass Index. *Years in school from 6 years 
of age onwards. †According to the Mini International Neuropsychiatric Interview 5 plus. 
Suicidality includes medium to high suicide risk. §Theoretical scores range from 30–210 (total 
scale), 7–49 (positive scale), 7–49 (negative scale), 16–112 (general psychopathology scale). 
Higher scores indicate more severe psychopathology. ¶ Theoretical scores range from 1–7; 
higher scores indicate greater severity of illness. ‡According to the Calgary Depression Scale for 
Schizophrenia. Theoretical scores range from 0–27; higher scores indicate more depression. ** 
measured in cm. 
Table 2: Mean doses of study medication used during the three phases of the trial 
 During phase I 
Amisulpride 
 




































Dosage is indicated in mg per day (SD). Mean dose is based on the dose of each individual 
patient at the last visit of the applicable phase. For instance, for phase I completers, the dose at 
visit 5 (end of phase I) is used. For a phase II drop out, the dose at the last visit before dropping 









































































































Benzodiazepine used to treat anxiety has been coded as ‘anxiolytic’; for all other indications for 
use, they have been coded as benzodiazepine. Anti-epileptics have been coded as ‘mood 
stabilizer’ if the indication for use was mood-related, e.g. ‘irritability’ or ‘impulsiveness’. That 
is, anti-epileptics prescribed for epilepsy were not included in this overview.  
 
Table 4. Symptom severity and side effects per treatment phase. 
 End of phase I End of phase II End of phase III 
PANSS total score 
change from baseline* 
-19.1 (17.9) AMI: -10.1 (19.9) 
OLZ: -6.1 (13.9) 
-18.4 (21.7) 
PANSS Positive Subscale 
change from baseline * 
-7.1 (5.7) AMI: -2.8 (6.0) 
OLZ: -1.1 (4.2) 
-5.5 (5.8) 
PANSS Negative 
Subscale change from 
baseline* 
-3.2 (5.6) AMI: -3.7 (6.8) 
OLZ: -1.8 (5.1) 
-4.5 (5.1) 
PANSS General Subscale 
change from baseline * 
-8.8 (9.6) AMI: -3.7 (10.3) 
OLZ: -3.3 (8.1) 
-8.4 (12.2) 
CGI Severity change 
from baseline † 
-1.1 (1.1) AMI: -0.33 (1.1) 
OLZ: -0.26 (0.9) 
Not assessed 
Sexual side effects †† 
     Male 
 







AMI: 2/33 (6.1%) 
OLZ: 8/39 (20.5%) 
AMI: 5/33 (15.2%) 








    Dystonia 
     
    Rigidity 
     
    Tremor     
     













AMI: 1/33 (3.0%) 
OLZ: 4/39 (10.3%) 
AMI: 3/33 (9.1%) 
OLZ: 9/39 (23.1%)  
AMI: 3/33 (9.1%) 
OLZ: 10/39  
AMI: 1/33 (3.0%) 










Weight change from 2.5 (4.0) AMI: 2.7 (2.9) 4.8 (5.5) 
baseline OLZ: 4.2 (3.6) 
Weight gain 7% or more 
from baseline 






from baseline**  
2.1 (4.7) AMI: 1.4 (2.7) 
OLZ: 4.2 (5.0) 
3.5 (5.9) 
Baseline for phase I is visit 2, the visit at which study medication is initiated. Baseline for phases 
II and III are the first visits of these respective phases, that is, visit 5 for phase II and visit 8 for 
phase III. Data are n/N (%) or mean (SD). Denominators change due to incomplete data. 
PANSS=Positive and Negative Syndrome Scale. CGI=Clinical Global Impression. 
AMI=amisulpride. OLZ= olanzapine. *Theoretical scores range from 30–210 (total scale), 7–49 
(positive scale), 7–49 (negative scale), 16–112 (general psychopathology scale). Higher scores 
indicate more severe psychopathology. † Theoretical scores range from 1–7; higher scores 
indicate greater severity of illness. ††Any symptoms scored on the Udvalg for Kliniske 
Undersøgelser questionnaire during the respective phase: for men: increased/decreased libido, 
orgastic dysfunction, gynaecomastia, or erectile/ejaculatory dysfunction (six items); for women: 
increased/decreased libido, orgastic dysfunction, menorrhagia, amenorrhoea, galactorrhoea, or 
dry vagina (seven items); an extensive list of adverse events is reported in the appendix. ** 
measured in centimeters. 
  
Table 5. Baseline characteristics of patients included in phase II, according to randomized 
treatment group  
   
 Amisulpride Olanzapine 
Sample size 47 46 
Age (years) 24.9 (5.4) 24.6 (5.5) 
Women 11 (23.4%) 12 (26.1%) 
White 43 (91.5%) 43 (93.5%) 
Years of education at baseline*  12.4 (2.9) 11.4 (2.3) 
Living independently at baseline 11 (23.4%) 9 (19.6%) 
Employed or student at baseline 17 (36.2%) 16 (34.8%) 
Schizophreniform disorder at baseline† 15 (31.9%) 14 (30.4%) 
Schizoaffective disorder at baseline† 1 (2.1%) 2 (4.3%) 
Schizophrenia at baseline† 35 (74.5%) 30 (65.2%) 
Comorbid Major Depressive Disorder at baseline† 5 (10.9%) 4 (8.9%) 
Suicidality at baseline† 6 (11.0%) 8 (17.8%) 
Substance abuse and/or dependence in past 12 
months at baseline† 
1 (2.2%) 2 (4.4%) 
Inpatient status at baseline 27 (57.4%) 26 (56.5%) 
Duration of untreated psychosis at baseline (months) 9.5 (7.8) 7.2 (6.6) 
PANSS total score§ 79.1 (16.2) 75.2 (16.2) 
PANSS Positive Subscale§ 18.2 (5.1) 17.0 (5.1) 
PANSS Negative Subscale§ 22.5 (6.8) 20.9 (6.5) 
PANSS General Subscale§ 38.4 (9.1) 37.2 (9.4) 
 
Baseline is visit 2, the visit at which study medication is initiated, except for the PANSS scores. 
Data are n (%) or mean (SD). PANSS=Positive and Negative Syndrome Scale.  
*Years in school from 6 years of age onwards. †According to the Mini International 
Neuropsychiatric Interview 5 plus. Suicidality includes medium to high suicide risk. 
§Theoretical scores range from 30–210 (total scale), 7–49 (positive scale), 7–49 (negative scale), 
16–112 (general psychopathology scale). Higher scores indicate more severe psychopathology. 
 
Appendix to ‘The OPTiMiSE trial: a three-phase, double blind randomised switching study in first 
episode schizophrenia and schizophreniform disorder comparing amisulpride and olanzapine followed 
by open treatment with clozapine’ 
 
Appendix 1: all adverse effects reported through the UKU scale 
 
Adverse effect End of phase I End of phase II End of phase III 
Concentration difficulties 118/371 (31.8%) AMI: 10/33 (30.3%) 




156/371 (42.0%) AMI: 8/33 (24.2%) 
OLZ: 14/39 (35.9%) 
3/18 (16.7%) 
Sleepiness/Sedation 156/371 (42.0%) AMI: 10/33 (30.3%) 
OLZ: 21/39 (53.8%) 
6/18 (33.3%) 
Failing memory 76/371 (20.5%) AMI: 3/33 (9.1%) 
OLZ: 10/39 (25.6%) 
0/18 (0%) 
Depression 98/371 (26.4%) AMI: 8/33 (24.2%) 
OLZ: 15/39 (38.5%) 
2/18 (11.1%) 
Tension/Inner unrest 112/371 (30.2%) AMI: 7/33 (21.2%) 
OLZ: 13/39 (33.3%) 
2/18 (11.1%) 
Increased duration of sleep 105/371 (28.3%) AMI: 10/33 (30.3%) 
OLZ: 19/39 (48.7%) 
4/18 (22.2%) 
Reduced duration of sleep 36/371 (9.7%) AMI: 2/33 (6.1%) 
OLZ: 1/39 (2.6%) 
0/18 (0%) 
Increased dream activity 80/371 (21.6%) AMI: 5/33 (15.2%) 
OLZ: 7/39 (17.9%) 
1/18 (5.6%) 
Emotional indifference 88/371 (23.7%) AMI: 8/33 (24.2%) 
OLZ: 10/39 (25.6%) 
3/18 (16.7%) 
Epileptic seizures 3/371 (0.8%) AMI: 1/33 (3.0%) 
OLZ: 1/39 (2.6%) 
0/18 (0%) 
Paraesthesias 21/371 (5.7%) AMI: 1/33 (3.0%) 
OLZ: 6/39 (15.4%) 
0/18 (0%) 
Table
Accommodation disturbances 25/371 (6.7%) AMI: 1/33 (3.0%) 
OLZ: 3/39 (7.7%) 
2/18 (11.1%) 
Increased salivation 56/371 (15.1%) AMI: 4/33 (12.1%) 
OLZ: 7/39 (17.9%) 
6/18 (33.3%) 
Reduced salivation 30/371 (8.1%) AMI: 1/33 (3.0%) 
OLZ: 7/39 (17.9%) 
1/18 (5.6%) 
Nausea/Vomiting 15/371 (4.0%) AMI: 1/33 (3.0%) 
OLZ: 4/39 (10.3%) 
1/18 (5.6%) 
Diarrhoea 16/371 (4.3%) AMI: 1/33 (3.0%) 
OLZ: 5/39 (12.8%) 
0/18 (0%) 
Constipation 41/371 (11.1%) AMI: 2/33 (6.1%) 
OLZ: 2/39 (5.1%) 
2/18 (11.1%) 
Micturition disturbances 17/371 (4.6%) AMI: 0/33 (0%) 
OLZ: 2/39 (5.1%) 
0/18 (0%) 
Polyuria/Polydipsia 39/371 (10.5%) AMI: 2/33 (6.1%) 
OLZ: 2/39 (5.1%) 
1/18 (5.6%) 
Orthostatic dizziness 42/371 (11.3%) AMI: 0/33 (0%) 
OLZ: 9/39 (23.1%) 
2/18 (11.1%) 
Palpitations/Tachycardia 32/371 (8.6%) AMI: 1/33 (3.0%) 
OLZ: 7/39 (17.9%) 
3/18 (16.7%) 
Increased tendency to 
sweating 
31/371 (8.4%) AMI: 2/33 (6.1%) 
OLZ: 4/39 (10.3%) 
0/18 (0%) 
Rash – morbiliform 1/371 (0.3%) AMI: 0/33 (0%) 
OLZ: 1/39 (2.6%) 
0/18 (0%) 
Rash - petechial  0/371 (0%) AMI: 0/33 (0%) 
OLZ: 1/39 (2.6%) 
0/18 (0%) 
Rash – urticarial 2/371 (0.5%) AMI: 1/33 (3.0%) 
OLZ: 0/39 (0%) 
1/18 (5.6%) 
Rash - psoriatic 0/371 (0%) AMI: 0/33 (0%) 
OLZ: 0/39 (0%) 
0/18 (0%) 
Pruritus 23/371 (6.2%) AMI: 1/33 (3.0%) 0/18 (0%) 
OLZ: 1/39 (2.6%) 
Photosensitivity 16/371 (4.3%) AMI: 1/33 (3.0%) 
OLZ: 1/39 (2.6%) 
1/18 (5.6%) 
Increased pigmentation 1/371 (0.3%) AMI: 0/33 (0%) 
OLZ: 0/39 (0%) 
0/18 (0%) 
Headache – tension headache 39/371 (10.5%) AMI: 1/33 (3.0%) 
OLZ: 2/39 (5.1%) 
0/18 (0%) 
Headache – migraine 2/371 (0.5%) AMI: 0/33 (0%) 
OLZ: 1/39 (2.6%) 
0/18 (0%) 
Headache – other forms 13/371 (3.5%) AMI: 0/33 (0%) 
OLZ: 1/39 (2.6%) 
1/18 (5.6%) 
Physical dependence 5/371 (1.3%) AMI: 0/33 (0%) 
OLZ: 0/39 (0%) 
0/18 (0%) 
Psychic dependence 14/371 (3.7%) AMI: 0/33 (0%) 







Appendix 2: OPTiMiSE (OPtimization of Treatment and Management of Schizophrenia in Europe) 
Study Group 
 
Principal Investigator / Sponsor: R S Kahn. 
Study Management Group: R S Kahn, I E Sommer (trial coordinator until end of 2012), I Winter van 
Rossum (trial coordinator since end of 2012), M Somers, P C Ywema. 
Executive Board: R S Kahn, S Kapur, P McGuire, M Leboyer, A Meyer-Lindenberg, S Lewis, S Leucht, B 
Glenthoj, C Arango, W W Fleischhacker. 
Office manager and Clinical Research Associate: P C Ywema. 
Clinical Research Associates: A L Meijering, J Petter, R van de Brug. 
Julius Centre Study Team: data management: J Schotsman, J Zwerver 
Participating investigators (CC=country coordinator; SC=site coordinator), 
centres, and countries:  
Austria: W W Fleischhacker (CC and SC Innsbruck); 
Belgium: J Peuskens (CC), M de Hert (CC), Erik Thys (SC Leuven); 
Bulgaria—L G Hranov (CC), V Hranov (SC); 
Czech Republic: J Libiger (CC), R Köhler (SC Hradec Králové), P Mohr (SC Prague); 
Denmark: B Glenthoj (CC), B Broberg (SC), S During (SC), L Baandrup (SC);  
France: M Leboyer (CC), S Jamain (SC); 
Germany: S Leucht (CC), S Heres (SC Munich), D Rujescu (SC Halle); I Giegling (SC Halle); 
Israel: M Weiser (CC), M Bar Heim (SC); M Davidson 
Italy: S Galderisi (CC), P Bucci (SC), A Mucci (SC); 
Netherlands: R S Kahn (CC), IWR (SC); 
Poland: J Rybakoswki (CC), A Remlinger-Molenda 
Romania: Ilan Gonen (CC), P Radu (SC) 
Spain: C Arango (CC), C Martinez Diaz Caneja (SC Madrid HGUG), M Díaz-Marsá (SC Madrid HCSC), A 
Rodriguez (CSC Madrid HCSC), T Palomo (SC H12O), R Rodríguez-Jimenez (SC H120), J Bobes (SC Oviedo), 
P García-Portilla (SC Oviedo), M Bernardo (SC Barcelona), C Vilares Oliveira (SC Barcelona); 
Switzerland: G Berger (CC), C Wild (SC); 
UK: P Dazzan (CC), R Perez-Iglesias (SC KC London), S Lewis (SC Manchester), R Drake (SC Manchester), S 
Gregory (SC WLMHT London), D Wilson (SC WLMHT London). 
 
Appendix 3: Participating centers: 
 
Austria 
Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria, A-6020 
 
Belgium 
Katholieke Universiteit Leuven (KU Leuven), Leuven, Belgium, B - 3070 
 
Bulgaria 
University Specialised Hospital for Active Treatment in Neurology and Psychiatry "St. Naum", 
Sofia, Bulgaria, 1113  
Czech Republic 
Psychiatrické centrum Praha, Prague, Ustavni 91, Czech Republic, 181 03 Praha 8-Bohnice 
 
Psychiatrická klinika LF UK, Fakultní nemocnice, Hradec Králové, Czech Republic, CZ - 500 05 
 
Denmark 
Center for Neuropsychiatric Research, Glostrup, Denmark, DK-2600 
 
France 
Institut National de la Santé et de la Reserche Médicale (INSERM), Créteil Cedex, France, 94010 
 
Germany 
Martin-Luther-University (MLU) of Halle-Wittenberg, Halle, Germany, 06097 
 
Ludwig-Maximilians University München, München, Germany, 80336 
 
Technische Universität München (TUM), München, Germany, 81675 
 
Israel 
Sheba Medical Centre Department of Psychiatry, Tel Hashomer, Israel, 52621 
 
Italy 
Department of Psychiatry University of Naples, Naples, Italy, 80138 
 
Netherlands 
University Medical Center Utrecht 
 
Utrecht, Netherlands, 3584 CX  
Poland 
Department of Adult Psychiatry, University of Medical Sciences, Poznan, Poland, 60-572 
 
Romania 
Obregia Psychiatric Hospital, Bucuresti, Romania, 7000 
 
Spain 
Hospital Clinic i Provincial, Barcelona, Spain, 08036 Barcelona 
 
Servicio Madrileño de Salud (SERMAS), Madrid, Spain, 28007 
 
Hospital Clínico San Carlos, Madrid, Spain, 28040 Madrid 
 
Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain, 28041 Madrid 
 
Universidad de Oviedo, Oviedo, Spain, 33011 Oviedo 
 
Switzerland 
Clienia Schlössli AG, Privatklinik für Psychiatrie und Psychotherapie, Oetwil am See/Zürich, 
Switzerland, CH-8618  
United Kingdom 
King's College London, Departments of Psychological Medicine, Psychiatry & Cognitive 
Neuroscience, London, United Kingdom, SE5 8AF  
West London Mental Health Trust, London, United Kingdom, W12 0NN 
 





Appendix 4: Protocol amendments, following the original protocol dated 05-11-2010 
 
Amendment 1 - 30-03-2011:  
 follow-up visits at 48 weeks (remission criteria assessment, for phase III non-remitters only) and 
72 (remission criteria assessment) were added to enable long term follow-up of participants. 
 contraceptive use as inclusion criteria was added on request of regulatory authorities. 
 inclusion criteria regarding the onset of illness was changed from ‘a maximum of 2 years since 
onset of positive symptoms’ to ‘a maximum of 2 years since onset of psychosis’. Many patients 
have experienced vague symptoms in their childhood, but the onset of psychosis was regarded 
a more relevant starting point. 
 For patients using clozapine, leucocyte checks need to be continued for at least 4 weeks when a 
patient discontinues clozapine. 
 Several reasons for withdrawal of participants were added: 1) The nature of the patients 
treatment is changed to coercive treatment (based on judicial ruling); 2) In contrast to the 
patient's status at enrollment, the patient is now represented by a legal guardian or under legal 
custody; 3) Emergence of one or more contraindications against any of the study drugs as 
mentioned in the Summaries of Product Characteristics (refer to Appendix B). In particular, 
clozapine use needs to be discontinued when one or more of the following adverse events 
occur: severe leucopenia (leucocyte count <3000/mm3 or 3.0x109/l) or neutropenia (count 
<1500/mm3 or 1.5x109/l), myocarditis or cardiac arrhythmias; 4) Patient becomes pregnant or 
initiates lactation  
 
Amendment 2 – 01-07-2011: 
 the recommended tapering schedule of study medication was adjusted to slow down the dose 
increase in order to decrease the chance on and severity of extrapyramidal symptoms, as the 
first patient who entered the study suffered from severe EPS. 
 on request of the participating centers, a titration recommendation for the transfer from phase I 
to phase II, and from phase II to phase III study medication was included.  
 target dose of 400 mg/day amisulpride was added, in line with findings from the EUFEST study. 
However, clinicians could deviate from the target dose as well as the titration scheme if deemed 
necessary.  
 
Amendment 3 – 04-07-2012: 
 the eligibility for entering the Psychosocial Intervention component after the pharmaco-
therapeutic component was no longer limited to patients meeting remission criteria, but also for 
drop outs and patients not meeting remission criteria, as they could also benefit from this 
intervention. 
 It was found that ‘Schizophreniform disorder’ could not be completely assessed through the 
M.I.N.I. diagnostic interview. Therefore the confirmation of this diagnosis was rephrased as 
follows: Schizophreniform disorder is assessed through a M.I.N.I. diagnosis of psychosis NOS 
complemented by a diagnosis of schizophreniform disorder according to DSM-IV criteria.  
 a clinical diagnosis was added to the long term f/u visit 22 (74 weeks) to gain insight into the 
stability of the diagnosis of participants at baseline. 
 
Amendment 4 – 15-11-2013: 
 closure of one participating center, addition of a new participating center. 
 increase of patient sample from 350 to 500, due to the high remission rate in phase I. 
 a third MRS scan was added, 10 weeks after baseline, providing a longer term follow up of the 
timing of any glutamate changes, and investigating any differential effects of amisulpride versus 
olanzapine on glutamate changes. 
 changes in Serious Adverse Event reporting were implemented: 1) pregnancy is no longer 
reported as SAE but rather an AE; 2) hospitalisation due to psychiatric exacerbation is reported 
only in the annual line listings, due to the high frequency of occurrence at this early stage of the 
illness and the fact that immediate reporting does not have added value. 
 
Amendment 5 – 07-05-2015: 
 recalculation of power analyses for MRS.  
 following changes in the amisulpride SPC, a safety procedure was added: if female patients have 
a history of breast cancer, and/or a first degree relative with a (history of) breast cancer, 
prolactin levels should be assessed at the local lab, at visit 2 and visit 5. 
 a blood count assessment was added to the biomarker blood draws, in order to support 
epigenetic analyses. 
 
Amendment 6 – 06-07-2015: 
The generic amisulpride used for the study thus far, was no longer commercially available, therefore a 
switch to another generic amisulpride was required.  
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No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 




2a Scientific background and explanation of rationale 5 
2b Specific objectives or hypotheses 5 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 6-7 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons Appendix 
Participants 4a Eligibility criteria for participants 6 
4b Settings and locations where the data were collected 6 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
7-8 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
7-8 
6b Any changes to trial outcomes after the trial commenced, with reasons n/a 
Sample size 7a How sample size was determined 10 
7b When applicable, explanation of any interim analyses and stopping guidelines n/a 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 7 




9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
7 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
7 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 7 
Table
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assessing outcomes) and how 
11b If relevant, description of the similarity of interventions 7 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 9 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 9 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
Figure 2 
13b For each group, losses and exclusions after randomisation, together with reasons 10-12 and 
Figure 2 
Recruitment 14a Dates defining the periods of recruitment and follow-up 10 
14b Why the trial ended or was stopped 10 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group Table 1 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 





17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
10-13 and 
Tables 2-4 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended 11 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
n/a 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) 12-13, table 4 
and appendix 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 14-18 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 15-18 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 14-18 
Other information  
Registration 23 Registration number and name of trial registry 3 & 6 
Protocol 24 Where the full trial protocol can be accessed, if available n/a 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 4 & 9 
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Laboratory sites  
 
 
Storage and analysis of blood samples: 
INSERM Pharmacogenetics Network.  
Prof. Dr. Marion Leboyer 
marion.leboyer@inserm.fr 
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Production of open label study medication:  
Piramal Healthcare - Pharma Solutions 
Whalton Road, Morpeth, Northumberland NE61 
3YA United Kingdom 
Phone +44 (0)1670 562412 
Fax: +44(0)1670 562401 
roger.bowie@piramal.com 
 
Production of double blind study medication: 




55131 Mainz, Germany 
Phone: +49 (0) 6131 17 4519 
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This study will focus on two goals: optimising current treatments in schizophrenia and 
explore novel therapeutic options for schizophrenia. The study intends to both 
address basic, but so far unanswered, questions in the treatment of schizophrenia 
and develop new interventions. It is expected that the project will lead to evidence 
that is directly applicable to treatment guidelines, and will identify potential 
mechanisms for new drug development. 
 
Objectives: 
I To test applicability of amisulpride as the first step in a treatment algorithm. 
II To test guideline recommendation that non-responders to an antipsychotic drug 
benefit from a switch to an antipsychotic with a different receptor binding profile. 
III To provide the acceptability and outcome data on the application of clozapine in 
non-responding patients within the first 10 weeks of their treatment initiation. 
IV To test if an IT-enabled psychosocial intervention can improve treatment 
adherence and global functional outcome in symptomatically remitted first-episode 
schizophrenia patients. 
V To test whether glutamatergic markers predict response to first and second line 
treatments. 
VI To test if a combination of pharmacogenetic, proteomics- and metabolomic 
markers can provide clinical valuable predictive value. 
VII To define the nature and prevalence of ’organic’ pathology in patients presenting 
with a first episode schizophreniform psychosis 
VIII To determine the extent to which MRI measures at first presentation predict the 
therapeutic response to subsequent antipsychotic treatment. 
 
Study design:  
Intervention study consisting of: medication intervention part (partly randomized, 
controlled, double-blind), psychosocial intervention part (randomized, controlled), 
MRI part. 
 
Study population:  
500 first episode schizophrenia patients, aged 18-40 years, will be included at 
multiple (18-30) sites. Patients can only be included if they have used less than 2 




MRI part: At screening an MRI scan will be made to screen for neurological 
pathology. Venous blood will be obtained for genetic and metabolic analyses. The 
MRI and blood values obtained at screening and baseline will be used to predict 
treatment response. 
Medication part: All patients will be provided open-label amisulpride for four weeks 
(phase I). Non-responders will enter the double blind phase of the study (phase II). In 
a randomized fashion, non-responders will either continue on amisulpride or switch to 
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olanzapine for six weeks. Patients who have still not responded will be prescribed 
clozapine open-label for twelve weeks (phase III).  
Psychosocial part: All patients who respond, either after four weeks, after ten weeks 
or on clozapine will be randomized to a psychosocial intervention (twelve weeks) or 
to treatment as usual. Patients who did not respond but do wish to participate in this 
study component may also be randomized. The psychosocial intervention consists of 
psychoeducation, motivational interviewing and SMS warnings to improve medication 
adherence. The medication that is prescribed during this phase is the choice of the 
patient and physician. 
 
Main study parameters/endpoints:  
The primary outcome for the medication part is the number of participants in 
remission at the end of phase I, II  and III. 
The primary outcomes for the psychosocial intervention are drug adherence rates 
defined categorically (adherent vs non-adherent) as a function of standardised self 
report measured through the Sellwood rating scale and Kemp rating scales; and 
global functioning at 1 year.  
The primary outcome for the MRI screening is the percentage first episode patients 
that show radiological abnormalities suggestive of neurological disorders. 
The primary outcome for the biological predictors is the percentage of non-
responders that show biological variations compared with the responders (eg: genetic 
variants). 
 
Nature and extent of the burden and risks associated with participation, benefit 
and group relatedness:  
Use of the study drugs will imply that there is a risk of side effects, as all anti-
psychotic drugs carry the risk of side-effects. In addition, participation in this study will 
take more time than regular treatment, because of the standardised interviews that 
will be done. The risks and discomfort of blood samples are the same as always if 
blood is drawn from a vein. Minor injuries and irritations can occur. In rare cases a 
local infection can occur. The MRI scan procedure is painless and safe and there are 
no known health risks.  
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1. Introduction and aims 
 
Despite nearly fifty years of pharmacological and psychosocial research, the overall 
prognosis of schizophrenia has improved only marginally. While the efficacy of most 
antipsychotic medication is generally uncontested, their overall functional impact has 
been modest. This disappointing fact may be attributable to three major issues: first, 
a considerable minority of patients still does not respond sufficiently to current 
treatments; second, patients who do respond to medication often discontinue it and 
relapse; finally, even patients who do respond well to treatment and do adhere to it, 
continue to suffer from substantial cognitive and functional deficits severely limiting 
their potential.In order to improve this unsatisfactory result, this study aims to 
optimize current treatments in schizophrenia and explore novel therapeutic options 
for schizophrenia. The study comprises a medication intervention part, a 
psychosocial intervention part, a biological predictor part and an MRI part. 
 
1.1 Medication intervention: Finding evidence for pharmacotherapy 
guidelines in first episode schizophrenia 
 
While effective antipsychotic treatments are available for nearly fifty years – the 
application and implementation of these treatments is far from optimal. There are a 
number of elementary questions in the treatment of schizophrenia that need to be 
answered. When a psychiatrist is faced with a new patient with schizophrenia he will 
no doubt use an antipsychotic to start treatment; however, he has little guidance on 
some very simple and fundamental questions. Is there a rational basis for choosing 
the first antipsychotic? Can I predict how well the patient will do? When the patient 
fails to respond to the first antipsychotic how long do I wait? Do I continue for some 
more time or do I switch to another antipsychotic? If so, which one?  
Once it has been decided that antipsychotic treatment is to be initiated the question 
arises how to prioritize the currently available treatments in a rational and optimal 
manner. While there are several ‘treatment’ algorithms for schizophrenia, all of them 
are agnostic as to the choice of the first antipsychotic (so long as it is not a depot or 
clozapine). In essence, all currently available antipsychotics are considered equal, 
even though we know they differ in mechanism of action. Although numerous 
national treatment guidelines for schizophrenia are available, recommendations for 
choice of drug (or switching in case of non-response) are usually vague. A case can 
be made that a drug which is cheap, widely available, and has the simplest and most 
specific known mechanism should be tried first. This drug is amisulpride – it is a 
specific D2 blocker, has atypical properties, is as effective as any of the other 
atypicals, has a benign profile on metabolic parameters and in the recently completed 
EUFEST trial of first episode patients showed the best rate of remission (40% after 4 
weeks of treatment).  
Aim: to test the widespread application, patient-acceptability and outcomes of 
amisulpride as the first step in the treatment of 500 patients with a first episode 
of schizophrenia. 
 
No one treatment will be adequate for all patients. Prospective, sequential studies are 
necessary to develop treatment algorithms for schizophrenia, but these are almost 
completely missing. While every year hundreds of studies on schizophrenia are 
published (the register of the Cochrane Schizophrenia Group currently includes 
12000 controlled clinical trials), most of the studies focus on the question whether a 
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specific drug or psychotherapeutic intervention works or not. What is, however, 
lacking are mechanism-based, rational, sequential studies that address how to deal 
with treatment non-response. Evidence is absent as to what the most appropriate 
follow-up actions should be: continue treatment, or switch to another antipsychotic 
(with another mechanism of action). The use of amisulpride as the first treatment has 
another benefit – it provides a rationale for the kind of drug that should be tried next. 
Amisulpride is a specific D2/3 blocker and thus differs from the other atypicals, which 
have multi-receptor blocking properties. While at a group level, it has been hard to 
show convincingly that one drug is superior to another; there may still be empirical 
support for a rational sequential strategy. Thus, for patients who do not show 
remission to amisulpride, we will compare the option of additional time on the same 
mechanism (the stay option) or moving to a drug with a widely different mechanism of 
action (the switch option).  
Aim: to provide the first randomised double-blind trial comparing a 
mechanistically based stay-or-switch algorithm as the second step in the 
treatment of schizophrenia.  
 
The unfortunate reality of schizophrenia is that despite all interventions and 
approaches, there is a small percentage of patients, who do not respond to first, or 
even second line treatments. The treatment algorithms are quite explicit about what 
to do next – switch to clozapine. This is one intervention that is best supported by 
evidence. However, in this instance there is a great gap between algorithms and 
reality. According to all treatment algorithms, if patients fail 6 weeks each for two 
antipsychotics at adequate doses they should be offered clozapine. This means that 
a first episode patient should be offered clozapine within 12 weeks of start of 
treatment. However, standard treatment evidence shows that the average patient 
being initiated on clozapine has often been psychotic for nearly 10-12 years. In a 
recent small trial, the first episode team in Toronto showed that clozapine can be 
systematically applied as the third line treatment within the first 6 months, and shows 
dramatic benefits for those who had failed two other atypical medications (Agid et al. 
2007). Clearly then, theory and initial evidence suggest that clozapine should be 
used early, not as a last resort. While one does not need another randomized trial to 
demonstrate the superiority of clozapine yet again – one does need a large scale 
demonstration of its early application and its superior impact on outcomes.  
Aim: to provide the acceptability and outcome data on the first systematic, 
large-scale, application of clozapine in non-responding patients within the first 
10 weeks of their treatment initiation. 
 
1.2 Psychosocial intervention: Finding interventions to improve 
medication adherence 
 
Fortunately, first episode patients do often respond reasonably well; the main 
challenge then becomes how to keep them well. The single best predictor of 
continued wellness for the patient is compliance with treatment. And while every 
psychiatrist knows this to be the case – there are few, if any, simple, effective and 
widely applicable manoeuvres at their disposal to increase compliance. 
The sad fact remains that more than half of these patients will stop their medications 
and the majority of them will relapse over the first year. Maintaining drug treatment 
will reduce risk of relapse by five fold – so the challenge is how to keep these 
patients on the medication to which they have responded well. While a number of 
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adherence interventions have been shown to have effect – most of them have been 
cumbersome, site-specific, and difficult to disseminate broadly. To be clinically 
relevant, we need individually-tailored yet widely applicable psychosocial 
interventions that incorporate elements that have been shown to be effective in 
previous studies. Several important elements in non adherence can be identified: 
lack of insight in mental illness, negative attitude to medication, no perceived 
benefits, and lack of support from family members, perceived side effects and 
forgetfulness. To address these, we have developed an IT-enabled programme 
comprising three elements: web-based psycho-education; a web-enabled personally-
delivered motivational intervention package; and electronic medication alerts and 
updates. As these elements of non-adherence may be especially present in patients 
who do not remit, we cannot justify excluding those non-remitted patients who wish to 
take part in this study component. 
Aim: to provide a controlled and randomized test of an IT-enabled, widely 
applicable, intervention to improve treatment adherence and measure its 
effects on adherence, symptoms and global functional outcome in first-episode 
schizophrenia patients. 
 
1.3 Finding biological predictors of treatment response 
 
While we expect that the objectives above will lead to greater clarity and 
effectiveness in the use of current treatments – there is no denying that even when 
our current medications work well and induce symptomatic remission, most patients 
with schizophrenia remain incapacitated. Two major problems linger – residual 
positive symptoms for a sizeable minority; residual cognitive and negative symptoms, 
for a sizeable majority. Five decades of D2-antispychotic research has failed to make 
a major improvement on these aspects of the illness. Thus, we need novel 
mechanisms and novel concepts. Part of the study will focus on the development of 
new treatments using agents that are already available and make use of translational 
studies using genetics/genomics and neurochemical imaging to identify new 
pathways for drug development. We intend to use genetic and genomic approaches 
to explore the possibility of segmenting patient groups and identifying new pathways 
for future drug development. We expect this component of the study to provide 
important novel leads for the development of new treatments in schizophrenia, 
especially for those aspects of the illness that are currently not adequately and 
effectively treated. 
No two patients are the same. Yet, currently, our algorithms make no allowance for 
individual differences. Treatments in psychiatry in general, and schizophrenia in 
particular, are chosen by ‘trial and error’ without reference to or guidance from the 
biological background of the individual. Yet, anyone who has treated patients knows 
that patients respond to one treatment, but not to another. Currently, we lack 
knowledge regarding reliable predictive (biological) markers nor do we have the 
associated technology to detect these markers for determining the most effective 
medication for an individual patient. Consequently, even if we would have at our 
disposal new treatments with alternative mechanisms, we lack the necessary 
knowledge and the associated diagnostic tools to individually tailor the treatment to 
the genetic profile of the patient. Thus, a critical challenge for the field (both to 
optimize current and to advance new treatments) is to develop the ability to deal with 
individual differences and the ability to predict who will respond to what and to 
develop biologically-informed, rather than DSM-IV-generic, treatments.  
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The likelihood of finding reliable biological markers is maximal if one chooses 
homogenous patients in a similar stage of disease. In this regard, the current study 
 with its focus on a homogenous subset in a similar stage of disease (first episode 
patients early in their illness) and all provided with a uniform and specific treatment 
(amisulpride, a relatively clean D2/3 blocker, used in a standardized regimen) 
provides the ideal background against which one can detect biological markers 
predictive of outcome. Which particular markers to focus on, is a matter of legitimate 
debate. We have focussed on two broad strategies – a combination of technology 
driven (pharmacogenetics, proteomics and metabolomics markers) and hypothesis 
driven (neurochemical, glutamate imaging) markers.  
In terms of empirical markers, we have chosen to evaluate pharmacogenetic, 
proteomic and metabolomic markers. These markers have been chosen as they 
provide a high-throughput and minimally invasive (only cheek-swab or blood-draw 
required) intervention and provide a comprehensive analysis. The main challenge 
with these markers is specificity. To overcome this we propose to apply advanced 
bioinformatics driven analysis, but, more empirically – a hypothesis generating set, 
the results from which will be confirmed in a hypothesis-testing set. In addition to 
empirical markers, we will also test imaging-derived hypothesis-driven markers. The 
choice of these markers is driven by the substantial progress in understanding the 
role of glutamate in schizophrenia, and the development of advanced techniques 
(MR Spectroscopy for glutamate) to measure them.  
Aim: to test whether glutamatergic markers predict response to first and 
second line treatments, and if an empirical combination of pharmacogenetic, 
proteomics- and metabolomic markers can provide clinical valuable predictive 
value.  
 
1.4 Testing the utility of MRI screening 
 
A prerequisite for the optimal treatment of schizophrenia is the ability to predict 
treatment outcome and the exclusion of patients whose psychotic symptoms are not 
due to the disorder but to underlying ‘organic’ pathology, such as a cerebral tumour. 
Antipsychotic treatment in these patients is inappropriate and may delay the initiation 
of potentially life-saving medical intervention. Interestingly, despite its obvious 
importance, it is unknown whether a screening for organic pathology in first-episode 
schizophrenia makes medical and economic sense. Guidelines on this question 
(depending on the country issuing these) are either vague or non-existent. This study 
will address this issue by examining the clinical utility of MRI in a sample that is much 
larger than those previously studied, and that is representative of the population of 
patients presenting with first episode schizophrenia or schizophreniform psychosis 
across Europe. Exclusion of patients who do not have schizophrenia or other 
‘functional’ psychoses (and will not respond to psychiatric treatment) through MRI at 
the point of first presentation will maximise the likelihood that antipsychotic treatment 
will be effective. To date, trials of treatment in schizophrenia have relied on clinical 
assessment to exclude organic psychoses: this will be the first study to employ 
neuroimaging for this purpose.   
A second issue is whether MRI abnormalities at first presentation of schizophrenia 
can predict the response to subsequent treatment. Although a number of studies 
have reported that enlarged ventricles and reduced grey matter volume are 
associated with a relatively poor response, these studies have generally involved 
small samples in which treatment was administered naturalistically, with patients 
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receiving a range of different types and doses of antipsychotics. Moreover, many 
involved chronically ill patients that had previously been treated with antipsychotics.  
 
To definitively assess the predictive value of MRI data requires a study in which 
previously untreated patients are scanned prior to the administration of a standard 
treatment, with their response assessed prospectively. Furthermore, the image 
analysis needs to use recently developed methods that take account of spatially 
distributed information in brain tissue data to achieve a better understanding of the 
differences between patients who do and do not respond to treatment.  
Aim: to collect a systematic sample of 200, standardised, high-quality, MRI 
images from first episode patients with minimal prior exposure to medication 
to determine if an MRI in this population has medical and clinical utility. 
1.5 Study objectives 
 
The current trial has eight objectives that are summarized in table 1 
 
Table 1. Objectives of OPTiMiSE. 
 Objectives of the study 
I To test applicability of amisulpride as the first step in a treatment 
algorithm 
II To test guideline recommendation that non-responders to an 
antipsychotic drug benefit from a switch to an antipsychotic with a 
different receptor binding profile 
III To provide the acceptability and outcome data on the application 
of clozapine in non-responding patients within the first 10 weeks 
of their treatment initiation 
IV To test if an IT-enabled psycho-social intervention can improve 
treatment adherence and global functional outcome in first-
episode schizophrenia patients 
V To test whether glutamatergic markers predict response to first 
and second line treatments 
VI To test if a combination of pharmacogenetic, proteomics- and 
metabolomic markers can provide clinical valuable predictive 
value 
VII To define the nature and prevalence of ’organic’ pathology in 
patients presenting with a first episode schizophreniform 
psychosis 
VIII To determine the extent to which MRI measures at first 
presentation predict the therapeutic response to subsequent 
antipsychotic treatment 
Protocol OPTiMiSE study, version 2.4 (July 6, 2015)                                         16 
 
2. Rationale for the study   
 
2.1 Rationale for design of the medication study 
 
In this study, the first episode schizophrenia patients will initially all be treated with 
amisulpride. Our decision on which a particular drug should be prescribed to a first-
episode patient in order to optimise symptom reduction and decrease the chance of 
treatment discontinuation, is partly based on the largest first episode schizophrenia 
study to date: EUFEST (Kahn et al. 2008).   
The EUFEST-study included 498 subjects diagnosed with schizophrenia, 
schizophreniform, or schizoaffective disorder and randomly assigned the patients to 
haloperidol, amisulpride, olanzapine, quetiapine, or ziprasidone. Amisulpride and 
olanzapine did clearly best in terms of the primary outcome ‘treatment 
discontinuation’ due to any cause and the proportion of patients in remission applying 
the remission criteria defined by Andreasen et al.(2005). Furthermore, all second 
generation antipsychotic drugs including amisulpride and olanzapine were associated 
with fewer extrapyramidal side-effects than low-dose haloperidol.  
Olanzapine and amisulpride are clearly effective first line agents with equivalent 
comparative efficacy according to five large randomised controlled trials including the 
Europe-wide randomised EUFEST study (Kahn et al.  2008, Lecrubier et al.  2006, 
Mortimer et al.  2004, Vanelle and Douki, 2006), a meta-analysis of studies 
comparing amisulpride and olanzapine head-to-head (Leucht et al.  2008a) and 
meta-analyses comparing both compounds with typical antipsychotics (Davis et al.  
2003, Leucht et al.  2002). According to these reviews both compounds are among 
the most efficacious antipsychotic drugs. Both are atypical antipsychotic drugs with 
good overall tolerability and few extrapyramidal side-effects (Duggan et al.  2005, 
Leucht et al.  2002), but their receptor binding profiles are very different. In essence 
amisulpride is a selective dopamine antagonist with no significant effects on other 
receptors. Its atypical properties are mainly explained by mesolimbic selectivity. In 
contrast, olanzapine has action on various central receptors, but its atypical 
properties are mainly explained by a stronger antagonism of central serotonin than of 
central dopamine receptors (Bymaster et al. 1999, Perrault et al. 2000). This 
difference in receptor binding profiles is essential for our study. 
In terms of atypical antipsychotics we had to choose two compounds with very 
different receptor binding profiles and similar efficacy. Amisulpride is an ideal choice 
here, because it is very different from all atypical antipsychotics being the only 
selective dopamine receptor antagonist (Perrault et al. 2000). Risperidone would 
have been another alternative, but its receptor-binding profile is less different from 
that of olanzapine (Bymaster et al. 1999). Olanzapine was chosen as another very 
efficacious atypical antipsychotic. There are some concerns supported by meta-
analyses (Davis et al. 2003, Leucht et al. 2007c, Leucht et al. 2008a) that other 
atypical antipsychotic drugs such as aripiprazole, quetiapine or ziprasidone are 
somewhat less efficacious and any such difference in efficacy would jeopardize the 
aims of the study. Clozapine is even more efficacious than amisulpride or olanzapine, 
but its use is complex due to a risk of agranulocytosis, and many other side-effects 
such as hypotension, fevers, constipation, myocarditis making among others slow 
titration necessary.     
If we had chosen a typical antipsychotic drug such as haloperidol the side-effect 
profile would have been too different making blinding a challenge. Despite the debate 
whether there really is a superiority of the atypical antipsychotic drugs it seems that 
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many patients do not accept typical antipsychotics such as haloperidol anymore 
making recruitment very difficult as was the case in a recent German multicenter 
study (Gaebel et al.  2007), this effect was also reported by Lieberman et al. 2005.  
We decided to start patients on amisulpride, because olanzapine is associated with 
considerable weight gain and subsequent metabolic problems. Furthermore, 
amisulpride is available as a generic which is important from a cost-effectiveness 
perspective. Thus, we propose that amisulpride should be the first and rational step 
in a treatment algorithm.  
However, we anticipate that 60% of the patients will not meet remission criteria by 4 
weeks. Whether these patients can benefit from a switch to an antipsychotic featuring 
an alternative receptor binding profile is unclear. Our study will provide the first 
definitive answer to this question. The main aim is to finally address the (unproven) 
guideline recommendation that non-responders to an antipsychotic drug benefit from 
a switch to an antipsychotic with a different receptor binding profile. In light of this, 
non-responders to the initial four-week treatment with the selective dopamine 
antagonist amisulpride will either be continued on amisulpride (control group that 
‘stays’) or switched to the multi-receptor antagonist olanzapine (intervention group) in 
a six-week double-blind trial. The duration of this double blind phase is in line with 
previous switch studies (e.g. Kinon et al., 2010), and comprises a reasonable time to 
prescribe an antipsychotic awaiting a response. 
 
Thus, OPTiMiSE will examine the clinical utility of switching from a selective 
dopamine antagonist to a multireceptor antagonist (i.e. an antipsychotic with a 
different receptor binding profile) in the treatment of first-episode schizophrenia or 
schizophreniform disorder with the goal of reaching symptomatic remission in a 
maximum proportion of patients within 10 weeks of initiating treatment. 
Even after phase II (10 weeks) we expect that about 25% of patients will not have 
reached remission. We will therefore offer these patients (open) treatment with 
clozapine. There is consensus and a lot of evidence that clozapine is the most 
efficacious antipsychotic drug, but it is associated with severe side-effects, especially 
potentially fatal agranulocytosis requiring weekly blood monitoring. Most treatment 
guidelines suggest that clozapine should be started after at least two other 
antipsychotic drugs that were given in sufficient doses and for a sufficient duration 
have failed. According to current recommendations, a patient who fails two trials of 6 
weeks with an antipsychotic should be offered clozapine, which would imply that a 
first episode patient should be offered clozapine within 12 weeks of start of treatment. 
However, this is hardly ever the case: standard treatment evidence shows that the 
average patient being initiated on clozapine has often been psychotic for nearly 10-
12 years! Recent data suggest however that clozapine can be systematically applied 
as the third line treatment within the first 6 months, and shows dramatic benefits for 
those who had failed two other atypical medications. Therefore we will explore 
whether treatment with clozapine will increase the number of first-episode patients 
who will reach remission after having failed adequate treatments with both 
amisulpride and olanzapine. Thus, OPTiMiSE will provide the acceptability and 
outcome data on the first systematic, large-scale, application of clozapine in non-
responding patients within the first 12 weeks of their treatment initiation. 
The choice of clozapine for the non-responders to both phases I and II is justified, 
because clozapine is generally considered to be the most efficacious compound in 
refractory patients by all treatment guidelines.   
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This has been documented by many single trials and meta-analyses (Kane et al. 
1988; Leucht et al. 2009; McEvoy et al. 2006; Rosenheck et al. 1997; Wahlbeck et al. 
1999). The evidence in first episode patients is more limited, but a recent small trial 
by the first episode team in Toronto showed that clozapine can be systematically 
applied within the first 6 months, and shows dramatic benefits for those who had 
failed other atypical medications (Agid et al. 2007).  
 
2.2 Rationale for selection of the primary study endpoint “symptomatic 
remission” 
 
Until some years ago, studies suffered from a lack of agreement on the best way to 
conceptualise response to treatment. Usually response was defined as a percentage 
reduction of a rating scale (PANSS, BPRS) total score, but many cut-offs have been 
used (20%, 30%, 40%, 50%) the lowest ones probably not being clinically significant. 
Furthermore, a PANSS reduction from 120 to 60 and from 60 to 30 both (after 
subtracting the 30 minimum PANSS points), are 50% reductions but the first patient 
is still much more ill than the second one. This issue was tackled by the 
Schizophrenia Working Group who developed a consensus definition of remission. 
Symptomatic remission will be defined according to the criteria of Andreasen et al. 
(2005): 8 specific symptoms (PANSS items P1, P2, P3, N1, N4, N6, G5 and G9) of 
schizophrenia as measured by the Positive and Negative Syndrome Scale (Kay et al.  
1987) are at the most only mildly present (maximum rating of “3”) so that they do not 
interfere with daily life functioning. This definition of remission shows good clinical 
validity and is associated with clinical and quality of life outcomes (see below). It has 
also been shown to be a realistic goal of antipsychotic drug treatment. Importantly, in 
the European First Episode Schizophrenia Trial (EUFEST) study, 40% of first-
episode patients treated with amisulpride and olanzapine reached the new remission 
criteria within the first four weeks, supported by other findings.   
Since the introduction by Andreasen et a in 2005 numerous studies have shown that 
the remission criteria are strongly associated with clinically valid outcomes such as 
quality of life, social and occupational functioning, cognitive functioning, subjective 
well-being and maintenance of symptomatic stability ( De Hert et al.  2007, Ciudad et 
al.2009, Dunayevich et al. 2006, Helldin et al. 2006, Helldin et al. 2007, Lambert et 
al.2006, San et al.  2007, Emsley et al.  2007, Nasrallah and Lasser 2006, Opler et 
al. 2007, van Os et al.  2006). Analyses of large databases showed that they are an 
achievable and realistic goal in antipsychotic drug trials (Leucht et al.  2007a). We will 
not analyse the time criterion of the remission criteria which only applies to long-term 
studies. Another advantage of these remission criteria is that they are easier to 
interpret than the mean change from baseline to endpoint of the PANSS. A 
symptomatic remission is also a harder outcome than a mean change of a rating 
scale. As remission means that key symptoms of schizophrenia are at the most only 
mildly present, such patients usually do not need further hospitalization. Therefore, 
this outcome will also emphasize the cost aspect of the early switching strategy. 
In summary, the new remission criteria are a clinically meaningful primary outcome 
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2.3 Rationale for selection of Study Population 
 
Although antipsychotics have been used in the treatment of schizophrenia for over 
half a century it is still not known whether switching from one antipsychotic to another 
is useful in patients who fail treatment with the first drug. In fact, studies that 
examined this issue are few and far between and are hampered by small sample 
sizes and methodological limitations. This paucity of studies is even more 
pronounced for people with a first episode of schizophrenia, although the first 
episode is a crucial stage of the illness where rapid and effective treatment is 
considered key for the subsequent clinical course and long-term outcome. Despite 
the lack of sound prospective studies on this question, treatment guidelines usually 
recommend switching to an antipsychotic drug with a different receptor binding profile 
in case the initial antipsychotic failed, but the underlying assumption has never been 
proven in an adequate trial. This is one of the objectives of the current trial. 
2.4 Rationale for studying biological predictors 
 
One of the major shortcomings in the current treatment of schizophrenia is that we 
have no valid criteria in clinical practice to decide which form of treatment should be 
chosen first. The identification of blood based biological markers of drug response 
with a good sensitivity and specificity would enable the physician to use these tests 
prior to choosing the antipsychotic treatment and therefore help the practitioner in his 
daily clinical practice. Secondly, the identification of these markers will help to identify 
new and more specific pharmacological targets as it will indicate which pathways are 
implicated in drug response. Currently, studies of biomarkers have been mostly 
performed in the field of candidate genes, and it has to be acknowledged that the 
overall yield has been disappointing. The few robust results have been in relation to 
side-effects, e.g., association of the DRD3 variant with extra-pyramidal symptoms, 
but no single biomarker can be considered to be strongly associated with drug 
efficacy. This lack of success is not surprising as most studies focused on only a few 
candidate genes, mainly dopaminergic receptors and transporters and serotoninergic 
receptors, not taking in consideration the large number of potential pharmacodynamic 
and pharmacokinetic targets which may be implicated in antipsychotic action either in 
terms of efficacy or tolerance. The second main weakness of these studies has been 
the quality of the clinical assessment. Drug response has been mostly measured 
retrospectively in very inhomogeneous cohorts mixing together first psychotic 
episodes and chronic schizophrenia patients. Finally, studies to date have examined 
the usual candidate genes, but have ignored the vast amount of literature and 
determinants known to influence pharmacokinetic and pharmacodynamic aspects.  
To overcome this we will use a special pharmaco-genetic (PG) chip developed at 
INSERM. This PG-chip, which is dedicated to genotyping 15,000 polymorphisms, 
makes it possible to reconstruct the haplotype diversity of 1292 genes implicated in 
the metabolism, transportation, and targeting of drugs as well as to genotype the 
functional polymorphisms that are indispensable for certain genes which are not 
included in GWA chips. This is a tool at the intermediate scale between a low-
throughput candidate gene approach, and a pan-genomic approach, for which 
virtually no pharmacogenetic cohort has sufficient power. This PG chip includes 
genes implicated in drug metabolism, drug transport, inflammation (including 158 
HLA genes), metabolism, apoptosis, inflammation, chemokines, cytokines, brain 
receptors and other proteins, signal transduction (carcinogenesis), and DNA repair. 
The OPTIMISE trial will make it possible to overcome the limitations of the previous 
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studies.  A) We will begin with a set of homogenous patients – by focussing on first 
episode patients at similar stage of disease. ; B) we will provide a uniform 
standardised treatment on the first step; C) we will provide relatively straight forward 
receptor blockage by choosing amisulpride, a relatively specific D2 blocker, and D) 
we will have a broad series of pharmacokinetic and pharmacodynamic markers so 
that we provide coverage for more potential predictors than the traditional 
dopamine/serotonin based markers in previous studies.  
Pharmacogenetics measures a fixed trait variable, whereas response in patients is 
likely determined by a mixture of fixed traits and dynamic variables. It is in this regard 
that focusing on distal and dynamic variables is equally relevant. There are several 
options to measure this dynamic profile. We will look at the pattern of protein and 
metabolic expression changes that are induced by the drug and use those to infer 
mechanisms and predict response. It should be acknowledged, that at this stage all 
these methods remain exploratory. However, we have chosen to focus on 
‘proteomic’, ‘metabolomic’ and ‘inflammatory’ approaches as these are the level of 
biology that is most proximal (as compared to genotype and gene-expression) to 
phenotypic outcome.  
Proteomics in relation to treatment response (pharmacoproteomics) is an emerging 
field. Holmes et al. (2006) found that metabolic profiles showed a highly significant 
separation of patients with first-onset schizophrenia from healthy controls. That short-
term treatment with antipsychotic medication resulted in a normalization of the 
disease signature in over half the patients indicates the potential for biomarkers as 
monitors for clinical treatment. However, the Holmes et al. (2006) sample was small, 
the treatment not fully controlled and the drugs used had multiple modes of action. 
We have two unique opportunities in our study. First, for the reasons mentioned 
above we will have data on a homogenous population, with standardized treatment 
and a specific agent – something that has been lacking in previous studies. Second, 
we will have sufficient size to undertake a ‘hypothesis-generating’ sample, followed 
by a ‘hypothesis-testing’ sample – thus providing us with sufficient rigour to make 
some conclusion. The discovery phase of the project will focus on the identification of 
novel specific biomarker patterns relevant to predicting and/or monitoring patient 
response to amisulpride treatment in serum/plasma, using 30 responders and 30 
non-responders matched for ethnicity, gender and age. In the discovery phase two-
dimensional gel electrophoresis will be used followed by labeled MS based 
discovery, which is more sensitive than label free methods. Any findings will be 
validated in an additional set of responders and non-responders by direct MS multiple 
reaction monitoring and immunodetection methods.  
Metabolomics can also provide valuable information about disease pathogenesis and 
result in metabolic signatures that could be developed as biomarkers for disease and 
progression. Pharmacometabolomics is emerging as a new field that could 
complement pharmacogenomics by providing precise intermediate phenotypes for 
drug response. Metabolomics could add significantly to our understanding of both 
pharmacokinetic and pharmacodynamic properties of drugs. We will use a method of 
targeted analysis of metabolites with high throughput quantitative mass spectrometry. 
This is a new and versatile tool for comprehensive analysis of large populations 
which includes lipids, sugars, and amino acids and many other analytes. 
There is considerable evidence that schizophrenia is associated with immune system 
dysregulation. For example, blood and cerebrospinal fluid (CSF) levels of 
proinflammatory cytokines are significantly increased in schizophrenic patients, and 
their normalization correlates with improvement in psychotic symptoms. Among 
schizophrenic patients, significant correlations between the levels of antigens issued 
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from HERV.W virus (GAG or ENV proteins) present in the blood and the levels of C-
reactive protein (CRP), which is considered as a hallmark marker for systemic 
inflammation, were identified. Some evidence also indicates that typical and atypical 
antipsychotics modulate immune function in vitro and in vivo studies and have anti-
inflammatory properties. We will therefore also study some inflammatory parameters 
during the OPTIMISE trial. The status of systemic inflammation will be determined by 
standard ELISA for C-Reactive Protein (CRP). The activation of the blood 
complement will be followed by the dosage of complement components (C1, C3, C4) 
by the mean of ELISA or functional standards assays. Several cytokines will be 
measured by standard ELISA in the blood, including those indicative of the immune 
and inflammatory status, such as the pro-inflammatory cytokines (IL1, IL6, IL8, TNF-
alfa, TGF-alfa and those indicative of the lymphocyte response commitment such as 
Th1 type cytokines (IFN-alfa), Th2 type (IL4, IL10) and Th17 type (IL17). 
The final biological predictor we will assess will be regional brain glutamate levels, as 
measured using MR Spectroscopy. A proportion of patients with schizophrenia do not 
respond well to treatment with antipsychotic drugs. This could be because, in these 
patients, dysfunction of the brain glutamate system is particularly important to their 
illness. As a result, treatment with antipsychotic drugs, which usually act on brain  
dopamine recptors but have little impact on the glutamate system, may be relatively 
ineffective. We aim to use MR spectroscopy to measure brain glutamate in a 
subgroup of the total sample. We predict that patients with a prominent disturbance 
of glutamate levels will be particularly unlikey to respond to treatment with 
amisulipiride, which only acts on the dopamine system.  
 
2.5 Rationale for the Psychosocial intervention 
 
The response rate to antipsychotic medication in first episode patients is high (Kahn 
et al, 2008). Maintenance treatment is effective in maintaining remission and 
reducing relapse rates by five fold after this (Robinson et al, 2003). Strategies such 
as intermittent, targeted treatment after the first episode appear not be as effective as 
continuous maintenance treatment (Wunderink et al, 2007) in preventing relapse. 
However, the real-life effectiveness of maintenance treatment is limited by high rates 
of non-adherence after the first episode, at 50% or higher during the first year. 
Negative attitudes to medication, perceived lack of efficacy, substance use, lack of 
insight, cognitive impairments and side effects (Mutsatsa et al 2003; le Quach et al 
2008) have been shown to contribute to non-adherence. 
 
Definitions of poor adherence vary but 42-60% of first episode sufferers show poor  
adherence in naturalistic cohorts followed-up for one year or more (Verdoux et al, 
2002, Mojtabai et al, 2002, Coldham et al, 2002). Poor adherence with treatment is a 
particular challenge in the first year compared to later stages of illness because 
placebo controlled trials show a greater benefit of antipsychotics in first episode 
treatment and first relapse prevention. Attention and time paid to therapeutic alliance 
at this stage may be returned later on. Several important elements in non adherence 
can be identified: lack of insight, negative attitude to medication, no perceived 
benefits, lack of family support and side effects (Kampman et al, 2002, Mutsatsa et 
al, 2003, Perkins et al, 2006). We will evaluate the effectiveness in maintaining 
remission of an IT-enabled programme comprising three elements: web-based 
psycho-education; a motivational intervention package; and electronic medication 
alerts and updates. The effectiveness of this programme will also be investigated 
within a group of non-remitted patients; as the elements of non-adherence may be 
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especially present in these patients, we cannot justify excluding non-remitted patients 
from this study. If they wish, they may be randomized into the psychosocial 
intervention component. 
 
2.6 Rationale for the MRI measurements 
 
The proportion of patients presenting with a first episode psychosis due to underlying 
organic pathology has been estimated in different studies at 1-10% (Woolley & 
McGuire, 2005; McGuire, 2007). The most effective means of detecting organic 
causes of psychosis is MRI scanning, and inclusion of MRI in the initial assessment 
of psychosis is considered good practice in most economically developed countries 
(American Psychiatric Association, 2004; Royal Australian & New Zealand 
Psychiatric Association, 2005). In the UK, NICE recently considered whether an MRI 
scan should be a routine part of the assessment of all new patients with psychosis, 
but deferred making a decision as the existing literature comprises studies of small, 
potentially unrepresentative samples (http://www.nice.org.uk/TA136). There is thus a 
need for a study that will determine the true prevalence of organic causes of first 
episode psychosis and shape future clinical management in this area.  
 
OPTiMiSE will address this issue by examining the clinical utility of MRI in a sample 
that is much larger than those previously studied, and that is representative of the 
population of patients presenting with first episode schizophreniform psychosis 
across Europe. Exclusion of patients who do not have schizophrenia or other 
‘functional’ psychoses (and will not respond to psychiatric treatment) through MRI at 
the point of first presentation will maximise the likelihood that antipsychotic treatment 
will be effective. To date, trials of treatment in schizophrenia have relied on clinical 
assessment to exclude organic psychoses: this will be the first study to employ 
neuroimaging for this purpose.   
 
A second aim within the scope of this objective is to evaluate whether the severity of 
volumetric MRI abnormalities (as identified using voxel-based morphometry (VBM)) 
or a particular topographic distribution of alterations in regional grey matter volume 
(as identified with a pattern recognition approach) at first presentation of 
schizophrenia can predict the response to subsequent treatment. A number of 
studies have reported that ventriculomegaly (Weinberger et al, 1980; Schulz et al, 
1983), and reduced total (Zipursky et al, 1998) and reduced regional (Molina et al, 
2003) grey matter volume are associated with a relatively poor response. However, 
these studies have generally involved small samples (n=12-45) in which treatment 
was administered naturalistically, with patients receiving a range of different types 
and doses of antipsychotics (Friedman et al, 1992). Moreover, many involved 
chronically ill patients who had previously been treated with other antipsychotics. To 
date, neuroimaging studies have related therapeutic response to differences that are 
localised in space and linear in nature, such as the volume of a particular brain 
region. However, the neuroanatomical changes that are associated with 
schizophrenia are subtle and spatially distributed, and may be more readily detected 
using image analysis methods that employ spatially distributed information 
(Davatzikos 2004), such as a Support Vector Machine (SVM) approach. To 
definitively assess the predictive value of MRI data requires a study in which 
previously untreated patients are scanned prior to the administration of a standard 
treatment, with their response assessed prospectively in a double-blind fashion. 
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Furthermore, the image analysis needs to use recently developed methods that take 
account of spatially distributed information in brain tissue data to achieve a better 
understanding of the differences between patients who do and do not respond to 
treatment.  
 
By applying these methods to MRI data at first presentation, and relating this to the 
subsequent response to a single antipsychotic drug, OPTiMiSe will provide for first-
of-its kind, methodologically sound evidence of MRI as a clinical predictor of 
antipsychotic response.  
 
OPTiMiSe will thus use state of the art MRI technology to study a representative 
sample of patients with first episode of schizophrenia who have not previously had a 
course of antipsychotic treatment, and from which patients with ‘organic’ psychoses 
have already been excluded. Patients will be scanned prior to treatment with 
amisulpride, administered according to a standardised dosing regimen. The proposed 
sample of n=200 represents the largest ever sample of patients with schizophrenia to 
be studied with MRI, and will provide sufficient power to determine the true 
prevalence of ‘organic’ psychoses in this population, and the extent to which the 
severity of volumetric abnormalities predicts the subsequent clinical response.  
 
It is expected that the study will provide: 1) A definitive assessment of the proportion 
of patients presenting with first episode psychosis that have an ‘organic’ aetiology 
(that requires non-psychiatric treatment); 2) A definitive assessment of the ability of 
MRI to predict response to treatment in schizophrenia. These are likely to be a key 
reference points for national guidelines for the optimal treatment of   schizophrenia. 
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3. Study design 
 
In the current study 500 patients with a first episode of schizophrenia or the diagnosis 
schizophreniform / schizoaffective disorder will be included From 200 of these 500 
patients, MRI will be acquired at screening to check for neurological disorders. In 
addition, spectroscopy will be performed at selected centres in 40 patients. This 
spectroscopy will be repeated 4 weeks after treatment.  
All 500 patients will enter a four week open-label treatment with the anti-psychotic 
amisulpride (phase I). Those patients who are not in symptomatic remission at the 
end of these four weeks enter a 6-week, randomised, double-blind phase of either 
continuation of amisulpride or switching to olanzapine (phase II). Those patients who 
are still not in symptomatic remission at the end of this phase are treated with open-
label clozapine for 12-weeks (phase III).   
 
Assignment to a treatment option in phase II of the study will be performed randomly 
to eliminate the possible influence of arbitrary delegation of patients on the study 
results. This is also done to evenly distribute known and currently unknown factors 
potentially influencing outcomes (such as demographic factors or findings at the 
baseline examination), which increases the validity of statistical analyses. The 
double-blind administration of medication is done to minimise the influence of 
expectancy regarding the type of medication on the measurement of clinical 
parameters and data collection. Antipsychotic treatment in phase I and phase III of 
the study is open-label as no alternative treatment option is available in these phases 
(uncontrolled study setting).  
 
The study flow and assessments that will be performed are depicted schematically in 
Flowchart 1. 
Patients in symptomatic remission, as defined by the criteria of Andreasen et al. 
(2005) at each stage of the trial, including those responding to the initial 4 week 
open-label treatment with amisulpride, those on amisulpride or olanzapine after the 
additional 6-week double-blind treatment phase, and those responding to 12-weeks 
open label clozapine treatment will be randomized to receive either a 12-week 
psychosocial treatment intended to increase medication adherence or to treatment as 
usual. The psychosocial adherence programme includes 3 components: psycho-
education of participant and (where available) family using web-based materials, 
motivational interviewing sessions and medication alerts and simple messaging and 
web interface via mobile phone. The effectiveness of this programme will also be 
investigated within a group of patients that are not remitted. These patients are either 
at the end of the pharmacological component or have dropped out during one of the 
phases of this component. If they wish, they may be randomized into the 
psychosocial intervention component. The study flow and assessments that will be 
performed for the psychosocial intervention are depicted schematically in Flowchart 
2. 
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4. Study population 
4.1 Population 
 
This study will include 500 patients with a first episode of schizophrenia or the 
diagnosis schizophreniform disorder. All patients fulfilling the inclusion and exclusion 
criteria as described below may, after a detailed description by a doctor and the 
written declaration of informed consent, participate in the study.  
200 of these 500 patients, in selected centers, will participate in the MRI part of the 
study. 
The MRI part of the study will also include 100 healthy controls, matched to the 
patient sample for age, gender, ethnicity, IQ and parental social class. Controls will 
be recruited by advertisements from each site in a similar proportion to the patients. 
These subjects will undergo the same MRI measurement as the patients, but will not 
participate in other parts of the study.  
4.2 Inclusion Criteria 
 
 Diagnosis of schizophrenia, schizophreniform or schizoaffective disorder as 
defined by DSM-IV on the basis of the Mini International Neuropsychiatric 
Interview Plus (M.I.N.I. Plus; Sheehan et al. 1998). Schizophreniform disorder 
is assessed through a M.I.N.I. diagnosis of psychosis NOS complemented by 
a diagnosis of schizophreniform disorder according to DSM-IV criteria.  
 Age 18-40 years  
 Written informed consent. 
 Female patients of childbearing potential need to utilize a proper method of 
contraception (the pill, vaginal ring, hormonal patch, intrauterine device, 
cervical cape, condom, contraceptive injection, diaphragm, abstinence).  
 
4.3 Exclusion criteria 
 
 A time interval between the onset of psychosis and study entry exceeding two 
years. 
 Prior use of antipsychotic medication longer than an episode of two weeks in 
the previous year and/or 6 weeks lifetime. 
 Intolerance to one of the drugs in this study. 
 Patients who are coercively treated at a psychiatric ward (based on a judicial 
ruling) 
 Patients who are represented by a legal guardian or under legal custody 
 The presence of one or more of the contraindications against any of the study 
drugs as mentioned in the IB texts (listed in Appendix B). 
 Pregnancy, as determined through a pregnancy test, or lactation 
 
Additional exclusion criterion, specifically for patients and healthy controls 
participating in MRI/MRS procedures (if patients meet this exclusion criterion, they 
can still participate in the remainder of the study):  
 Presence of any contraindication to MRI scanning (e.g. implanted metallic 
object or electronic device) 
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4.4 Sample size and power calculation 
 
Power calculation for objective I, II and III: Finding evidence for 
pharmacotherapy guidelines in first episode schizophrenia 
The first phase of this study will include 500 first-episode patients. Data of the 
EUFEST study, which is one of the largest first-episode trials to date, showed that 
about 40% of the patients on amisulpride were in symptomatic remission (as defined 
by Andreasen et al. 2005) within four weeks  which therefore seemed a realistic goal 
for phase I in which all patients will be treated for four weeks with amisulpride. This 
assumption would require 350 patients to be enrolled into the study. However, 
halfway through the study almost 60% of phase I patients met remission criteria. 
Subsequently, the power analyses was adjusted to the following: 
Statistical power phase II 
After these four weeks, we will classify patients who are in symptomatic remission 
within four weeks (~60%) as responders. The patients who are not in symptomatic 
remission within four weeks (~40%) will be classified as non-responders. We will test 
whether symptomatic remission rate is improved in patients who are switched to 
olanzapine in comparison to patients who stay on amisulpride (phase II). Based on 
EUFEST we expect that 50% of the four-week non-responders who stay on 
amisulpride will be in symptomatic remission after another six weeks of treatment (10 
weeks from treatment initiation). If the percentage of patients in remission increases 
from 50% to 70% as a result of switching to olanzapine (which is an estimation, as 
there are no prior studies on this topic), the two treatment arms will have to contain 
90 patients each to obtain a statistical power of .79 with a type-I error rate of .05. If 
we consider that the drop out rate is approximately 30% and the remission rate is 
60% (both observations after 250 patients have been enrolled into the study), than 
this implies that at least 487 patients will have to be included at baseline, taking into 
account a drop-out of 30% during phase II (observation in first 50 phase II patients). 
 
Power calculation for objective IV: Finding psycho-social interventions to 
improve medication adherence 
A power calculation based on non-adherence shows that, with a 2 tailed alpha of 
0.05, a sample size of 180 (264 randomised with a 30% dropout rate), would have 
90% power to show a reduction in non-adherence rates from 50% with routine care to 
25% in the psychosocial program arm. If dropout rates are 20%, power increases to 
96%. With the functional outcome, n=180 would have over 80% power to detect a 10 
point difference in mean GAF score (common GAF SD 19, data from SoCRATES 
trial). When the remission rates and drop out rates during the study indicate that 180 
patients can be expected to complete the psychosocial intervention component, 
inclusion of new subjects into this component will be closed. 
 
Power calculation for objective V and VI: Finding biological predictors of 
treatment response 
Our decision on the number of participating centres was based on the sample size 
required to test our hypothesis and the expertise and infrastructure available at each 
site. We have based our sample size on our primary predictive variable of r > 0.6, 
with a Type I error of < 0.05 and a power of 80% (Type II error of < 0.2). Under these 
conditions we will need 32 completed subjects with baseline scans and final ratings, 
and assuming a 20% dropout rate, we seek 40 subjects for 32 completers. 
Given that this is an intensive study, and assuming that 33% of participants who take 
part in the clinical protocol at a given Centre will also agree to take part in this 
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neuroimaging study – we have selected Centres which have a combination of well 
established first episode programs and a track record of successful MRS imaging 
studies in schizophrenia. We expect that of the 32 subjects who will complete the 
baseline imaging and clinical part of the trial, 20-25 would be willing to undergo a 
second scan to examine the effect of treatment and this would provide us with an 
ability to detect correlations of r>0.7 between change in glutamate parameters and 
treatment outcome with a Type I error of < 0.05 and a power of 80% (Type II error of 
< 0.2).  
 
We have since analysed the MRS data collected until March 2013 and recalculated 
the power analyses using the values from these data. The data until March 2013 
showed a true difference in mean glutamate levels (scaled to creatine) between 
responders and non-responders as 0.25, associated with a standard deviation of 
0.31. Power analysis was performed using these values and following parameters: 2 
tailed t-test, alpha = 0.05, power = 0.8, ratio of responders: non-responders =  6:4. 
This returns a total sample size of 52 completed subjects, estimated to comprise of 
31 responders and 21 non-responders. Using the same 20% drop-out rate we 
therefore seek 63 subjects for 52 completers. The increase from our additional 
estimate is likely due to additional variability arising from data acquisition using 
multiple MRI scanners. While we are still collecting empirical data on this variability, 
the revised power analysis inherently accounts for this, as it is based on actual multi-
centre data. 
 
65% of subjects recruited to March 2013 also completed a second MRS scan. This 
suggests a total of 34 subjects would be willing to undergo a second scan from a 
sample of 52. Using the same drop-out rate, we estimate 22 of these subjects would 
be willing to undergo a third MRS scan. Based on the same data as above, to detect 
a within-subjects change in glutamate levels of 0.2, power analysis suggests that 
follow-up scans in 20 subjects (alpha = 0.05; power = 0.8; SD =0.31) are required. 
 
For the biological markers the power calculation was based on genetic predictors as 
they are the most studied at the time. The sample size (500 patients) will provide us 
with an ability of detecting an Odds Ratio of 1.9 with a Type I error of < 0.05 and a 
power of 86% (Type II error of < 0.14) when comparing responders and non-
responders at Week 4. For that we hypothesize that the proportion of responders will 
be around 60%. 
 
Power calculation for objective VII and VIII: Testing the utility of MRI screening 
The effect size for volumetric data predicting treatment response in schizophrenia 
varies widely between studies, which may have been due to differences in the 
samples investigated in these studies, with the largest effect size (3.1) in a study of 
younger patients with a relatively brief history of previous treatment. The effect size 
for differences in cortical grey matter volume between good and poor responders in a 
first episode schizophrenia sample was approximately 0.75. In the volumetric 
analysis, assuming a more modest effect size or 0.5, at a statistical threshold of 
p=0.05, we would require subgroups of n=63 subjects to detect differences between 
responders and non-responders at 80% power. The minimum number of subjects 
needed for training and testing classifiers in order to obtain a statistically significant 
sensitivity and specificity in pattern recognition approaches has yet to be 
investigated. However, a number of studies have demonstrated that it is possible to 
obtain a good classification of subjects with sample sizes of 30 - 70. Thus, in the 
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current sample of 200 patients, we will have substantial statistical power to detect 
differences between responders and non-responders.  
5. Primary and secondary study endpoints 
 
For all four main goals of the study (described in section 1), the primary and 
secondary endpoints are defined below: 
5.1 Primary study endpoint 
 
I Finding evidence for pharmacotherapy guidelines in first episode 
schizophrenia 
The primary outcome is the number of participants in remission at the end of phase I 
(4 weeks open treatment with amisulpride), phase II (double-blind treatment with 
amisulpride or olanzapine, comparison between arms) and phase III (open treatment 
with clozapine).  Symptomatic remission will be defined according to the criteria of 
Andreasen et al. (2005): 8 specific symptoms (PANSS items P1, P2, P3, N1, N4, N6, 
G5 and G9) of schizophrenia as measured by the Positive and Negative Syndrome 
Scale (Kay et al.  1987) are at the most only mildly present (maximum rating of “3”) 
so that they do not interfere with daily life functioning. The PANSS itself is a validated 
measure (Kay et al.  1987) and it is the most widely used scale to assess the 
symptoms of schizophrenia.  
 
II Finding interventions to improve medication adherence 
The primary outcomes will be (i) drug adherence rates defined categorically 
(adherent vs non-adherent) as a function of standardised self report and Sellwood 
rating scales; and (ii) global functioning (SOFAS score) at 1 year. Based on self 
report, the most widespread definitions of non-adherence are (a) stopping medication 
for at least one week during follow up (b) taking the prescribed drug less than 90% of 
the time.   
 
III Finding biological predictors of treatment response 
 
The primary outcome for biological predictors will be drug response defined 
categorically (remission vs non-remission) as a function of biological profile (eg: 
presence or absence of genetic variants, proteomic profile, metabolomic profile, 
immunologic profile). The primary outcomes of the MRS scans are the difference 
between responders and non-responders in regional glutamate levels a) at baseline 
and b) between baseline and after one month of treatment with amisulpiride.  
We will addionally acquire a third MRS scan after 10 weeks of treatment (end of 
Phase II) to determine whether a) in patients randomised to amisulpride in phase II 
whether changes in glutamate take some time longer to appear, by comparing 
baseline and 10 week data and b) comparing second (end of phase 1) and third 
scans (end of phase 2) in patients randomised to amisulpride versus olanzapine in 
phase II whether a multireceptor agent (olanzapine) has greater effect on glutamate 
than a dopaminergic agent (amisulpride).   
IV Testing the utility of MRI screening 
Primary outcome is the percentage of first episode patients that show radiological 
abnormalities suggestive of neurological disorders which may explain the occurrence 
of psychotic symptoms. 
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5.2 Secondary study endpoints 
 
I Finding evidence for pharmacotherapy guidelines in first episode 
schizophrenia 
The secondary outcome measure is all-cause treatment discontinuation. Number and 
reason for premature discontinuations (treatment discontinuation) of the amisulpride 
and the olanzapine group will be compared. 
Other measures which are included are the severity and improvement subscores of 
the Clinical Global Impressions Scale (CGI; Guy 1976) which will assess the overall 
severity and improvement of the participants. Levels of depression will be assessed 
with the Calgary Depression Scale for Schizophrenia (CDSS, Addington). The Global 
Assessment of Functioning scale (GAF; Jones et al. 1995) will be used to assess 
social functioning. The UKU side effects rating scale will be used to assess adverse 
effects of antipsychotic medication (Lingjaerde et al., 1987). We will assess weight 
gain, abdominal circumference and further adverse events with open interviews. The 
safety and tolerability of the study drugs will be monitored by the frequency and 
severity of side-effects. 
 
II Finding interventions to improve medication adherence 
Two process measures will also be used at baseline and 3 months, to test whether 
any improvements in adherence seen in the psychosocial intervention group can be 
attributed to the interventions: psycho-education assessed by Knowledge About 
Psychosis Scale (adapted from KASI scale and MI assessed by Drug Attitude 
Inventory (DAI-30). Secondary analyses include a comparison of all-cause treatment 
discontinuation between treatment groups as well as further investigation of 
adherence improvements in the group of patients that entered this component while 
not being in remission versus those who were in remission.  
 
III Finding biological predictors of treatment response 
The secondary outcomes are:  
1. the ability of biological markers to predict response to antipsychotic in 
schizophrenia considered  as a continuous variable (percentage of diminution of the 
PANSS total and sub-scores)  
2. the ability of biological markers to predict antipsychotic treatment tolerability. 
 
IV Testing the utility of MRI screening 
The secondary outcome is the ability of MRI to predict response to antipsychotic 
treatment in schizophrenia. 
6. Treatment of subjects 
6.1 Treatment strategy and dosing 
 
Dosing of study drugs  
The dose ranges of the study medication in acutely ill patients with schizophrenia are 
well documented. Amisulpride will be given in doses between 200 and 800 mg/day 
(target dose 400 mg/day), for olanzapine the dose range will be 5-20mg/day. The 
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dose range of clozapine will be 100-900mg/day (Kane et al. 1988). The distribution of 
the doses over the day will be at the discretion of the investigators.  
 
Phase I 
After screening and inclusion in the study, the participants will receive open-label 
treatment with amisulpride in the first week. The following titration schedule is 
suggested, but variations are allowed as long as the patient is at a dose of 
amisulpride of 200, 400, 600 or 800 mg at the end of phase I. Intermediate dosage 
(i.e., 100, 300, 500 or 700) will cause serious problems in the transition to double 
blind phase II medication. Suggested titration: 
- start with 100mg (half a tablet) 
- day 4: increase to 200mg 
- day 8: increase to 300mg 
- day 12: increase to 400mg 
 
For some patients, the target dose of 400mg may not be tolerated. In these patients, 
a stable dose of 200mg can be used. However, a dose decrease should only be 
chosen if a patient suffers side-effects. In others, 400mg may not be sufficient, in 
which case the dose of 600 or 800mg may be preferred.  
 
Phase II  
Those patients who are in symptomatic remission at the end of Phase I according to 
the criteria by Andreasen et al. (2005) will be randomized to either the psycho-social 
intervention to increase adherence or to treatment as usual (see section 9.2.2).  
Those patients who are not in symptomatic remission will be randomized to six 
weeks double-blind treatment with either amisulpride at flexible doses between 200 
and 800 mg/day, or olanzapine with flexible doses between 5 and 20mg/day. In the 
control group of patients staying on amisulpride, the patients will receive the same 
amount and size of capsules as in the olanzapine group to maintain the blind. This is 
accomplished by the creation of capsules which contain either 5mg of olanzapine or 
200 mg of amisulpride. At the start of phase II, patients will receive one capsule per 
day instead of one 200mg tablet of amisulpride of their previous dosing in phase I. 
Switching from phase I to phase II will occur between day 1 and day 7 of phase II, 
dependent on the dose a patient receives in phase I. Titration of the tablets 
amisulpride to the capsules amisulpride or olanzapine is described in Table 2 below. 
The left column provides the 4 possible amisulpride dosages at the end of phase I 
(200, 400, 600 and 800 mg/day); on the respective rows the titration schedule for the 
first 7 days of phase II are provided. For instance, if a non-responder used 400 
mg/day at the end of phase I, this patient will continue to use 2 tablets a day for the 
first 2 days of phase II, replace one tablet with one capsule per day on days 3 and 4, 
and stop using the tablets altogether on day 5, only using capsules in a dosage that 
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Table 2. Titration schedule from tablets (phase I) to capsules (phase II) 
  
After all tablets have been substituted by capsules, dose may be adjusted if deemed 
necessary by the physician, to a minimum of 1 and a maximum of 4 capsules. 
However, a dose decrease should only be chosen if a patient suffers from side-
effects. Patients who drop out during this phase due to a lack of effect of amisulpride 
or olanzapine, may continue into phase III of the study. 
 
Phase III 
Those patients who are still not in symptomatic remission after 10 weeks from 
treatment initiation will continue in an open-label phase in which they will be treated 
with clozapine. The previous treatment with amisulpride or olanzapine will be 
gradually tapered off during the first 2 weeks of this phase. Refer to Table 3 for a 
suggested schedule on tapering off the double blind medication. The left column 
provides the 4 possible double blind dosages at the end of phase II (1-4 capsules a 
day); on the respective rows the titration schedule for the first 7 days of phase III are 
provided. For instance, if a non-responder used 3 capsules a day at the end of phase 
II, this patient will continue to use 3 capsules a day for the first 4 days of phase III, 
decrease to 2 capsules a day during days 5-8, decrease to 1 capsule a day on days 
9-12, and stop using the double blind capsules on day 13 altogether. 
 
Table 3. Titration schedule capsules end of phase II 
Number of double 
blind capsules in 
phase II 
Day of phase III 
Days 1 - 4 Days 5 - 8 Days 9 - 12 Day 13 
1 capsule 1 capsule 1 capsule 1 capsule 0 capsules 
2 capsules 2 capsules 1 capsule 1 capsule 0 capsules 
3 capsules 3 capsules 2 capsules 1 capsule 0 capsules 
4 capsules 3 capsules 2 capsules 1 capsule 0 capsules 
 
Clozapine will be started at a test dosage of 12.5 mg/day on day 1, 25mg/day on day 
2 and 3, 50 mg/day on day 4 and 5, and 75 mg on day 6 and 7. In the second week, 
dose will be increased daily by 25 mg until a target dose of 400mg/day is reached at 
day 20 (see titration schedule in table 4 below). Titration can be slowed or stopped 
below the target dose if subjects can not tolerate the standard titration schedule 
because of adverse effects. The target dose is 400mg, but can be adjusted to a lower 
Amisulpride 
daily dose 
in phase I 
Day of phase II 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
200mg/ day 1 tablet 
0 
capsules 
1 tablet  
0 
capsules 
1 tablet  
0 
capsules 
0 tablet  
1 
capsule  
0 tablet  
1 
capsule 
0 tablet  
1 
capsule 
0 tablets  
1 
capsule 
400mg/ day 2 tablets 
0 
capsules 
2 tablets  
0 
capsules 
1 tablet  
1 
capsule 












600mg/ day 3 tablets 
0 
capsules 
2 tablets  
1 
capsule 
2 tablets  
1 
capsule 
1 tablet   
2 
capsules 









800mg/ day 3 tablets  
1 
capsule  
3 tablets  
1 
capsule 
2 tablets  
2 
capsules 
2 tablets  
2 
capsules 
1 tablet  
3 
capsules 
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dose if a patient develops serious side effects. In addition, if a patient fails to respond 
and side effects are minor, the dose can be increased. In all cases, patient should 
reach a dose between 100 and 900mg/day at day 20 of Phase III. 
 
Table 4. Titration schedule clozapine (phase III) 
Day Clozapine dosage / day 
1 12.5 mg 
2 25 mg 
3 25 mg 
4 50 mg 
5 50 mg 
6 75 mg 
7 75 mg 
8 100 mg 
9 125 mg 
10 150 mg 
11 175 mg 
12 200 mg 
13 225 mg 
14 250 mg 
15 275 mg 
16 300 mg 
17 325 mg 
18 350 mg 
19 375 mg 
20 400 mg 
   
The blood level of clozapine (and n-desmethylclozapine) will be measured 4 weeks 
after the start of phase III. If the clozapine level is not between 400-1000ng/ml (Kane 
et al., 1988) and patients have not obtained remission criteria, dose should be 
adjusted in order to reach blood levels within the described range. If clozapine levels 
are not within the specified range but the patient meets remission criteria, clozapine 
dose should not be increased simply to reach the specified range of clozapine blood 
levels.  
 
In case blood levels are not within the target range of 400-1000 ng/ml at visit 12 
and/or the patient is not in remission at visit 16, a second blood sample needs to be 
drawn at visit 16, to guide therapeutic adjustments. When blood levels are still not 
within this target range at visit 20 and/or the patient is not in remission at visit 20, a 
third blood sample needs to be drawn at visit 20. In case a patient has reached 
remission criteria, clozapine measurements do not need to be repeated. 
 
6.2. Concomitant medication 
 
6.2.1 Non-permissible medication 
 
During the course of phase I, II and III, the use of antipsychotics in addition to the 
study medication is not permitted.  
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6.2.2 Concomitant medication 
 
Mood stabilisers, benzodiazepines, antidepressants and anticholinergic medications 
are allowed but doses per day need to be documented throughout phase I, II and III.  
 
6.3 Treatment after the medication part of the study 
 
At the end of the medication part of the study patients can continue treatment with an 
antipsychotic of their own choice following a consultation of their treating psychiatrist. 
In phase I and phase III of the study, medication is open-label and can be continued 
with the identical drug if chosen so by the patient and the psychiatrist.  
 
In phase II of the study, medication is double-blind. At the end of this phase, it is 
important for patients meeting remission criteria and investigators to know which 
treatment was used during phase II, because the patient responded well to this 
treatment which should therefore be continued. Unblinding patients at the end of 
phase II is sensitive, as it is not acceptable that the advantages of a double blind 
study are diminished by the possibility to change previously collected data after the 
treatment is unblinded. Therefore, a database lock of the eCRF of phase II (and 
phase I) data will occur per patient before that individual patients’ treatment can be 
unblinded by the central study team, which has read-only access to the eCRF. After 
this lock, any changes to the collected data can only occur through standardised 
queries by the data management center, and will be appropriately documented. This 
procedure, ‘unblinding according to protocol’, needs to be performed in a very precise 
manner. As several data completeness checks need to be performed before the 
unblinding can take place, one week is scheduled in to ensure proper conduct. For 
this period, patients who meet remission criteria receive 1 week additional double 
blind medication. Once the treatment is known, they subsequently flow to the 
psychosocial intervention. 
 
Patients not meeting remission criteria will start tapering off double blind medication 
at the end of phase II immediately and start clozapine simultaneously. The unblinding 
of these patients is not urgent and may taken place during phase III once all 
requirements for the ‘unblinding according to protocol’ procedure (described above) 
are fullfiled.  
 
The randomisation table is only known to the drug manufacturer (Piramal), to prevent 
unintentional unblinding. The procedure for unblinding in this context is explicitly 
separate from the procedure that needs to be followed for emergency unblinding, 
where unblinding envelopes are used at the investigation sites. During monitoring 
visits and at the end of the study, unblinding envelopes are checked and collected to 
ensure that treatment for each individual patient was blinded throughout the period 
that the collected data could be adjusted. In case treatment was known, data from 
that individual patient will be excluded from analyses. 
 
In all cases the decision regarding antipsychotic treatment after the medication study 
or discontinuation will be made by the treating physician and should be based on 
routine clinical practice and taking into account the administration of all possible 
study drugs in the respective phases of the study (i.e. concerning drug-drug-
interactions or other safety issues).    
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7. Investigational product 
 
7.1 Formulation, packaging and labelling 
 
Study medication will be provided by the central pharmacy (Piramal) for Phase I and 
II, but not for Phase III. except when a different construction is required by local 
authoritiesFor Phase III clozapine will be prescribed regularly by the treating 
physician. In centers were regular prescription of study medication is unacceptable, 
clozapine will also be provided centrally. 
 
For study phase I, a tablet formulation will be used for the administration of the study 
medication amisulpride. Amisulpride tablets will be provided in packs: per visit, one 
pack will be dispensed containing sufficient medication for the applicable visit 
window. 
For study phase II, a capsule formulation will be used for the administration of the 
study medication (either amisulpride or olanzapine tablets), that will have identical 
appearance to maintain blinding of treatment assignment. Capsules contain either 
200 mg amisulpride or 5 mg olanzapine. Capsules will be packed in bottles that 
contain a sufficient number of capsules of study medication for the applicable visit 
window. Each bottle will be labelled in the national language according to the national 
requirements. Labels will at least list study identification (protocol code and 
abbreviated title), the randomisation number, the quantity of capsules, the capsules’ 
possible contents (type and strength), the expiry date, information on the use of the 
drug (oral application, dosage regimen), rules for appropriate storage, instructions for 
return a safety (children’s) warning, the study phase and a disclaimer to its use in a 
clinical trial exclusively.  
 
7.2 Drug accountability 
 
The patient will be provided with sufficient medication until the next dispensing visit, 
including spare medication to overcome a potential delay until the next visit.  
All dispensed study medication will be returned by the patient to the investigator at 
the next applying visit and new bottles will be handed out in accordance with the 
study protocol.  
Accountability and subject compliance will be assessed by maintaining adequate drug 
dispensing and return records.  
A Drug Dispensing Log must be kept current and should contain the following 
information: 
 the identification of the subject to whom the study medication was dispensed 
 the date[s], quantity of the study medication dispensed to the subject 
 the date[s] and quantity of the study medication returned by the subject 
 
This inventory must be available for inspection by the Monitor. All supplies, including 
partially used or empty containers and the dispensing logs, must be returned at the 
end of the study. 
 
 




All protocol procedures and the most relevant study documents are described in 
detail in the separate Investigator Manual, with all practical information for the correct 
conduct of this study. 
8.1 Randomization of treatment and blinding 
Randomisation, blinding and unblinding is described in more detail in the separate 




Randomization of study subjects will be performed by a randomization website  which 
has been developed by the Data Management department of the Julius Center, 
University Medical Center Utrecht, the Netherlands. This website is a password 
protected online application that has been used for randomization in over 40 studies. 
It has been developed in VB.Net with access to a SQL Server back end database. 
The application implements stratification, multiple sites, double blind randomization 
and the minimization method for randomization. Access to the system (individual 
username and password) is provided by the Data Management department of the 
Julius Center. 
 
Non-responders after four weeks of amisulpride treatment will be randomized to 
double-blind treatment out of two treatment arms (switching to olanzapine OR 
continuation of amisulpride). Randomization will be stratified according to site and 
gender. 
  
Patients who do respond after phase I, II or III will be randomized to one of two 
treatment arms (routine care plus psychosocial intervention OR routine care alone). 
Randomization will be stratified according to i) phase where remission was reached 
(I, II or III); ii) substance misuse; iii) specialized first episode clinic or generic clinic. 
 
8.1.2 Unblinding procedures 
 
Unblinding of study medication before the end of phase II may only occur on an 
individual basis if the information can help treat an (S)AE and for safety reasons. The 
decision to unblind is at the discretion of the investigator. For this purpose, every 
medication box used in phase II of the trial will be supplied with a set of 2 sealed 
envelopes comprising the information on the type of medication stored in the 
medication box; one set will be send to the investigator site together with the 
medication while the other set will be send to the central study team. In the case of a 
medical emergency situation as described  below, the envelope can be opened and 
the treatment assignment of a patient will be unblinded. This patient will be excluded 
from subsequent statistical analyses. 
 
Emergency unblinding is indicated in the following situations only: 
1. unblinding is necessary for the subjects emergency treatment at the 
investigators discretion 
2. unblinding is required by local laws or regulations (in case of SUSAR) 
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3. the Data Safety Monitoring Board decides that unblinding is necessary for 
proper study management of the subjects and the overall safety of the other 
subjects in the study  
 
All patients who are unblinded will be excluded from analyses. Depending on their 
clinical status, they are welcome to flow to phase III or the Psychosocial Intervention 
component. When a study site is closed all closed envelopes will be collected and 
returned to the manufacturer of the study medication. For patients who meet 
remission criteria at the end of phase II and are unblinded following the ‘unblinding 
according to protocol procedure’, the emergency unblinding envelopes at the sites 
remain sealed as the unblinding is performed by the central study team. Opened 
envelopes will be kept in the Investigator Site File at the center. After closing of the 
data base every site will be informed about each patient’s assignment to a treatment 
group.  
 
8.2  Study procedures 
8.2.1 Medication part 
Study examinations scheduled in the course of the trail are listed in table 5 below: 
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Visit 1 Screening  -1 to 0 X X X X X    X X            
Visit 2 
 
Phase I Baseline 0      X  X   X  X X X X X X    
Visit 3   1           X  X  X X X X    
Visit 4   2        X   X    X X X X    
Visit 5 
 
 Last visit 
phase I 
4     X X X† X X  X X X X X X X X  X  
 Phase II Baseline                       
Visit 6   6        X   X  X  X X X X    
Visit 7   8        X   X    X X X X    
Visit 8 
 
 Last visit 
phase II 
10     X X  X X  X X X X X X X X  X  
 Phase III Baseline                       
Visit 9   11                X X X X   
Visit 10   12           X  X  X X X X X   
Visit 11   13                X X X X   
Visit 12   14           X X X X X X X X X X  
Visit 13   15                X X X X   
Visit 14   16                X X X X   
Visit 15   17                X X X X   
Visit 16   18         X  X X X X X X X X X X*  
Visit 17   19                X X X X   
Visit 18   20                X X X X   
Visit 19   21                X X X X   
Visit 20  Last visit 
phase III 
22      X   X  X X  X X X X X X X*  
Visit 21 F/u non 
responder 
 48         X  X X     X     
Visit 22   74           X X         X 
Protocol OPTiMiSE study, version 2.4 (July 6, 2015)                                          40 
 
† = randomisation to phase II only when patient does not meet remission criteria at visit 5.  
* clozapine levels will be tested at visit 16 and/or visit 20 if the clozapine concentration was not within the specified range during the previous test 
(visit 12 or visit 16, respectively) and/or the patient does not meet remission criteria at visit 16 and/or visit 20. **Blood sampling concerns the blood 
markers for WP5 in all patients. In addition, if female patients have a history of breast cancer, and/or a first degree relative with a (history of) breast 
cancer, prolactin levels should be assessed at the local lab, at visit 2 and visit 5. 
DUP=duration of untreated psychosis; abd circ= abdominal circumference; MINI= Mini-International Neuropsychiatric Interview; MRI=Magnetic 
Resonance Imaging; MRS=Magnetic Resonance Spectroscopy; ECG=Electrocardiogram; PANSS=Positive and Negative Syndrome Scale; PSP= 
Personal and Social Performance scale; CGI=Clinical Global Impression; CDSS=Calgary Depression Rating Scale for Schizophrenia; 
SWN=Subjective Well-being under Neuroleptics; UKU= Udvalg for Kliniske undersogelser Side Effect Rating Scale. 
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Screening 
Patients will be screened for eligibility to the study, after informed consent is 
completed. Potentially existing contraindications concerning the use of any of the 
study drugs will to be ruled out prior to starting antipsychotic treatment in the study. 
Diagnosis will be checked using the MINI plus interview. Physical health will be 
checked in a physical examination. Several demographical and clinical variables will 
be assessed, including date of birth, sex, educational level, handedness, prior 
psychiatric disorders and duration of untreated psychosis. In specific centers, MRI 
and MRS measurements will take place. All female patients are asked whether they 
have a history of breast cancer, and/or a first degree relative with (a history) of breast 
cancer. All female patients are counselled on the importance of a routine breast 
(self)examinations. 
So the screening phase serves the dual purpose of conducting or completing such 
examinations and, if necessary, gradually reducing medication which may no longer 
be administered after treatment start with study medication. The screening phase 
preferably does not exceed 1 week in duration.  
 
Baseline examination 
 At baseline, blood samples will be taken and substance abuse will be measured. If 
female patients indicated at screening that they have a history of breast cancer 
and/or a first degree relative with (a history of) breast cancer, prolactine levels are 
assessed through the local lab at this baseline visit (visit 2) and at visit 5. 
Management of any prolactin values exceeding the local reference ranges is in line 
with normal daily practice and at the discretion of the investigator. The amount of 
blood required for this assessment differs per local lab. The use of concomitant 
medication and medical conditions/adverse events will be recorded, and study 
medication will be dispensed for the first time. In addition, the standard rating scales 
will be used for the first time, including PANSS, CGI, PSP, CDSS and the UKU (see 
below for details of these scales). 
 
Visits phase I, II and III 
Visits 6 until and including 22 (phase II, III and follow-up) will only apply when 
patients are NOT in symptomatic remission. All patients leaving the study early, 
regardless of the reason, will be requested to return to the site for one final visit, 
which will consist of all procedures that were scheduled for the upcoming visit. If the 
patient is not willing to participate in all this procedures, they will be requested to at 
least participate in the PANSS assessment.  
 
There is some flexibility in the visit window intervals in phases I, II and III. Visits can 
be performed with a range of +/- 3 working days. However, regardless of the extend 
of the deviation in individual visits intervals (as described here) it is essential that the 
completion of the complete phases fall within a certain interval. That is, it is very 
important that:  
 all patients complete phase I (visit 2, 3, 4 and 5) within 28 (minimum) to 40 
days (maximum). 
 all patients complete phase II within 5 weeks (minimum) to 7 weeks 
(maximum) 
 all patients complete phase III within 11 weeks (minimum) to 14 weeks 
(maximum). 
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Follow-up visits 
Follow-up visits are scheduled after the pharmacotherapy phase is completed or 
when a patient is discontinued, to assess the current status of the patient after that 
part of the study; one follow-up visit is specifically intended for patient that did not 
meet remission criteria during phase III, and a second follow-up visit is intended for 
all patients that have entered phase I. During the final follow-up visit, investigators 
are requested to provide the most recent clinical diagnosis of the patient. 
 
Rating scales 
 Positive and Negative Syndrome Scale (PANSS) (Kay et al. 1987): this is a 30-
item rating scale designed to measure severity of psychopathology in adult 
patients with schizophrenia. Five components have been reported: positive, 
negative, depression, agitation-excitement, and disorganisation.  
Symptomatic remission will be defined according to the criteria of Andreasen et 
al. (2005): 8 specific symptoms (PANSS items P1, P2, P3, N1, N4, N6, G5 and 
G9) of schizophrenia are at the most only mildly present (maximum rating of “3”) 
so that they do not interfere with daily life functioning. 
 Clinical Global Impression Scale (CGI; Guy 1976). Two 7 point scales are used, 
one for present state, the CGI Severity and another for change, the CGI 
Improvement scale. 
 Personal and Social Performance scale (PSP), a clinician-reported measure of 
severity of personal and social dysfunction 
 Calgary Depression Rating Scale for Schizophrenia. (CDSS) (Addington et al. 
1992). This scale is designed to assess depression in patients with schizophrenia 
without overlap with negative symptoms and extrapyramidal symptoms. 
 The Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale for side-
effects of anti-psychotic medicationextrapyramidal syndromes: this scale is 
designed to assess the more common side effects associated with anti-psychotic 
treatment (Lingjaerde et al. 1987).  
 Subjective Wellbeing under Neuroleptics (SWN): self assessment scale of the 
subjective experience of patients during treatment with neuroleptics (De Haan et 
al., 2002) 
 
An investigators meeting will be arranged for the introduction of the study protocol 
and corresponding training in the use of these scales.   
 
Proper conduction of the PANSS interview, the instrument used to measure the 
primary study outcome, will be taught using instructional videos and checked via the 
assessment of a test video. Participants in this training will provide information on 
their experience in using the PANSS through a questionnaire. The number of raters 
per study site will be limited. Participants whose individual assessment differs by 
more than 1 point from the master rating on any individual item of the PANSS scale 
will be re-trained on the relevant assessment criteria. All raters will go through online 
re-training after 12 and 24 months to refresh training under identical circumstances. 
All other scales will also be introduced and discussed in their relevance and 
administration during the investigators meeting.  
 
Additional measures 
Weight will be measured at the start and end of each phase during study visits. In 
addition, abdominal and hip circumference, height and body mass index (BMI) will be 
noted. An electrocardiogram (ECG) will be performed at baseline. Recreational use 
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of psychoactive substance use will be recorded. Frequency and quantity of use of 
alcohol and cannabis will be scored. For other psychoactive substances only 
frequency will be scored.  
At each visit, the presence of adverse events is evaluated. During phase III, the 
adverse events that are most likely to occur with clozapine are explicitly checked: 
somnolence, dizziness, tachycardia, hypertension, postural hypotension, 
constipation, hypersalivation, weight gain, nausea, vomiting, syncope, incontinence 




Blood samples for the prediction of treatment response from biological markers will 
be drawn at baseline (week 0), at the last visit of phase I (week 4), at the last visit of 
phase II (week 10) and at the last visit of Phase III (week 22) of the medication study. 
Each blood draw for the biological markers analyses will consist of 50.5 ml, divided 
over 7 tubes. In case not all tubes can be filled for whatever reason (e.g., objections 
from the local ERB, patient wants to stop the blood draw, not enough blood can be 
drawn, etc) it is preferred to leave out 1 STII tube and/or 1 PAXgene tube. This way, 
at least 1 STII tube and and least 1 PAXgene yube is collected. Leaving both tubes 
out decrease the amount of blood drawn to 39 ml. Blood count is assessed through 
local lab, at each blood marker blood draw, in support of the epigenetic analyses (the 
required amount for this standard assessment differs per local lab). 
 
At the end of phase I and II, together with the samples for biological markers, 1 ml 
extra blood will be drawn in order to determine the concentration of the antipsychotic 
used. This measurement provides a reliable indication of the treatment compliance of 
individual patients, although high-metabolisers of antipsychotics may (seldomly) be 
included. Samples during phase I and II need to be centrifuged and the supernatant 
should be frozen immediately (-20 degrees Celsius) and subsequently can be 
shipped up to one year after the sample was drawn. 
 
In phase III, clozapine blood levels will be measured at 4 weeks after start of 
clozapine treatment (visit 12). These values will be used to adjust individual doses of 
clozapine. Target blood levels should be between 400 and 1000 ng/ml (Schulte 2003; 
Kane et al., 1988). In case blood levels are not within this target range at visit 12 
and/or the patient is not in remission at visit 16, a second blood sample needs to be 
drawn to guide therapeutic adjustments at visit 16. When blood levels are still not 
within this target range at visit 20 and/or the patient is not in remission at visit 20, a 
third blood sample need to be drawn at visit 20. As clozapine concentrations are 
used for therapeutic guidance, samples need to be shipped immediately after they 
are drawn (room temperature). Additionally, in line with standard practice guidelines 
for clozapine use, leucocytes will be measured weekly during phase III. For patients 
using clozapine, leucocyte checks need to be continued for at least 4 weeks when a 
patient discontinues clozapine. For patients who remain on clozapine therapy, 
leucocyte counts should be continued weekly until 18 weeks after the start of phase 
III and thereafter on a monthly base.  
 
8.2.2 Psychosocial intervention 
 
All patients that have reached symptomatic remission as defined by the Andreasen et 
al. (2005) criteria will be randomized to either treatment as usual, or an additional 
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psycho-social intervention aimed to increase adherence to medication. In addition, 
patients who drop out during the pharmacotherapeutic component or who are not in 
remission at the end of phase III may also be randomized within this study 
component. There is a maximum of 1 week between the last visit of the medication 
component of this study and the baseline visit of the psychosocial intervention. In 
case patients are entering the psychosocial intervention from phase II, medication 
needs to be unblinded as described in section 6.3 (Treatment after the medication 
part of the study). This procedure takes up to 1 week. During this time, the baseline 
visit for the psychosocial intervention can take place. However, unblinding needs to 
be completed before visit 1 can take place. The baselinevisit for this study 
component can be planned directly subsequent to visit 8, but no later than 1 week 
after visit 8. Therefore, the minimum period between visit 8 of phase II and visit 1 of 
the psychosocial intervention is the time needed to unblind according to the 
applicable procedures and perform the baseline visit, whereas the maximum period 
is 2 weeks (one week from visit 8 phase II to baseline visit, and 1 week between 
baseline visit and visit 1). 
 
The visit schedule is provided in table 6 below.  
 
Table 6: Patient visits and examinations specified per visit for the Psychosocial 








































































































































-1 to 0 X    X†   X  
Visit 1 1  X   X†     
Visit 2 2  X  X#      
Visit 3 3  X        
Visit 4 4  X        
Visit 5 5  X        
Visit 6 6  X X X  X X  X 
Visit 7 12   X X  X X X  
Visit 7.1‡ 18    X      
Visit 8 52   X X  X X X  
MI=motivational Interviewing. SOFAS=Global Assessment of Functioning Scale; KPI= 
Knowledge about Psychosis Inventory; DAI=Drug Attitude Inventory; EQ-5D=Euroqol quality 
of life scale; SCS=Sellwood Compliance Scale; CALPAS=Therapeutic Alliance Measure 
* only for patients randomised to Psychosocial intervention; ** only for patients randomised to 
Psychosocial intervention, to be given to patient at the end of therapy by the therapist, and 
returned to the therapist in a sealed envelope. 
† these instructions will be provided as soon as possible following randomisation, during min.  
2 to max. 4 sessions. Study personnel remains available during the study for additional  
questions. Additional PANSS assessments are included for specified patients, to facilitate a  
direct comparison between patients at exactly 22 weeks after start of the study: 
# only for patients who transferred from phase III; ‡ only for patients who transferred directly 
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Rating scales 
 Global Assessment of Functioning Scale symptoms and disability (SOFAS) 
subscales: administered by doctor or nurse on basis of several sources. 
 Knowledge about Psychosis Inventory (KPI) (Barrowclough et al. 1987)  
 Drug Attitude Inventory (DAI) 
 EQ-5D (“Euroqol”) 5-item health related quality of life scale  
 Sellwood Compliance Scale (SCS)(Sellwood et al. 2003) 
 CALPAS Therapeutic Alliance Measure; self assessment scale for patients  




The intervention consists of the following three elements. 
 
1. Web-based psychoeducation 
Psycho-education, especially with family involvement, has been shown to increase 
adherence with medication in meta-analyses amongst chronic patients with 
schizophrenia (Pekkala and Merinda, 2005). This intervention is particularly relevant 
following first episode psychosis, where response to acute treatment and subsequent 
remission is usually good. Data from Nordentoft’s OPUS trial indicated that a 
comprehensive intervention systematically involving family members increased 
adherence with medication at one- and two-years follow-up (Petersen 2005, le 
Quach 2008), and this increased adherence with medication in the experimental 
condition partially, but not totally explained the positive effect of the experimental 
intervention on psychotic symptoms.  
 
Psychoeducation in this study will be web-based.The home page of the website will 
include buttons to take the viewer to the relevant country/language page. Access to 
the website will be restricted by password login to participants (and their relatives) 
randomly allocated to the experimental treatment arm. A facility for secure on-line 
submissions of Q&A will be included. At baseline, participants will be given the option 
to select a hard copy version of the website as a manual.  
The website will be constructed by the IT team in Manchester and hosted on a 
University of Manchester server under a specific domain name. The content of the 
website will be drafted by: Dr. Shôn Lewis, Dr. Richard Drake, Dr. Gillian Haddock, 
Dr. John Ainsworth (from University of Manchester) and by Dr. Merete Nordentoft 
(University of Copenhagen) and Dr. Peter Jones (University of Cambridge). The 
website will focus on first episode psychosis, outlining the nature of the disorder, 
symptoms, outcomes and treatment approaches, with an emphasis on the pros and 
cons of antipsychotic medication and the importance of maintenance during first 
remission. The content will be drafted with the input of patients and carers. Two 
facilitated panels of patients in Manchester and Copenhagen with diagnoses of 
schizophrenia, will be involved. Family members from each site will also be included. 
The website will then be translated with patient and relative input encouraged, and 
locally-specific details added. The final content will be translated locally by the 
research team, or centrally by EU support if available. Backtranslation will not be 
required. The final text will then be uploaded to the website. A website counter will 
count the number of times the participant/family access the site.  
 
2. Motivational interviewing 
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Motivational interviewing will be used as an important part of the psychosocial 
intervention. Motivational interviewing was developed to help people stop smoking or 
drinking by eliciting their own motivation for change [Miller, 1983;Miller and Rollnick, 
1991]. Important elements in motivational interviewing are analyses of advantages 
and drawbacks of continued abuse, instruction in coping skills in relation to craving 
and situations that usually trigger abuse and development of personal strategies for 
avoiding or handling these situations. In programmes offering help to behavioural 
changes, analyses of the change process is often used. The circle of change 
[Prochaska, 1991;Prochaska and Diclemente, 1992] describes changes in behaviour 
as a process that runs through phases of pre-contemplation, contemplation, 
preparation, starting, and maintenance. 
 
Although adherence to medication is a different issue, some of the elements 
described in motivational interviewing can be transferred to this area. Motivational 
interviewing includes collaborative techniques to facilitate making links between the 
problems or life goals of importance to the patient and drug treatment, and hence 
increase their awareness of the importance of adherence if they are to make 
progress in the areas of their life they hold of value. Most important is the 
acknowledgement of the patients own thoughts and experiences with medication. It is 
crucial to get knowledge about which reasons the patients consider important for 
taking or not taking medication. Therefore it is necessary to create an atmosphere in 
which the patients feel they can state their opinions frankly. The goal is to elicit the 
patient’s own wish to get help from medication and this can only be achieved if 
patients are allowed to express also their mistrust and bad experiences, and they 
should get a clear experience of their concerns being listened to and taken seriously. 
The sessions aim to help the patient decide how best to weigh up the advantages 
and disadvantages of taking medication. 
 
As part of the intervention, relatives will be invited to participate in sessions together 
with the patients and they will be informed about the principles behind motivational 
interviewing in order to help them to adopt some of the same principles in their 
contact with the patients. 
 
A standardised motivational interviewing package will be developed. The elements 
included in the package are information about effects and adverse effects of 
medication, open discussions about advantages and disadvantages with medication, 
discussions about the role of medication in the process of remission and recovery, 
identifying barriers for taking medication and exploration of possibly helpful 
procedures for remembering to take medication at a given time during the day, 
related to their routines. The process must include a possibility of acknowledging that 
although patients have accepted to participate in a drug trial, the patient’s 
perceptions of adverse effects can be of such serious nature that changing 
medication will be a relevant alternative. This process will be manualised and put on 
the study website. Training of doctors/ nurses will take place during a 2-day training 
session. Training and supervision for all doctors / nurses will be performed by the 
psychology postholder at Copenhagen, supervised initially by professors Nordentoft 
and Haddock. The researchers that provide the psycho-social intervention cannot 
also obtain clinical evaluations, as the clinical rater should be blind to whether the 
patient receives this intervention or treatment as usual. 
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The motivational interviewing sessions will take place weekly for the first six weeks 
after randomization. The sessions will last one hour and can be in patients home or 
the mental health team base, whichever the patient will prefer.  The patient’s relatives 
are encouraged to participate in the programme as well. A web-based fidelity 
checklist will be constructed and completed by all nurses / doctors after the first and 
last session with each participant. 
 
3. Mobile phone adherence management 
There will be two main components to this: SMS medication reminders and real-time 
symptom and side effect assessment over een period of 1 year. A central secure 
server at the University of Manchester will be used for the medication management 
programme. This will involve a web page on the prescribers’ website (see above) 
where details of the prescribed medication schedule for each participant enrolled will 
be entered locally by the doctor or nurse within two days of randomisation. SMS 
message alerts, whose content has been agreed with the individual participant, will 
be sent daily or twice daily to the participant’s mobile phone according to their 
medication schedule. The message will be modifiable, regarding content as well as 
frequency/timing, by clinician and participant.  
 
In addition a web interface will be constructed to be held on the central server to 
allow participants to be cued by SMS to enter simple data on levels of symptoms and 
side effects. The level of detail will be limited by the screen size and time 
considerations and will be finalised during the beta testing phase. It is likely to consist 
of a maximum of four questions each on symptoms and side effects with a four-level 
(none-mild-moderate-severe) response field, taking no more than two minutes to 
complete. The responses will be wirelessly uploaded automatically to the server with 
full privacy and security. Summary details will be made available to the clinical team 
each week with the participants’ initial consent. Participants will be given two twenty 
minute training sessions alongside the psychoeducation sessions. Participants will 
twice weekly be prompted by SMS to complete the ratings. The system will be beta-
tested (field trialled) in eight patients from Manchester and Copenhagen, with the 
option of 1-2 patients from each participating site. 
Detailed arrangements for deploying the system via local service providers will be 
established through links with the new m-Health Innovation Centre at the University 
of Manchester in association with GSMA (www.gsmworld.com). GSMA aims to 
establish a network of mobile health (m-Health) Innovation Centres across the world, 
providing support and infrastructure for m-Health research, innovation and 
commercialisation of new m-Health services. In October 2009, GSMA established 
Manchester as the first of these Centres. A major focus of the centre is the area of 
Assisted Living (included mental health). The deployment of enabled handsets for the 
Optimise trial across different EU sites is one of the first partnership tasks to be 
adopted by the Manchester m-health innovation centre. 
 
Participant assessments 
Baseline measures, assessed at the start of the psycho-social intervention study will 
be as follows:  
 
Participant 
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1. Global Assessment of Functioning Scale symptoms and disability (SOFAS) 
subscales: administered by doctor or nurse on basis of several sources. 2 
minutes of participant time. 
2. Knowledge about Psychosis Inventory (KPI) (Barrowclough et al. 1987) (10 
minutes) 
3. Drug Attitude Inventory (DAI)(10 minutes) 
4. EQ-5D (“Euroqol”) 5-item health related quality of life scale (5 minutes)  
5. Sellwood Compliance Scale (Sellwood et al., 2003; 1 minute) 
 
Prescribing clinician 
Kemp compliance scale (Kemp et al., 1998). 




All of these scales will be re-administered at 3 and 12 months post-randomisation by 
an independent assessor who will be blind to treatment allocation. Blindness will be 
maintained by a range of measures including geographical separation of raters and 
password protected databases. 
 
At the end of the 6 weeks series of motivational interviewing sessions, the CALPAS 
Therapeutic Alliance Measure will be completed by the patient. 
 
Following randomisation, participants and, where possible, family members in the 
experimental treatment arms will meet with the research nurse on two (or up to four if 
needed) occasions either at home or at the clinic to learn how to (i) access and 
navigate the psychoeducation website and (ii) operate the SMS and mobile phone 
interface and complete the rating scales. Thereafter, the research nurse will be 
available to discuss issues arising out of the website material.  
 
8.2.3 MRI measurement 
 
A separate protocol describes the MRI and MRS measurements that are included in 
detail. Below basic information on this study component is provided. 
 
Site requirements  
Each site must have access to an MRI scanner, preferably, but not necessarily 3T.  
1.5T scanners may also be used.  
Volumetric imaging data will be acquired using the ADNI protocols. These have been 
specifically developed for multi-centre imaging studies, and can be run on most 
recent scanners from Siemens, Phillips, and GE. The WP leader centre (IOP) already 
has experience in successfully implementing this protocol in another multi-centre MRI 
study funded by the EU to assess brain processes related to addiction in a sample of 
2000 subjects (FP6; I MAGEN).  
 
Each MRI site will be assisted by our subcontractor IXICO (www.ixico.com), a 
company that specializes in MRI data handling in multi-centre studies. This will help 
to ensure quality control, and appropriate data collection and data transfer. The data 
will be stored centrally by IXICO in London. Both the radiological assessments and 
the MRI data analysis will be performed at the Institute of Psychiatry in London. 
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Image acquisition  
The scanning sequences are not complicated and the scanning session is likely to 
take about 45 minutes in total. Data will be acquired using standard localiser (‘scout’) 
images, followed by 2D T2-weighted and FLAIR scans on different planes with 
parameters suitable for radiological assessment. Scan times for these sequences will 
differ slightly between scanner manufacturers, but should total less than 10 minutes 
at all sites. This will be followed by a 3D (‘volumetric)’ T1-weighted MP-RAGE scan, 
based on the protocol devised and validated by the ADNI consortium.112 This will 
take a further 9½ minutes. Data will be archived by each site according to existing 
local procedures, and will also be transferred (using the DICOM protocol supported 
by all scanners) to a project-specific computer, where, following basic consistency 
checks, it will be anonymised for transfer to the central coordinating/analysis site 
using the IXICO software (which will be provided to all sites).  
 
Collation of MRI data at central coordinating site  
MRI data plus associated demographic data from each site will be transferred from 
the LDC at each site to a central computer system. Data transfer and management 
will be conducted in collaboration with SME IXICO (www.ixico.com) to ensure 
efficient dataflow, auditing and central quality control. IXICO has a wealth of 
experience running multi-centre MRI studies worldwide.  
 
Standardisation of data quality across sites  
To ensure high quality data, standard QA protocols (using the ACR MRI phantom) 
will be run at regular intervals (monthly) at all sites. Data will be analyzed locally (to 
allow a rapid 'turn round' if any issue is uncovered requiring servicing of the scanner), 
and also transferred to the central analysis site, where they will also provide 
information for inter -site calibration of voxel sizes.  
 
A group of healthy volunteers (n=5) will be scanned at a subgroup comprising the 
largest participating sites using the standardised acquisition protocol. This will 
establish the comparability of the MRI data across centres, and provide measures of 
within- and between- scanner variability.  
 
Data analysis  
Radiological assessments will be performed at the coordinating site for MRI 
assessments (Institute of Psychiatry, King’s College Londen) by one of two 
experienced neuroradiologists who are blind to the nature and purpose of the study. 
Using software provided by IXICO, they will assess all MRI images for any 
abnormalities as they would in conventional clinical practice, and will be asked to 
specify whether abnormalities require clinical action. They will be blind to whether 
subjects are patients or controls. The neuroradiological evaluation will assess: 
a) Absence or presence, location and number of lesions scored on a scale of 0 to 
3 (0=none; 1=single lesion; 2 more than one lesion in the same hemisphere; 
3=more than one lesion in both hemispheres) 
b) The ventricular system size and shape; Subarachnoid spaces and basal 
cisterns. Size will be reported on a scale of 0 to 1 (0=normal; 1=enlarged). 
c) Septum Pellucidum and its variants will be scored from 0 to 3 (0=normal; 
Cavum Septi Pellucidi=1; Cavum Vergae=2; Cavum Veli Interpositi=3) 
d) A whole brain gradient (anterior-posterior) and asymmetry (left-right) atrophy 
visual evaluation will be made in order to assess absence or presence and 
type of atrophy: overall proportional atrophy, cerebral convexity only, widened 
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Sylvian fissure, focal atrophy. Frontal and parietal lobes will be rated on a 
scale from 0 to 4 (0=none; 1=minimal; 2=mild; 3=moderate; 4=severe). Four 
regions of the temporal lobes will be investigated as proposed by Galton: 
hippocampus, amygdala, fusiform gyrus and parahyppocampal gyrus on a 
scale from 0 to 4 (0=none; 1=minimal; 2=mild; 3=moderate; 4=severe) 
e) Absence or presence, location and characteristics of signal intensity 
abnormalities. Lesions will be scored on a rating scale from 0 to 6, as 
proposed by Scheltens with separate scores for each of the cerebral lobes, 
the periventricular, the subcortical regions, and the infratentorial brain 
structures. Perivascular spaces will be disregarded. 
f) Height, width, and anteroposterior diameter of the pituitary gland will be 
reported together with morphological characteristics of the pituitary stalk.  
 
Measurements and ratings will provide data for inter-rater reliability calculations. 
8.3  Withdrawal of individual subjects, premature termination of the 
study 
 
There are several reasons which may lead to prematurely terminatation of a patient’s 
participation, a study center’s contribution to the trial, or a complete cessation of the 
whole trial. These reasons are indicated below. 
Reasons to terminate a patient’s participation: 
 The patient withdraws her/his consent 
 Intolerance to the study drug 
 The nature of the patients treatment is changed to coercive treatment (based on 
judicial ruling)  
 In contrast to the patient's status at enrollment, the patient is now represented by 
a legal guardian or under legal custody  
 Emergence of one or more contraindications against any of the study drugs as 
mentioned in the Summaries of Product Characterics (refer to Appendix A). In 
particular, clozapine use needs to be discontinued when one or more of the 
following adverse events occur: severe leucopenia (leucocyte count <3000/mm3 
or 3.0x109/l) or neutropenia (count <1500/mm3 or 1.5x109/l), myocarditis or 
cardiac arrhythmias. 
 Patient becomes pregnant or initiates lactation  
 The investigator considers a patient’s continued participation in the study to be 
unjustifiable on medical grounds (i.e., because of side effects or unusual risks).  
If an individual patient is discontinued due to one of the above mentioned reasons, 
this patient will be treated as usual in normal daily practice.  
 
Study center: 
 Inability to conduct the study in accordance with protocol at a particular study site, 
inability to maintain agreements made with the study sponsor, or inability to meet 
ICH-GCP guidelines 
 Insufficient inclusions, i.e. < 5 patients included per year 
If a study center discontinues the study on behalf of one of the above mentioned 
reasons. The patients that have already been included will be followed up, but no 
new inclusions will be made. 
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Study: 
 The approval conditions or risk profile of study medication amisulpride, clozapine 
or olanzapine changes, making a new assessment of the use of these drugs in 
this study necessary 
In case the entire study is discontinued, patient will followed-up and/or be treated as 
usual in normal daily practice, depending on the severity of the changes in risk profile 
and the extent to which this increase in risk is applicable for individual patients. 
 
All patients leaving the study early, regardless of the reason, will be requested to 
return to the site for one final visit, which will consist of all procedures that were 
scheduled for the upcoming visit. If the patient is not willing to participate in all this 
procedures, they will be requested to at least participate in the PANSS assessment. 
There are no consequences if a patient also refuses this. 
 
 
9. Statistical analysis 
 
9.1 Data analysis 
Data analysis for objective: Finding evidence for pharmacotherapy guidelines 
in first episode schizophrenia  
The primary outcome will be the number of patients in symptomatic remission 
according to Andreasen et al. 2005. The proportion of patients meeting remission 
criteria will be estimated at the end of phase I, phase II, and phase III. Logistic 
regression analyses will be used to test whether the probability of remission is 
significantly different between the amisulpride and olanzapine treatment arms at the 
end of phase II. Duration of untreated psychosis, age, and gender will be included as 
covariates in this analysis. The secondary outcome measure is all-cause treatment 
discontinuation, which will also be compared between treatment arms with survival 
analyses including Cox regression analyses and Kaplan-Meier functions. 
 
Data analysis for objective: Finding biological predictors of treatment response 
DNA analysis 
DNA will be used to study genetic markers with a pharmaco-genetic (PG) chip 
developed at INSERM. This PG-chip, which is dedicated to genotyping 15,000 
polymorphisms, makes it possible on the one hand to reconstruct the haplotype 
diversity of 1292 genes implicated in the metabolism, transportation, and targeting of 
drugs  and, on the other hand, to genotype the functional polymorphisms that are 
indispensable for certain genes which are not included in GWA chips. This is a tool at 
the intermediate scale between a low-throughput candidate gene approach, and a 
pan-genomic approach, for which virtually no pharmacogenetic cohort has sufficient 
power. This PG chip includes genes implicated in: drug metabolism, drug transport, 
inflammation (including 158 HLA genes), metabolism, apoptosis, inflammation, 
chemokines, cytokines, brain receptors and other proteins, signal transduction 
(carcinogenesis), and DNA repair. This PG-chip has come into production early 2009 
(Pr Beaune INSERM). DNA will also be used to characterize the methylation profiling 
before and after treatment with amisulpride. DNA collected before and after treatment 
will be converted using bisulfite treatment and hybridized on HumanMethylation27 
BeadChips on Illumina platform (Integragen). These BeadChips contain 27,578 CpG 
islands spanning more than 14,000 genes. Methylation data analysis will be analysed 
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using the BeadStudio software, which will allow the integration with gene expression 
data (Dr Jamain, INSERM). 
 
Metabolomics analysis 
Plasma will be portioned and snap-frozen as soon as possible after collection. 
Plasma (50µL) is required for a single assay. Samples will be processed in a fully 
automated manner in multiwell plates using Hamilton robotics station. Metabolite 
spectrum is designed to monitor the metabolism of sugars, acylcarnitines, amino 
acids, glycerophospholipids, sphingolipids and many other analytes. The resulting 
dataset will be subject to several levels of data analyses, starting with metabolite 
identification and quantification based on the raw multiplexed MS/MS spectra and the 
knowledge of the spiked isotope reference markers. In this step, BIOCRATES Life 
Sciences MarkerIDQ™ software shall be used as provided with the AbsoluteIDQ™ 
kit. In a second step, correlations within the metabolite dataset will be combined with 
external biochemical knowledge (e.g. from metabolic pathway maps, KEGG), using 
bioinformatics tools developed specifically for every project at HMGU-IBIS.  
 
Proteomics analysis 
Plasma will be used to look for proteomic biomarkers of response in 30 responders 
and 30 non-responders after phase I matched for ethnicity, gender, and age. The 
discovery phase of the project will focus on the identification of novel specific 
biomarker patterns relevant to predicting and/or monitoring patient response to 
amisulpride treatment in serum/plasma. In the discovery phase two-dimensional gel 
electrophoresis will be used followed by labelled MS based discovery, which is more 
sensitive than label free methods. Any findings will be validated in the full set of 
responders and non-responders by direct MS multiple reaction monitoring and 
immunodetection methods. (Pr Lovestone’s and Pr Collier, proteomics laboratory at 
the Institute of Psychiatry). 
 
MRS analysis 
Measurement of glutamatergic function.  
MRS spectra (PRESS (Point RESolved Spectroscopy); TE=30ms, TR=3000ms, 96 
averages) will be acquired in the anterior cingulate and left thalamus, using an  
established protocol (Stone et al, 2009). Shimming and water suppression will be 
optimised, with auto-prescan being performed twice prior to each scan. The anterior 
cingulate Region of Interest (ROI) will be prescribed from the midline sagittal 
localiser, and the centre of the 20mm x 20mm x 20mm ROI was placed 13mm above 
the anterior section of the Genu of Corpus Callosum at 90o to the AC-PC line. A 
15mm x 20mm x 20mm (right-left, anterior-posterior, superior-inferior) left thalamus 
ROI will be defined at the point in the coronal slices where the thalamus is widest, 
using sagittal and coronal localisers to ensure that the voxel was clear of CSF 
contamination. After the subject leaves the scanner, each scanning session will 
conclude with the collection of a PRESS spectrum from a phantom containing 
standard concentrations of brain metabolites to provide calibration data for the 
LCModel program. All spectra will be analysed using LCModel version 6.4. This 
generates water-scaled values. To generate metabolite concentrations, SAGE 
(General Electric, Milwaukee, USA) will be used to combine data from the 8 channel 
head coil, which uses unsuppressed water peaks to scaled data from each head coil 
relative to each other but does not scale the combined signal relative to water. The 
combined data will then be analysed using the integrated SAGE GUI for LCModels. 
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Data analysis for objective: Testing the utility of MRI screening 
 
The statistical analysis of the MRI data will use two approaches: 1) A well established 
volumetric method; 2) Pattern recognition analysis (Support Vector Machine).  
 
The volumetric analysis will use voxel-based morphometry (VBM), as implemented in 
SPM, the most widely used statistical software package for this purpose. This 
analysis will be performed at the Institute of Psychiatry, King’s College Londen , who 
were the first to apply this approach in MRI analysis and have extensive experience 
in its application in schizophrenia. 
 
The pattern recognition analysis will investigate spatially distributed information on 
brain tissue structure, using multivariate pattern recognition approaches. Statistical 
pattern recognition is concerned with automatic discovery of regularities in data 
through the use of computer algorithms, and with the use of these regularities to 
classify the data into different categories. Brain scans are treated as spatial patterns 
and statistical methods are used to identify statistical properties of the data that 
discriminate between groups of subjects (e.g. responders vs. non-responders to 
treatment). This analysis will be performed at the Institute of Psychiatry King’s 
College Londen,by the investigators and their collaborators. The Institute of 
Psychiatry has pioneered the application of pattern recognition and machine learning 
methods in psychiatry. To date, most analysis methods used in MRI studies of 
schizophrenia have sought to distinguish subjects at a group level; this approach 
permits MRI analysis at the level of the individual patient. 
 
9.2 Drop-out rates and missing values 
 
Fleischhacker and Kemmler (2007) reported an average drop-out rate of 28% in 
current, double-blind, randomised studies with short treatment duration (up to 12 
weeks). This was a registration study performed by the pharmaceutical industry 
which included active treatment arms only. As the current study will not be conducted 
using substances that are in the approval phase and phase I is a single-arm, open-
label intervention, adding up to expected lower drop-out rates, we based our 
calculations on a drop-out rate of 20% over the complete course of phase I and II.  
  
Several strategies are planned a priori to deal with missing study data concerning the 
primary study outcome from patients who aborted treatment: 
(a) Reasons for treatment discontinuation will be registered, as this will provide 
information on the missing data process which may either be Missing at 
Random (missingness is related to observed variables) or Missing Not at 
Random (missingness is related to unobserved data (Little & Rubin) 
(b) Analysis of the primary study outcome will be done according to the Intention 
To Treat (ITT) method. In addition multiple imputation using Rubin’s 
propensity score method (Rubin 1987) will be used in its implementation in the 
software “SOLAS for missing data analysis“(version 3.0).  
(c) An additional analysis of study completers who completed the entire study 
according to protocol will be conducted (protocol analysis) 
(d) Baseline characteristics of patients who later dropped out of the study will be 
compared with those of study completers in the non-switch and the switch 
groups to identify possible factors influencing later drop-out 
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(e) Analysis of the primary study outcome will be done according to the ITT 
method. The last-observation-carried-forward (LOCF) method will be used to 
deal with missing values 
(f) In addition multiple imputation using Rubin’s propensity score method (Rubin 
1987) will be used in its implementation in the software “SOLAS for missing 
data analysis“(version 3.0). Here, 5 datasets are created with imputed missing 
values, resulting in 5 complete datasets  
(g) An additional analysis of study completers who completed the entire study 
according to protocol will be conducted (Per Protocol (PP) analysis) 
 
10. Analysis of risks and benefits 
 
Participants included in the study will have recently experienced a deterioration of 
their health, exhibit the clinical symptoms of schizophrenia, schizoaffective or a 
schizophreniform disorder, and hence require an antipsychotic, medication-based 
treatment. Both types of medication in the study used in phase I and phase II have 
been licensed for the treatment of schizophrenia in most European countries (with 
the exception of amisulpride in The Netherlands) for over 10 years and are routinely 
used in clinical practice. The examinations performed for the study will only 
marginally stress participants more than routine therapy would. 
 
If the hypothesis that early switching to an alternative antipsychotic featuring a 
different receptor profile in case of poor initial response is confirmed, a patient who 
initially experiences little benefit from open-label treatment with amisulpride in phase 
I of the trial and is switched to the treatment with the alternative antipsychotic drug 
olanzapine in phase II may have a higher chance of reaching remission by the end of 
phase II.  Nonetheless, patients cannot expect guaranteed individual benefits in 
phase II of the trial as treatment assignment is randomized and patients in phase II 
may stay on the identical antipsychotic they were on in phase I of the trial. However, 
patients are carefully followed up regarding their individual benefit from the treatment 
in phase I and phase II and are then switched to clozapine in phase III. In routine 
treatment this extensive monitoring of the treatment effect is not applied and so 
patients may benefit from the thorough examinations during study participation. 
Insufficient response cannot be overlooked which is an advantage of study 
participation compared to routine care.  
 
The OPTiMiSE study’s results could indicate a future treatment strategy for patients 
who initially respond poorly to antipsychotic treatment. This means that the 
ineffective continuation of treatment of patients with a poor initial response could be 
prevented.  Additionally this would prevent unnecessarily long hospitalizations, 
reducing the treatment cost of an acute episode since hospitalization costs comprise 
the largest part of the total cost of therapy. 
In the face of the small amount of additional burden to the patient of participation as 
compared to routine treatment, the possibility of individual benefit, and the possible 
positive outcome for future treatment, offering participation to selected patients 
appears to be justified. 
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11. Feasibility of patient recruitment 
 
Although there are no pilot studies for the current trial, the study design resembles 
that of many randomised, double-blind approval studies in which patients received 
antipsychotics. Given that many such studies have already been successfully 
completed, it seems reasonable to assume that with respect to sample size, the 
chosen statistical methods, and the estimated number of patients who will drop out, 
the present study can be realised. The present study will not use any medication 
which is yet to be approved and does not ask many extra activities of the patients, 
making recruitment all the easier.  
 
The current study is supposed to be executed in 30 centers and run over a course of 
five years. This means that the mean number of inclusions per center per year is only 
5, which should not be too demanding.  
 
The broadly chosen inclusion and exclusion criteria (which differ markedly from the 
often very restrictive criteria of approval studies of pharmaceutical companies) allow 
a higher degree of generalisation of the results and at the same time make 
recruitment easier. The conducted examinations and treatment in the study only 
minimally differ from the clinical routine, with the exception of blinding and the 
randomisations.  
 
Finally, the trial builds on the previous experience with the EUFEST study, which 
included 498 first episode patients in two years. With a few adjustments, the same 
centers involved in EUFEST will also participate in OPTIMISE. As the case number 
in EUFEST (n=498) was reached in two years, the current trial (n=500), the 
recruitment aim should be reached.    
 
12. Safety reporting 
Safety aspects are described in more detail in the separate Standard Operating 
Procedure ‘Satefy Review and Reporting Procedure’. 
 
12.1 General aspects 
 
This study will be performed according to the Declaration of Helsinki (2008) and the 
International Conference on Harmonisation - Good Clinical Practice (ICH-GCP). The 
definitions of adverse events and serious adverse events described in these 
guidelines will be used for the present study.  
 
All medication to be administered in this study has been used in clinical pratice for 
the treatment of schizophrenia and schizophreniform disorder in Europe for more 
than 10 years. Therefore, no special checks are included except the once that are 
routinely used for clinical treatment using the medication applied in this study.   
 
The investigator will inform the subjects and the reviewing accredited Ethics 
Committee if anything occurs, on the basis of which it appears that the 
disadvantages of participation may be significantly greater than was foreseen in the 
research proposal. The study will be suspended pending further review by the Ethics 
Committee, except insofar as suspension would jeopardise the subjects’ health. The 
investigator will take care that all subjects are kept informed. 
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12.2.1  Definitions 
 
Adverse Events (AE) are defined as any undesirable experience occurring to a 
subject during a clinical trial, whether or not considered related to the investigational 
drug.  
 
In case a female participant becomes pregnant during the course of the study, this 
will be reported as an AE. 
 
A Serious Adverse Event (SAE) is any untoward medical occurrence or effect that at 
any dose results in: 
- death 
- is life threatening (at the time of the event) 
- requires inpatient hospitalisation or prolongation of existing hospitalisation 
- results in persistent or significant disability/incapacity 
-  is a congenital anomaly/birth defect 
- is an important medical event that may not be immediately life-threatening or result 
in death or hospitalisation, but may jeopardise the subject or may require intervention 
(e.g. medical, surgical) to prevent one of the other serious outcomes as listed above 
 
The following events which may occur during this study, will be regarded as SAEs if 
they meet the criteria, yet will not need to be reported immediately to the sponsor 
(UMC Utrecht, the Netherlands), but rather within a time period of 1 month: 
-exacerbation or de novo occurrence of schizophrenia symptoms, including positive, 
negative and cognitive symptoms. 
-severe forms of well known and common side effects, such as acute dystonia, 
severe sedation, epileptic seizures or agranulocytosis, which are rated in the eCRF 
using a specific rating scale (UKU) and on the applicable adverse event pages. 
 
Hospitalisation due to exacerbation of psychosis-related symptoms is a very common 
occurrence during the first years of the illness. Although this is regarded as being an 
SAE, these hospitalisations are part of the illness course and are therefore not 
reported to the authorities immediately. Rather, they will be reported once a year as 
part of the Annual Safety Report (section 12.2.4). Immediate reporting will not have 
any added value for the authorities in evaluating patient’s safety and will result in 
over-reporting. 
 
An event qualifies as a SUSAR when: 
- the criteria for an SAE are met 
- it is plausible that the event is caused by the study medication 
- the event is not expected, based on the ‘summary of product characteristics’ (that 
is, it is not a known side effect). 
12.2.2 AE, SAE and SUSAR reporting procedures 
 
All AEs reported spontaneously by the subject or observed by the investigator or his 
staff will be recorded in the patient file and eCRF by the investigator.  
 
Any SAE must be immediately reported to the sponsor (UMC Utrecht, the 
Netherlands) regardless of their estimated relatedness to the study drug. SAE’s 
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should be reported by filling out the SAE form in the eCRF within 24 hours after the 
investigator came aware of an SAE. By means of the eCRF an email alert will be 
send to the UMCUtrecht for report to the regulatory authorities. When the eCRF 
system does not function, reporting must be performed by facsimile transmission of 
the completed SAE form to the trial assistant, fax number: +31- 88-7555466.  
 
Should the investigator become aware of an SAE that occurs within 30 days after 
stopping the study treatment, the SAE must be reported in accordance with 
procedures specified above. This can be either 30 days after Phase I, Phase II or 
Phase III, dependent of the number of treatment Phases the individual patient 
needed to obtain remission criteria. 
 
SUSAR’s will be reported using the same procedure as SAE’s described above. One 
important difference is that the patient will be unblinded when the SUSAR occurs 
during the double blind phase (phase II). 
 
In case an SAE or SUSAR is reported, all other investigator sites will be informed by 
the central study team with regards to this event. Any information that is needed to 
adhere to local laws and regulations of participating countries will be provided by the 
trial co-ordinators and/or the project manager. All SAEs and SUSARs will be reported 
by the central study team and the investigator site to the appropriate Dutch 
authorities, in accordance with local laws and regulations. However, SAEs and 
SUSARs cannot be reported centrally on a European level, so each investigator 
needs to ensure that local laws and regulations are followed in case an SAE occurs 
in their centre, that is: the ERB or other national authorities may need notification. All 
information regarding SAEs, SUSARs and the reporting of these events will be filed 
in the central study file as well as the investigator site files. 
 
As stated above, hospitalisation due to exacerbation of psychosis-related symptoms, 
exacerbation or de novo occurrence of schizophrenia symptoms and severe cases of 
common side effects of antipsychotics that meet SAE criteria, do not need to be 
immediately reported as SAEs in the standard procedure. Hospitalisations due to 
exacerbation of psychosis-related symptoms will only be reported in the Annual 
Safety Report (section 12.2.4). Regarding exacerbation or de novo occurrence of 
schizophrenia symptoms and severe cases of common side effects of antipsychotics 
that meet SAE criteria; these will need to be reported to the sponsor (UMC Utrecht) 
within 1 month of the occurrence of the SAE. ERBs and/or other local authorities 
may wish to receive a list of the events of hospitalisations, symptom exacerbations 
and severe common side effects that did meet SAE criteria. This list will be 
periodically composed and distributed amongst investigative sites, at least once a 
year, depending on the requests of ERBs and/or other local authorities. The report 
for the SAEs that can be reported with delayed timelines, can be entered into the 
eCRF or can be reported through facsimile transmission of the completed SAE form 
to the trial assistant, fax number: +31- 88-7555466.  
 
Next to this list of hospitalisations and exacerbations, a list of all SAEs and SUSARs 
will be provided for the appropriate authorities (developed by the central study team, 
submitted by the investigators), including a summary table arranged on organ 
systems and a statement of the Data Safety Monitoring Board regarding a cost-
benefit evaluation. 
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12.2.3  Follow-up of adverse events 
 
All adverse events (AE’s, SAE’s and SUSARs) will be followed until they have 
abated, or until a stable situation has been reached. Depending on the event, follow 
up may require additional tests or medical procedures as indicated, and/or referral to 
the general physician or a medical specialist. 
 
12.2.4  Annual safety report 
 
Once a year, the central study team develops a list of all SAEs and SUSARs that 
have occured during the study. This annual safety report will be distributed among all 
investigator sites, to be submitted to the appropriate local authorities and filed in the 
investigator study file. This safety report includes a summary table arranged on organ 
systems. In addition, a statement on the cost-benefit balance for study participants by 
the Data Safety Monitoring Board is included, based on a complete safety analysis 
and an evaluation of the balance between the efficacy and the harmfulness of the 
medicine under investigation.  
 
12.2.5  Data Safety Monitoring Board 
 
The safety of the study will be judged by an independent committee of experts on 
regular basis, at a frequency of at least once a year. The members of this board will 
have access to the unblinded data of phase II, to all SAEs and SUSARs and to the 
inclusion and drop-out rates. This Data Safety Monitoring Board (DSMB) will suggest 
changes to the protocol or provide an altered judgement of feasibility if information 
from the annual safety report or new information about the applied study medication 
has become available.  
 
13. Ethical considerations  
 
13.1 Regulation statement 
 
The study will be conducted in accordance with the principles of the Declaration of 
Helsinki (59th WMA general assembly; October 2008), with the ICH-GCP guidelines 
and other applicable (national) laws and regulations. In line with these guidelines, 
insurance is arranged by the sponsor for all participating sites.  
All investigators involved in the present study will receive a copy of the guidelines 
and important points will be discussed at the investigators meeting at the beginning 
of the study and in detail during site initiation. 
Every investigator involved in the study is responsible for compliance with protocol, 
compliance with ICH-GCP guidelines and other existing laws and regulations.  
 
13.2 Statement regarding ethical practicability of the current study 
 
All patients will receive open-label amisulpride treatment for 4 weeks. Subsequently 
patients with a poor response to treatment will either continue the treatment with the 
identical drug (amisulpride) or switch to the alternative study drug (olanzapine).  
Since current treatment guidelines for schizophrenia therapy recommend continuing 
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medical treatment for 4 to 8 weeks, the total treatment length of 10 weeks in the case 
of a continuation of the initially started study drug amisulpride will only slightly exceed 
these recommendations.  
Both study drugs have been approved in most countries for the treatment of 
schizophrenia for over 10 years, so that no significantly higher medical risk arises 
from participation compared to routine treatment with amisulpride or olanzapine, with 
the exception of the double-blind study conditions and the randomised assignment of 
medication. 
According to the study’s hypothesis, patients with poor initial response to treatment 
would improve their chances of reaching remission if they were assigned to the 
alternative treatment arm (olanzapine) in phase II of the trial. This may represent a 
potential benefit of the study. 
There is consensus that clozapine is the most effective antipsychotic drug available. 
There is a concern about the possibility of agranulocytosis in approximately 1% of the 
treated individuals. This risk must be balanced with the considerable percentage of 
patients, who do not respond to first, or even second line treatments. The treatment 
algorithms are quite explicit about what to do next – switch to clozapine, as is the 
case in OPTIMISE. The problem of agranulocytosis will be controlled by weekly 
blood-counts. In addition, the clozapine part of the trial is open label, allowing to 
closely monitor side-effects and to intervene immediately.  
The study is preceded by a thorough informational discussion with a doctor, during 
which the patient will be informed about every aspect of the course of the study, the 
potential individual benefits, and the personal risk. Participation is only possible after 
submission of written consent, whichcan be revoked at any time without citing 
reasons. 
Every participant receives a study number. Data on participation is recorded in a 
pseudonymous way, i.e., the study site passes on, stores, and analyses the data and 
study results without stating the participants’ name  or address. Merely the study site 
could match a study participant to his or her personal data via the patient 
identification list in case of emergency.  
 
14. Independent ethical committees, informed       
consent procedure and data privacy 
 
14.1 Submission to independent ethical committees 
 
Before study start the principal investigator of each participating site will submit a 
complete set of relevant documentation to the respective independent ethics 
committee for approval according to the national / local regulations data. 
The study will only begin when all documents have been evaluated by the ethics 
committee and have been accepted without reservations. A written confirmation of 
the unreserved acceptance of the proposal under consideration of the presented 
documents must be present.  
Over the study’s course, the principal investigator of each participating site is also 
responsible for informing the ethics committee on the progress of the study and 
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14.2 Informed consent 
 
Participation in the study is preceded by a thorough counselling by a doctor in 
accordance with the Declaration of Helsinki and with ICH-GCP guidelines, during 
which the patient must be informed about the entire course of the study, potential 
individual benefits and personal risk. Here it must be re-emphasized that participation 
is absolutely voluntary, and treatment alternatives aside the present study must be 
explained to the patient. Patients are given sufficient time to read all the provided 
information, counsel partners or relatives, and clarify any questions with the 
investigator.  
Regarding data privacy, patients will be informed about pseudonymous recording 
and sharing of data in accordance with the requirements for documentation and 
information. In case patients cannot agree to this passing on of data they cannot 
participate in the study.  
Participation only becomes possible after handing in written consent. This consent 
can be revoked at any time without citing reasons. No examinations or other activities 
will take place before the participant has handed in written consent to participate. 
A copy of the consent form and patient information will be given to the participant 
along with a copy of the insurance certificate for study participants.   
In case patient information or the consent form change, participants will be informed 
immediately and relevant information will be passed on to the ethic committees for 
approval. New patient information and consent will be discussed in detail again, the 
participant will again be asked for written consent, and a copy of the documents will 
be given to the patient.  
 
14.3 Data privacy 
 
Privacy laws and regulations will be adhered to during all phases and procedures 
related to this study. The collection and processing of participants’ personal 
information will be limited to what is necessary to insure the study’s scientific 
practicability, the evaluation of efficacy, adherence, side-effects and the treatment’s 
safety. Information collected about participants during this clinical investigation will be 
treated confidentially. The local investigator or her/his co-workers will collect data and 
transfer it without recording the patient’s name or date of birth coded with a patient 
identification number.  
 
Pseudonymous data will be relayed to the study center for scientific analysis or made 
available, if necessary, to the responsible federal supervisory authority (in case it 
audits the course of the study). Only qualified and authorised collaborators of the 
study sponsor will enter the pseudonymous data into a computerised database. 
The acquired data will be used without participants’ names for scientific analysis and 
can be used in related or other future studies. Participants’ names will not be 
mentioned in any publication of study results. 
To ensure data accuracy, the study coordinator will conduct a direct comparison of 
the data with medical records available to or assembled by the investigators at the 
study site. These documents will only be checked by qualified and authorised 
personnel. Persons monitoring the data are required to keep information confidential 
and to respect data privacy. 
Participants have the right to look into their data and can check their data in 
accordance with the relevant judicial regulations and procedures.  
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 15. Study administration 
 
15.1 Changes in protocol 
 
Changes to the protocol will be documented in a protocol amendment and  submitted 
to the Ethics Committees and, if necessary, National Authorities according to the 
regulations.  
 
15.2 Study registration 
 
Before the start of the study all required documents will be submitted to the 
responsible Ethics Committees and regulatory authorities. The study is registered as 
an interventional study at the European center for clinical studies (EudraCT). 
Furthermore, the study will also be registered on the website 
“www.ClinicalTrials.gov“of the American Department of Health, a data base for 
clinical studies conducted world-wide.  
 
15.3 Documentation of study results 
 
Local investigators will enter the acquired data and examination results into an 
electronic case record form (eCRF) that is accessible via the internet. Investigators 
will receive personal user names and passwords for this purpose, and data will be 
encrypted for transfer. For each site, it will be agreed before the start of the study 
which documents serve as source documents for all data entered into the eCRF. 
 
The investigator must (electronically) sign that entries into the eCRF are true and 
complete. 
 
15.4 Quality control of data acquisition 
 
Study sites and associated investigators will be carefully selected and 
comprehensively informed and trained regarding Good Clinical Practice (GCP), all 
study procedures and the required examinations and documentation. 
 
The quality of data acquisition will be ensured by regular monitoring visits. After data 
have been submitted to the study center, another thorough inspection of the 
completeness and plausibility of entries will be conducted. If needed, questions for 
clarification will be addressed to the sites. Only after all questions regarding data 
quality have been answered, the database will be locked (data-lock).  
 
15.5 Archiving of study documents 
 
In accordance with national laws and guidelines and the specifications of the ICH-
GCP guidelines, the investigators from participating sites and the coordinating center 
are obligated to archive all documents pertaining to the study for 15 years after the 








Monitoring will be performed by a CRA from the central study team, UMC Utrecht, 
The Netherlands according to national laws and guidelines and the specifications of 
the ICH-GCP guidelines. Details will be documented in a separate monitoring plan. 
Study monitors will visit study sites at regular intervals to monitor the execution of the 
study. Monitors will have access to all documents that are needed to perform their 
task according to the above mentioned guidelines. Monitors will check whether 
requirements to conduct the study are met and study procedures are followed 
correctly, and will check the study site’s documentation, the participants’ source data, 




The study sponsor or responsible regulatory authorities can audit, i.e., thoroughly 
investigate a study site at any time. In this case, auditors are to be given access to all 
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Appendix B 
Contra-indications and warnings/precautions of study medication 
  
Amisulpride – contraindications 
 hypersensitivity to (in)active ingredients 
 prolactin-dependent tumors (e.g. breast cancer) 
 phaeochromocytoma (neuroendocrine tumor of the medulla of the andrenal glands 
 use of medication that can induce torsades de pointes: 
 class Ia antiarrhythmic agents (e.g. quinidine, procainamide) 
 use of class III antiarrhythmic agents (e.g. sotalol, amiodarone) 
 other medications such as methadone, bepridil, cisapride  
 
Amisulpride – warnings/precautions 
 Neuroleptic Malignant Syndrome  
 Hyperglycaemia – check & manage 
 Decrease dose in case of renal insufficiency  
 Lowering of seizure threshold – monitor patients with history  
 Caution in combination with alcohol 
 Patients with a history or a family history of breast cancer should be closely monitored 
during amisulpride therapy. 
 
Need for ECG monitoring during study is assessed at individual basis. The dose of 
amisulpride needs to be reduced if the QT-interval is prolonged, and discontinued if QTc-
interval is > 500ms. 
 
Acute withdrawal symptoms are rare but include: 
Nausea, vomiting, insomnia, recurrence of psychotic symptoms and EPS. 
 
Olanzapine – contraindications 
 hypersensitivity to (in)active ingredients  
 known risk of narrow-angle glaucoma  
 
Olanzapine – warnings/precautions 
 Neuroleptic Malignant Syndrome  
 Hyperglycaemia – check & manage 
 Lipid alterations – check & manage 
 Decrease dose in case of hepatic insufficiency  
 Lowering of seizure threshold – monitor patients with history  
 Caution in combination with alcohol 
 
Acute withdrawal symptoms are rare but include: 
Sweating, insomnia, tremor, anxiety, nausea & vomiting. 
 
Clozapine – contraindications 
 hypersensitivity to (in)active ingredients  
 patients not able to have blood frequently drawn  
 history of agranulocytose (either due to clozapine or not) 
 bone marrow dysfunction  
 uncontrolled epilepsy  
 alcohol and drugs 
 circulatoire collaps or CNS depression  
 serious renal or cardiac impairment  
 specific hepatic dysfunctions  
 paralytical ileus  
 use of medication associated with agranulocytose 




Clozapine – warnings/precautions 
 agranulocytosis (stop medication if this occurs)* 
 myocarditis / cardiopathy (stop medication if this occurs) 
 orthostatic hypertension may occur  
 QT interval prologation may occur  
 dose-related seizures may occur– monitor patients with history  
 monitor patient with hepatic dysfunctions  
 monitor existent prostate enlargements & narrow-angle glaucoma  
 monitor fever  
 hyperglycaemia – check & manage 
* Check SPC for explicit leucocyte blood counts & treatment instructions  
 
Acute withdrawal symptoms include: 
Insomnia, sweating, headache, nausea, vomiting & diarrhea. 
 
Beware of the following aspects: 
1. In line with general practice, test for leucocyte count each week according to local 
guidelines. 
2. Warn patient NOT to stop smoking SUDDENLY without discussion this with physician. 
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This appendix describes the policy for data analysis and publications for Optimization of 
Treatment and Management of Schizophrenia in Europe (OPTiMiSE). This plan was derived 
from policies and practices that were utilised in other multicenter academic studies and is in 
accordance with the principles and standards of scientific research and scholarship within the 
fields of biomedical research and scientific journalism. The goals of the policy are:  
1) to provide for the timely, scholarly and comprehensive reporting of the data in the scientific 
literature;  
2) to provide for the assignment of authorship and data analytic opportunities to study 
investigators in a manner that is equitable and supports career development;  
3) to ensure that the analysis and reporting of data are consistent with regulatory agency 
requirements.  
 
2. Administrative Structure 
The data analysis and publication strategy will be determined by the Executive Board 
comprised by all study collaborators and investigators. All study publications must be 
submitted for review to the Executive Board. No treatment group information will be made 
available until after study completion.  
 
3. Data Analyses  
Data analyses will be conducted in a timely fashion in a manner that ensures the study’s 
scientific integrity. The final analysis will be done after all patients have completed the follow 
up visits, queries have been solved and the database is locked. No interim analysis is 
planned. Data will be analysed first for the comprehensive sample. After the first publication 
of the comprehensive sample has been published, reports of individual sites’ data may be 
developed. Data from the individual sites may be used in the development of grant 
applications at any time provided it doesn’t compromise the study’s integrity.   
 
4. Levels of Analysis  
It is expected that there will be at least four levels of analyses and reports from the study. 
The first contains analyses specified in the primary hypotheses and variables of the protocol. 
The second consists of those specified in the secondary hypotheses and variables of the 
protocol. In the third there are analyses of variables or sub-variables that are not specified in 
the primary and secondary hypotheses or are directly derivative of them. The fourth level 
consists of analyses of individual site(s) data. The primary and secondary analyses are 
described in the Description of Work, and will be managed by the Work Package leaders. In 
case conflicts arise, these may be resolved by the Executive Board. 
 
5. Submission and review procedures for tertiary and quaternary analyses 
Proposals for data analyses and manuscript development will be submitted to the Executive 
Board for review. Prof. Kahn will co-ordinate this process. Each proposal will be logged in 
and distributed to each country co-ordinator. The format for the proposal will be no more than 
two pages and include 1) Specific Aims; 2) Hypotheses; 3) Background and Rationale; 4) 
Variables to be analysed including time period. Preliminarily approved proposals will be 
assigned for development to the proposing investigator and interested investigators from 
other sites. Manuscripts will be developed as per the guidelines below. All documentation will 
be kept by the central study team. 
 
6. Determination of Authorship 
The number and composition of co-authors will be defined based on prevailing standards of 
scientific scholarship.  
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The following criteria will be utilised in a system for allocation of authorship. 
 Expertise 
 Source of idea for analysis or report 
 Role in the study’s development and implementation 
 Role in data analyses 
 Role in writing the article 
 Study recruitment 
 
7. Conditions and Limitations on Authorship 
The following conditions and limitations on authorship are relevant: 
 The first overall study publication will include (at least) the Principal Investigators, 
Trial Coordinators and country co-ordinators as authors 
 Every site will not necessarily get a first author comprehensive study publication. 
 Some form of rotation will be developed for authorship on comprehensive study 
publications. 
 The Executive Board will review site-specific proposals for publication. 
 A time limit within which lead authorship assignments must be initiated and/or 
completed will be established (e.g. six months from assignment and availability of 
data to the production of a first draft of manuscript). After this time has elapsed lead 
authorship will be reassigned. 
 
To resolve any differences or questions regarding authorship or prioritisation of data 
analyses the following criteria will be used:  
1. Scientific merit of the topic 
2. Resource requirements in terms of time and effort of the request 
3. Number of prior proposals and requests of the investigator 
4. Number of prior first authored papers by the investigator 
5. Overall contribution to the study 
 
